

Reseptregisteret
2006–2010

The Norwegian
Prescription Database
2006–2010



Reseptregisteret 2006–2010

The Norwegian Prescription Database 2006–2010

Christian Berg
Kari Furu
Milada Mahic
Irene Litleskare
Marit Rønning
Solveig Sakshaug
Randi Selmer
Svetlana Skurtveit
Hanne Strøm

Rapport 2011:2
Nasjonalt folkehelseinstitutt /
The Norwegian Institute of Public Health

Tittel/Title:

Reseptregisteret 2006–2010

The Norwegian Prescription
Database 2006–2010

Redaktør/Editor:

Christian Berg

Forfattere/Authors:

Christian Berg
Kari Furu
Irene Litleskare
Milada Mahic
Marit Rønning
Solveig Sakshaug
Randi Selmer
Svetlana Skurtveit
Hanne Strøm

Publisert av / Published by:

Nasjonalt folkehelseinstitutt
Postboks 4404 Nydalen
NO-0403
Norway

Tel: + 47 21 07 70 00
E-mail: folkehelseinstituttet@fhi.no
www.fhi.no

Design/Layout

Houston911

Acknowledgement:

Julie D.W. Johansen (English version)

Forsideillustrasjon / Front page illustration:

iStockPhoto

Trykk/Print:

www.wj.no

Opplag / Number printed:

400

Bestilling/Order:

publikasjon@fhi.no
Fax: +47-21 07 81 05
Tel: +47-21 07 82 00

ISSN: 1890-9647

ISBN: 978-82-8082-457-8 trykt utgave/printed version

ISBN: 978-82-8082-458-5 elektronisk utgave/electronic version

Tidligere utgave / Previous edition:

2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007.

2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian
Prescription Database 2004–2008

2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende
legemidler / The Norwegian Prescription Database 2005–2009. Topic: Addictive drugs



Forord

Bruken av legemidler i befolkningen er økende. En viktig målsetting for norsk legemiddelpolitikk er rasjonell legemiddelbruk. En forutsetning for arbeidet med å optimalisere legemiddelbruken i befolkningen er kunnskap om hvilke legemidler som brukes, hvem som bruker legemidlene og hvordan de brukes. For å få bedre kunnskap på dette området, vedtok Stortinget i desember 2002 å etablere et nasjonalt reseptbasert legemiddelregister (Reseptregisteret). Oppgaven med å etablere registeret ble gitt til Folkehelseinstituttet som fra 1. januar 2004 har mottatt månedlige opplysninger fra alle apotek om utlevering av legemidler til pasienter, leger og institusjoner.

Denne rapporten er fjerde utgave av den årlige statistikken fra Reseptregisteret. Generell informasjon om Reseptregisteret, legemiddelstatistikk, klassifikasjon av legemidler og målemetoder finnes i rapportens del 1. Del 2 inneholder noen nøkkeltall fra Reseptregisteret og et omfattende tabellverk med opplysninger om antall individer som har fått utlevert legemidler etter resept fra apotekene i Norge i siste femårsperiode (2006–2010). Opplysningene er fordelt på enkeltlegemidler og legemiddelgrupper. ATC (Anatomisk Terapeutisk Kjemisk)-klassifikasjon er benyttet i tabellene. For 2010 er informasjon om alders- og kjønnsfordeling og kostnader inkludert i tabellene. ATC/DDD-versjon gjeldende fra januar 2011 er benyttet i rapporten, se også www.whocc.no.

Reseptregisteret har også en nettside der man kan finne kompletterende informasjon. Nettstedet er: www.norpd.no (engelsk versjon) eller www.reseptregisteret.no (norsk versjon). Det er også mulig å søke om utlevering av data fra Reseptregisteret til forskning eller til andre formål som er i henhold til formålet for Reseptregisteret. Mer informasjon om dette finnes i bokens del 1 og på nettsiden til Folkehelseinstituttet (www.fhi.no).

Avdeling for legemiddelepidemiologi
Folkehelseinstituttet
April 2011

Preface

The use of drugs in the population is increasing. An important goal of the health policies regarding pharmaceuticals in Norway is rational drug use. In order to improve drug use, knowledge about which drugs are used, how they are used and who uses them is vital. In December 2002, the Parliament decided to establish a national prescription database in Norway (NorPD). The task of building up the register was given to the Norwegian Institute of Public Health (NIPH). Since 1st January 2004, the institute has received monthly data on prescriptions from all Norwegian pharmacies.

This report is the fourth edition of the annual statistics from NorPD. General information about NorPD, drug statistics, classification of drug and measurement methods is included in part 1 of the report. Part 2 contains some key figures from NorPD and the main tables with information about the number of individuals who had prescriptions dispensed from pharmacies in Norway during the latest five years period (2006–2010). The information includes particular drug substances as well as drug groups. ATC (Anatomical Therapeutic Chemical) classification is used in the tables. For 2010, information about age, gender and costs are included in the tables. The ATC/DDD version of January 2011 has been used in the report, see also www.whocc.no.

NorPD also has a website where you can find complementary information. The website is: www.norpd.no (English version) or www.reseptregisteret.no (Norwegian version). It is also possible to apply for data from NorPD for research or for other purposes which are according to the objectives of NorPD. More information about this can be found in part 1 of the report, and at the website of the Norwegian Institute of Public Health (www.fhi.no).

Department of Pharmacoepidemiology
Norwegian Institute of Public Health
April 2011

Innhold

Forord	6
1. Generelt om Reseptregisteret og legemiddelstatistikk	11
1.1 Reseptregisteret	11
1.2 Nordiske reseptregistre	14
1.3 Grossistbasert legemiddelstatistikk	14
1.4 Anatomisk Terapeutisk Kjemisk (ATC)-klassifikasjon.....	15
1.5 Definert Døgndose (DDD).....	16
1.6 WHO Collaborating Centre for Drug Statistics Methodology.....	17
2. Reseptregisteret 2006–2010	19
2.1 Utvalgte nøkkeltall fra Reseptregisteret.....	19
2.2 Beskrivelse av hovedtabellene	23
2.3 ATC main groups	27
2.4 ATC group A – Alimentary tract and metabolism	28
2.5 ATC group B – Blood and bloodforming organs	38
2.6 ATC group C – Cardiovascular system	41
2.7 ATC group D – Dermatologicals.....	48
2.8 ATC group G – Genito urinary system and sex hormones	54
2.9 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins	59
2.10 ATC group J – Antiinfectives for systemic use	62
2.11 ATC group L – Antineoplastic and immunomodulating agents	68
2.12 ATC group M – Musculo-skeletal system	71
2.13 ATC group N – Nervous system	75
2.14 ATC group P – Antiparasitic products, insecticides and repellents	84
2.15 ATC group R – Respiratory system	86
2.16 ATC group S – Sensory organs	90
2.17 ATC group V – Various	94
Folkemengde i Norge 2006–2010 (per 1. juli)/	95
Folkemengde etter alder i 2010 (per 1. juli)/	95
Liste over publikasjoner basert på data fra Reseptregisteret per mars 2011	96

Contents

Preface	7
1. Information about the Norwegian Prescription Database (NorPD) and drug statistics	11
1.1 About the NorPD.....	11
1.2 Prescription databases in the other Nordic countries	14
1.3 The Norwegian Drug Wholesales Statistics	14
1.4 The Anatomical Therapeutic Chemical (ATC) classification system	15
1.5 The Defined Daily Dose (DDD)	16
1.6 The WHO Collaborating Centre for Drug Statistics Methodology	17
2. The Norwegian Prescription Database (NorPD) 2006–2010	19
2.1 Selected key figures from NorPD.....	19
2.2 Description of the main tables	23
2.3 ATC main groups	27
2.4 ATC group A – Alimentary tract and metabolism	28
2.5 ATC group B – Blood and bloodforming organs	38
2.6 ATC group C – Cardiovascular system	41
2.7 ATC group D – Dermatologicals.....	48
2.8 ATC group G – Genito urinary system and sex hormones	54
2.9 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins	59
2.10 ATC group J – Antiinfectives for systemic use	62
2.11 ATC group L – Antineoplastic and immunomodulating agents	68
2.12 ATC group M – Musculo-skeletal system	71
2.13 ATC group N – Nervous system	75
2.14 ATC group P – Antiparasitic products, insecticides and repellents	84
2.15 ATC group R – Respiratory system	86
2.16 ATC group S – Sensory organs	90
2.17 ATC group V – Various	94
Population in Norway 2006–2010 (as of 1st July)	95
Population by age in 2010 (as of 1st July).....	95
List of publications based on data from the Norwegian Prescription Database (NorPD) per April 2011.....	96



9th St
Loving Company
1000 9th St
San Francisco, CA 94103
Tel: 415 774 1116
www.lovingcompany.com

1. Generelt om Reseptregisteret og legemiddelstatistikk

1.1 Reseptregisteret

Datainnsamling og variabler i Reseptregisteret

Ny apoteklov trådte i kraft 1. mars 2001, og ifølge den nye loven ble apotek forpliktet til å videresende reseptdata til en ny nasjonal legemiddeldatabase. I oktober 2003 ble ny detaljert forskrift for Reseptregisteret (hjemlet i Helseregisterloven) vedtatt av Kongen i Statsråd (1). Formålet med Reseptregisteret (jf forskriftens § 1-3) er å samle inn og behandle data om legemiddelbruk hos mennesker og dyr for å:

- kartlegge forbruket i landet og belyse endringer over tid
- fremme og gi grunnlag for forskning og utredning for å kunne belyse positive og negative effekter av legemiddelbruk
- gi myndighetene et statistisk grunnlag for kvalitets sikring av legemiddelbruk og overordnet tilsyn, styring og planlegging
- gi legemiddelrevirer et grunnlag for internkontroll og kvalitetsforbedring

Forskriftens formål bestemmer hva Reseptregisteret kan brukes til. Forskriften bestemmer også hva slags data vi kan samle inn fra apotek og administrative registre.

Reseptregisteret inneholder følgende variabler:

- *Pasient*
Personidentifikasjon (kryptert), fødselsmåned/-år, døds måned/-år, kjønn, bosted (kommune og fylke)
- *Forskriver*
Personidentifikasjon (kryptert), fødselsår, kjønn, yrke, spesialitet
- *Legemiddel*
Nordisk varenummer (merkenavn, styrke, legemiddelform, pakningsstørrelse), antall pakninger, ATC-kode, antall definerte døgndoser (DDD), reseptkategori, kode for refusjon (fra mars 2008: ICD10, ICPC koder og enkelte koder definert av Lege-

1. Information about the Norwegian Prescription Database (NorPD) and drug statistics

1.1 About the NorPD

Data collection and variables in NorPD

New legislation in the Norwegian pharmacy sector came into force on March 1st 2001. According to the new act, pharmacies were obliged to forward prescription data to a new national drug database. In October 2003, new, detailed regulations for the NorPD were approved (1). The objectives of the NorPD, as defined in authoritative regulations, are to collect and prepare data on drug use in individuals and animals in order to:

- describe drug use patterns, highlighting changes over time
- promote and form a basis for research and review of the safety and effectiveness of drug use
- serve as a management tool for the authorities in order to assure prescribing quality in addition to general surveillance, control and planning
- give the prescribing doctors a basis for internal control, as part of an audit method to improve the quality of prescribing practices

All NorPD data use must be in accordance with these objectives. The regulation also determines what kind of data can be collected from the pharmacies and administrative registers.

The NorPD contains the following variables:

- *Patient*
Person-identifier (encrypted), month/year of birth, month/year of death, gender, place of residence (municipality & county)
- *Prescriber*
Person-identifier (encrypted), month/year of birth, gender, profession, speciality
- *Drug*
Nordic article number (unique product identifier stating brand name, strength, pharmaceutical

middelverket, fullstendig implementert fra mars 2009), bruksområde og forskrevet dose (fritekst), utleveringsdato, pris (apotekets utsalgspris)

- *Apotek*

Apoteknavn, konsesjonsnummer, kommune og fylke

Det nordiske varenummeret er en unik identifikasjon for hver pakning av et legemiddel og muliggjør kobling til andre registre som gir detaljert informasjon om legemidlene. Indikasjon for forskrivning ble de første årene ikke registrert i databasen, kun overordnede refusjonskoder som for enkelte legemidler fungerte som grov diagnosekode. Fra mars 2008 ble forskriver pålagt å angi mer spesifikke diagnosekoder på blåresepter som erstatning for de gamle sykdomspunktene. Det skal benyttes enten International Classification of Diseases versjon 10 (ICD-10) eller International Classification of Primary Care (ICPC). I tillegg har Legemiddelverket på enkelte områder definert egne koder. Ordningen er fullstendig implementert fra mars 2009.

Fra 1. januar 2004 har Folkehelseinstituttet mottatt månedlig informasjon om reseptutleveringer fra alle apotek i Norge (2). I alle apotek er det tilrettelagt for automatisk innsending av rapport til Reseptregisteret til fast tidspunkt hver måned, slik at apotekene kan oppfylle sin rapporteringsplikt uten vesentlig ekstra arbeid. Reseptregisteret inneholder informasjon om alle legemidler som er forskrevet og utlevert til enkeltpasienter utenom sykehus og institusjoner. Legemidler foreskrevet på godkjenningsfritak er også inkludert, men legemidler som selges reseptfritt er ikke registrert i Reseptregisteret (se også side 3). Hvis reseptfrie legemidler er forskrevet på resept vil de imidlertid bli registrert i databasen.

De viktigste dataene i Reseptregisteret er basert på resepter forskrevet til enkeltpersoner, men også forskrivning av legemidler fra veterinærer til dyr og forskrivning til egen praksis registreres i Reseptregisteret. Når det gjelder pasienter som er innlagt i sykehus eller sykehjem, samler registeret inn kun aggregerte data på institusjons- eller avdelingsnivå, fordi innsamlingen baseres kun på informasjon som apotekene registrerer når de leverer legemidler til institusjoner.

Datasikkerhet

Som illustrert i figur 1.1 blir registreringer av utleverte legemidler fra apotek elektronisk og automatisk overført til Statistisk sentralbyrå (SSB) før de kommer til FHI og inkluderes i Reseptregisteret. SSB fungerer som en såkalt tiltrodd tredjepart og er en del av datasikkerheten for å ivareta konfidensialitet og informa-

form and pack size), number of packs, ATC code, number of Defined Daily Doses (DDD), prescription category, reimbursement code (from March 2008: ICD10, ICPC codes or codes defined by the Norwegian Medicines Agency, completely implemented from March 2009), intended use and prescribed dose (free-text according to pharmacy label), dispensing date, price (pharmacy retail price)

- *Pharmacy*

Name, licence number, municipality and county

The Nordic article number is the important link to other registries providing detailed information about the drugs. The indication for prescribing was in the first years not recorded in the database, only the code of reimbursement which in some cases, acted as a proxy of diagnosis. From March 2008, prescribers had to use either the International Classification of Diseases version 10 (ICD10), or the International Classification of Primary Care Codes (ICPC) or special codes assigned by the Norwegian Medicines Agency as the code of reimbursement on the prescriptions. This was fully implemented from March 2009.

Since 1st January 2004, the NIPH has received monthly data on prescriptions from all Norwegian pharmacies (2). Monthly electronically reports are automatically generated in all pharmacies, thus avoiding extra work for the pharmacy. NorPD contains information about all drugs prescribed (reimbursed or not) and dispensed at pharmacies to individual patients living outside institutions, i.e. ambulant care. Unlicensed drugs are also included, but drugs sold over-the-counter (OTC) are not recorded in NorPD (see also page 3). However, if the OTC drugs are prescribed by a physician and dispensed, then they will be recorded in the database.

The main data in NorPD are based on prescriptions to individual humans, but also prescribed drugs by veterinarians to animals and prescribing to a physician's own practice are collected in NorPD. For patients in nursing homes and hospitals, the register collects figures on drug use at the level of the institution or the department, i.e. on an aggregate level.

Data protection

As illustrated in figure 1.1 the pharmacy records of dispensed drugs are electronically and automatically transferred through Statistics Norway before they arrive at NIPH and are included in NorPD. Statistics Norway acts as a so-called "trusted third party centre" and is a part of the data protection to ensure confidentiality of personal information. Statistics Norway only has access to the patient's personal identity number and the prescriber's health personnel number and



Figure 1.1: Data flow, the Norwegian Prescription Database (NorPD)

sjonssikkerhet for all personlig informasjon. SSB har tilgang til pasientens fødselsnummer og forskrivers helsepersonellnummer, og erstatter begge med et pseudonym. SSB kan ikke lese noen annen informasjon fra reseptene, fordi denne informasjonen er kryptert før SSB mottar dataene. Når SSB sender data er fødselsnummer og forskrivers helsepersonellnummer fjernet, og FHI kan dekryptere helseopplysningene som fremgår av resepten igjen. Prinsippet for pseudonymisering er at ingen, heller ikke den som tildeler og forvalter pseudonymer, skal kunne ha samtidig tilgang til både pseudonym, helseopplysninger og personens identitet. Begrepet "Pseudonymiserte helsedata" er definert i Helseregisterloven: "Personlig helsedata som identitet er kryptert, eller på annen måte skjult, men likevel individuell, slik at det er mulig å følge hver person gjennom helsesystemet uten at vedkommendes identitet blir avslørt (4). Dette betyr at identiteten til pasienter og forskrivere har blitt kryptert i henhold til norsk lovgivning, men likevel er individuell, slik at det er mulig å følge enkeltpersoner over tid, og gjøre registerkoblingsstudier.

Kvalitetssikring

For kvalitetssikring blir et antall søk gjennomført månedlig eller halvårlig for å identifisere mulige feil eller uoverensstemmelser. FHI gjør ulike rutinemessige kontroller på data før de overføres til Reseptregisterets database. I Reseptregisteret er det nordiske varenummeret knyttet til det nasjonale vareregisteret for legemidler med gyldige ATC-koder og DDD-verdier (5). Dette registeret oppdateres månedlig. FHI sjekker også om dataleveranser fra hvert apotek er av rimelig størrelse. Det totale antallet reseptbelagte poster, totalt antall pasienter og forskrivere blir sjekket hver måned. Statistikk for apotekene blir rutinemessig kjørt. Denne rutinen vil identifisere uvanlige varia-

replaces both with a pseudonymised identifier. Statistics Norway cannot read any other prescription data because this information is encrypted before Statistics Norway receives the data. When Statistics Norway sends the data including the pseudonymised identifiers to the NIPH, the NIPH is allowed to decrypt the prescription information again. The term "Pseudonymous health data" is defined in the Personal Health Data Filing System Act (in Norwegian: Helseregisterloven): "personal health data in which the identity has been encrypted or otherwise concealed, but nonetheless individualized so that it is possible to follow each person through the health system without his identity being revealed" (4). This means that the identity of patients and prescribers has been encrypted according to Norwegian legislation, but nonetheless individualized, so that it is possible to follow individuals over time and perform record-linkage studies. Data linkage is based on the unique identification number system which is available in all the Nordic countries.

Quality checks

For quality assurance, a number of queries are carried out monthly or half-yearly to identify possible errors or inconsistencies. NIPH performs different routine checks on the data before they are transferred to the NorPD. In the NorPD, the Nordic article number is linked to the national register of medicinal products with validated ATC codes and DDD values (5). This register is updated monthly. NIPH also checks if the data deliveries from each pharmacy are of a reasonable size. The total number of prescription records and the total number of patients and prescribers are checked every month. Statistics for the pharmacies are checked by routine. Unusual variations in size of data files from month to month are identified and any missing data is caught, such as missing special data type deliveries or empty

sjoner i størrelsen på dataleveranser fra måned til måned, og fange opp manglende leveranser av spesielle typer data, eller hvis en datalevering fra ett apotek er tom i en måned på grunn av tekniske feil på apoteket eller hos tiltrodd tredjepart (SSB). Fødselsnummeret kontrolleres hos SSB mot Folkeregisteret. Når fødselsnummeret er ugyldig eller mangler, lager SSB et spesielt pseudonym. Disse personene er ikke mulig å følge over tid, og heller ikke mulig å koble til andre datakilder, men det rapporterte antall ordinasjoner og DDD knyttet til disse personene kan likevel inkluderes i totalstatistikken.

1.2 Nordiske reseptregistre

På slutten av 1980-tallet, tok apotek i de nordiske landene gradvis i bruk elektroniske systemer ved ekspedering av resepter. Dette gjorde det mulig å samle inn reseptdata fra apotek på en enklere og mer effektiv måte. Selv om helsevesenet ikke er organisert likt i de nordiske landene, har alle fem land et helsevesen med universell dekning for helseutgifter. Alle borgere, uavhengig av sosioøkonomisk status, har ubegrenset tilgang til helsetjenester, inkludert delvis eller fullstendig refusjon av kjøpte legemidler. Nasjonale reseptdatabaser, som er basert på data fra ekspederte og utleverte legemidler fra apotek til individer utenfor sykehus/sykehjem, har vært tilgjengelig siden 1994 i Finland og Danmark, siden 2004 i Norge, siden 2005 i Sverige og siden 2006 på Island. Databasene dekker til sammen 25 millioner innbyggere (Danmark: 5,5 millioner, Finland: 5,3 millioner; Island: 0,3 millioner; Norge: 4,9 millioner og Sverige: 9,2 millioner). Det er mulig å koble disse dataene til ulike helseutfall og andre data basert på det unike fødselsnummeret/-koden som alle innbyggere i disse landene har. Databasene er en viktig ressurs for å kunne gjennomføre longitudinelle og registerkoblede studier med helseundersøkelser og andre registre. Databasene representerer også et godt kunnskapsgrunnlag for nasjonale beslutninger innen legemiddelbruk. En artikkel fra 2010 gir en oversikt over datainnsamlingsprosedyrer og innhold i de nordiske landenes reseptregistre (6).

1.3 Grossistbasert legemiddelstatistikk

Statistikk basert på totalt salg av legemidler fra grossist til apotek, sykehus/sykehjem har vært tilgjengelig i Norge siden 1970-tallet. Grossistbasert legemiddel-

data files caused by technical error at the pharmacy or at the trusted third party. The Personal Identification Number is checked in Statistics Norway against the Central Population Registry. If the Personal Identification Number is invalid or missing, Statistics Norway creates a special pseudonym, but it is not possible to track these individuals or link them to other data sources. However, the reported total number of ordinations and DDDs can be included in the total statistics.

1.2 Prescription databases in the other Nordic countries

During the late 1980s, pharmacies in the Nordic countries gradually computerised their records of dispensed prescriptions which made it possible to collect data efficiently. Although healthcare systems are not organised identically in the Nordic countries, all five countries have a tax-supported public health service with universal coverage. All citizens, independent of socioeconomic status, have unrestricted access to health services, including partial or complete reimbursement of purchased medicines. National prescription databases, containing data on drugs dispensed at pharmacies (exposure data) to individuals receiving ambulatory care, have been available since 1994 in Finland and Denmark, since 2004 in Norway, since 2005 in Sweden and since 2006 in Iceland. The databases together cover 25 million inhabitants (Denmark: 5.5 million; Finland: 5.3 million; Iceland: 0.3 million; Norway: 4.9 million; and Sweden: 9.2 million) and have the potential to link these data to different health outcomes and other data based on the unique personal identity number of each resident in these countries. The databases serve as a resource for conducting longitudinal and record-linkage studies with health surveys and other registries. They also offer a sound evidence base for national decision-making in the field of drug utilisation. An article from 2010 provides an overview of the data collection procedures and content of the Nordic countries' prescription databases (6). In addition, the article discusses their unique potential for cross-national record linkage and for analytical pharmacoepidemiological studies.

1.3 The Norwegian Drug Wholesales Statistics

Statistics based on total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes has been available in Norway since the 1970s. The Norwegian Drug Wholesales Statistics database includes

statistikk omfatter alt salg av legemidler fra grossist til apotek, sykehus/sykehjem, dagligvaredetaljister og andre med tillatelse til å omsette legemidler. Legemidler til dyr og mennesker, både reseptfrie og reseptbelagte, er inkludert i statistikken. Statistikken gir en oversikt over utviklingen i legemiddelomsetningen over tid. Statistikken inneholder imidlertid ikke opplysninger om den enkelte legemiddelbruker.

Legemiddelforbruket i Norge – årlig publikasjon

Årlig publiseres data fra den Grossistbaserte legemiddelstatistikken i publikasjonen *Legemiddelforbruket i Norge*. Hver utgave omfatter 5-årsoversikter over totalsalget av reseptfrie og reseptbelagte legemidler i Norge (7). Boken er tilgjengelig på nettsiden www.legemiddelforbruk.no. Nærmere informasjon vedrørende utlevering av data fra den grossistbaserte legemiddelstatistikken finnes på Folkehelseinstituttets nettside www.fhi.no.

1.4 Anatomisk Terapeutisk Kjemisk (ATC)-klassifisering

Alle legemidler som er registrert i Norge er gruppert etter ATC-systemet. I ATC-systemet inndeles legemidlene i grupper på 5 nivåer: På 1. nivå fordeles legemidlene på 14 anatomiske hovedgrupper. Det neste nivået (2. nivå) er en terapeutisk eller farmakologisk undergruppe. 3. nivå og 4. nivå er terapeutiske, farmakologiske eller kjemiske undergrupper, mens 5. nivå representerer den kjemiske substansen.

ATC- koden

En fullstendig klassifisering av legemiddelsubstansen spironolakton (vanndrivende middel) med ATC-koden C03DA01 kan illustrere oppbyggingen av ATC-systemet:

C	Hjerte og kretsløp (1. nivå, anatomisk hovedgruppe)
C03	Diuretika (2. nivå, terapeutisk undergruppe)
C03D	Kaliumsparende midler (3. nivå, farmakologisk undergruppe)
C03DA	Aldosteronantagonister (4. nivå, farmakologisk undergruppe)
C03DA01	Spironolakton (5. nivå, kjemisk substans)

Alle spironolakton preparater (Aldactone® og Spirix®) gis i dette systemet koden C03DA01.

Ved hjelp av dette klassifiseringssystemet kan man lage statistikker over legemiddelforbruk gruppert på fem ulike nivåer, fra tall som viser totalforbruket av alle

total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes and non-pharmacy outlets and others with permission to sell medicines. Total sales of prescription and non-prescription human and veterinary medicines are included in the statistics. The statistics give an overview of developments in drug consumption over time. The statistics, however, contain no information about the individual drug user.

Drug Consumption in Norway – published annually

Data from the Norwegian Drug Wholesales Statistics Database have been published annually in *Drug Consumption in Norway* (7) since 1977. Each issue includes total sales data for 5 year periods for both prescription- and non-prescription drugs in Norway. The book is available from the website www.drugconsumption.no. Further information on the Norwegian Drug Wholesales Statistics database, including how to apply for data, can be found at the Norwegian Institute of Public Health's website www.fhi.no.

1.4 The Anatomical Therapeutic Chemical (ATC) classification system

In the ATC system the drug substances are classified into groups at 5 different levels. The drugs are divided into fourteen main groups (1st level), with one pharmacological/ therapeutic sub-group (2nd level). The 3rd and 4th levels are chemical/pharmacological/ therapeutic sub-groups and the 5th level is the chemical substance.

The ATC code

A complete classification of the drug spironolactone (diuretic) with the ATC code C03DA01 illustrates the structure of the ATC system:

C	Cardiovascular system (1st level, anatomical main group)
C03	Diuretics (2nd level, therapeutic sub-group)
C03D	Potassium-sparing agents (3rd level, pharmacological sub-group)
C03DA	Aldosterone antagonists (4th level, pharmacological sub-group)
C03DA01	Spironolactone (5th level, chemical substance)

All medicinal products containing plain spironolactone (Aldactone® and Spirix®) are thus assigned the code C03DA01.

The ATC classification system makes it possible to compile drug consumption statistics on 5 different levels, i.e., figures showing total consumption of all

preparater klassifisert f.eks. under hovedgruppe C – Hjerte og kretsløp (1. nivå), tall for de ulike undergruppene (2., 3. og 4. nivå) og ned til tall som viser forbruket av det enkelte virkestoff.

ATC-kode for hvert enkelt preparat er angitt i *apotekenes vareregister*, og i preparatomtalene (SPC) som er publisert i *Felleskatalogen*. Ved å bruke "Anatomisk terapeutisk kjemisk legemiddelregister" (Felleskatalogens gule del), vil man få en oversikt over hvilke produktnavn hver enkelt ATC-kode omfatter.

1.5 Definert Døgn-dose (DDD)

I enkelte tabeller i del 1 i boken er volum av legemiddelbruk angitt i antall DDD. Ved å benytte definerte døgn-doser (DDD) som måleenhet, får man bedre mulighet for sammenligninger mellom alternative legemidler uavhengig av prisdifferanser. Vurdering av volum av legemiddelforbruket gjennom lengre tidsperioder, nasjonalt og internasjonalt, blir enklere og bedre ved bruk av definerte døgn-doser. Måleenheten DDD er definert som *den antatt gjennomsnittlige døgn-dose brukt ved preparatets hovedindikasjon hos voksne*.

Døgn-dosene fastsettes på bakgrunn av en vurdering av bruken internasjonalt, selv om de nasjonale terapitradisjonene kan variere fra et land til et annet (f.eks. bruksområde og doseringsanbefalinger). Den definerte døgn-dose (DDD) bør derfor betraktes som en teknisk måleverdi.

Legemidler som benyttes ved forskjellige indikasjoner kan by på spesielle problemer som det må tas hensyn til ved vurdering av døgn-dosestatistikk. Dosen ved hovedindikasjonen benyttes normalt ved fastsettelse av DDD. Med unntak for noen få spesielle barnepreparater benyttes doseringer for voksne. Ofte vil DDD for ulike administrasjonsformer være like med unntak av der biotilgjengeligheten er svært forskjellig. For preparater der man benytter en støtdose og en vedlikeholdsdose, vil døgn-dosen være basert på vedlikeholdsdosen. Hvis mulig er DDD angitt i mengde aktiv substans. Er det umulig, som f.eks. ved kombinasjonspreparater og enkelte flytende preparater, angis DDD som antall enkelt-doser (antall tabletter, kapsler, milliliter osv).

DDD representerer ikke nødvendigvis den mest forskrevne eller brukte dose, noe som må tas i betraktning når tallene vurderes. Det vil derfor ofte være vanskelig å beregne antall brukere ved kun å bruke DDD som måleenhet. Dette gjelder særlig

preparations classified in main group C – Cardiovascular system (1st level), figures for the various sub-groups (2nd, 3rd and 4th levels), and down to figures showing consumption of each active ingredient.

The ATC code for all pharmaceuticals on the Norwegian market can be retrieved from *the pharmacy medicinal product register* and in the monographs of the national drug catalogue "*Felleskatalogen*". The yellow section of the latter, entitled *The Anatomical Therapeutic Chemical Medicines Register*, lists all medicinal products belonging to each of the ATC 5th level codes.

1.5 The Defined Daily Dose (DDD)

In some tables in part 1 in this book the sales volume of drug consumption is given in number of DDDs. Using DDDs as the unit of measurement allows better comparison between alternative medications, regardless of price differences. The evaluation of drug consumption volumes over time, nationally and internationally, is simplified and improved by the use of DDDs. A DDD is defined as *the assumed average maintenance dose per day for a drug used on its main indication in adults*.

The DDDs are determined on the basis of evaluation of international use of the substance in question, bearing in mind that national therapy traditions (indications, dosages) often differ greatly. Each DDD should therefore be regarded as a technical measuring unit.

Drugs used for more than one indication may cause particular problems which are important to consider when evaluating statistics based on DDDs. With the exception of a very few specially formulated pediatric preparations, adult dosages are used. The DDD for a substance will often be one and the same, irrespective of the route of administration. However, drugs with different bioavailabilities depending on their administration route will have more than one DDD, each of them linked to a specific dosage form. For medications where a booster dose is followed by a smaller maintenance dosage, the maintenance dose will form the basis for determining the DDD. Whenever possible, the DDD is indicated as the quantity of active substance. When this is impossible, as is the case with combination preparations and some liquid preparations, the DDD is indicated as the number of single doses (number of tablets, capsules, millilitres etc.).

The DDDs are not necessarily the most frequently prescribed or used doses. This must be considered when evaluating the data. This must be considered when evaluating the data. Accordingly it will often be

der doseringsanbefalingene kan variere mye etter bruksområde. Salgstallene kan angis i DDD/1000 innbyggere/døgn og beregnes på følgende måte :

$$\frac{\text{Samlet forbruk i antall DDD} \times 1000}{365 \times \text{antall innbyggere}}$$

Dette tallet vil gi et estimat av andelen av befolkningen i promille som får en bestemt medikamentell behandling. Et estimert salg av et legemiddel på 10 DDD/1000 innbyggere/døgn indikerer at 10 av 1000 personer (dvs. 1 % av befolkningen) daglig kan bruke dette legemidlet. Dette estimatet blir imidlertid kun riktig dersom det er samsvar mellom DDD og dosen som faktisk brukes.

1.6 WHO Collaborating Centre for Drug Statistics Methodology

ATC/DDD-systemet administreres og videreutvikles av WHO Collaborating Centre for Drug Statistics Methodology. Dette senteret er en del av Avdeling for legemiddelepidemiologi ved Nasjonalt folkehelseinstitutt. Nærmere beskrivelse av systemet finnes i publikasjonen Guidelines for ATC classification and DDD assignment (8). ATC Index with DDDs, som inneholder en liste over alle fastsatte DDD, kan bestilles fra WHO senteret (9). Begge publikasjonene finnes i engelsk og spansk versjon. Senterets webside har følgende adresse: www.whocc.no. ATC- og DDD- endringer som er vedtatt, blir publisert årlig og gjort gjeldende ved årsskiftet. ATC/DDD-versjon gjeldende fra januar 2011 er benyttet i rapporten. Publikasjonene kan bestilles fra WHO Collaborating Centre for Drug Statistics Methodology.

difficult to estimate the number of users by using the DDD as the measuring unit.

The sales can be given as the number of DDDs/1000 inhabitants/day, calculated as follows:

$$\frac{\text{Total consumption measured in number of DDDs} \times 1000}{365 \times \text{number of inhabitants}}$$

This figure offers an estimation of what proportion of the population that may receive a certain drug treatment. An estimated drug consumption of 10 DDDs/1000 inhabitants/day corresponds to a daily use of this drug by 1% of the population. This estimate is, however, only valid if there is good correlation between the DDD and the actual consumed dose.


1.6 The WHO Collaborating Centre for Drug Statistics Methodology

The WHO Collaborating Centre for Drug Statistics Methodology is responsible for the administration and development of the ATC/DDD system. The Centre is located at the Department of Pharmacoepidemiology at the NIPH. Further information about the ATC/DDD system is given in the publication Guidelines for ATC classification and DDD assignment (8). The ATC Index with DDDs which includes a list of all assigned DDDs can be ordered from the Centre (9). Both publications are available in English and Spanish. The website for the Centre is www.whocc.no. ATC and DDD changes are published annually and are made official by the end of the year. ATC/DDD version from January 2011 has been used in the book. The ATC/DDD publications can be ordered from the WHO Collaborating Centre for Drug Statistics Methodology.

Referanser/References:

1. Forskrift om innsamling og behandling av helseopplysninger i Reseptbasert legemiddelregister (Reseptregisteret). 20-10-2003.
2. Strøm H. Reseptbasert legemiddelregister: et viktig verktøy for å oppnå detaljert legemiddelstatistikk. *Nor J Epidemiol.* 2004;14(1):53-55.
3. Furu K. Establishment of the nationwide Norwegian prescription Database (NorPD) – New opportunities for research in pharmacoepidemiology in Norway. *Nor J Epidemiol* 2008;18(2):129-36
4. Helseregisterloven [Personal Health Data Filing System Act]. Lov av 18.mai 2001
5. Rønning M, Litlekare I, Addis A et al. Recommendations for national registers of medicinal products with validated ATC codes and DDD values. *Italian J Public Health* 2006;3(1):30-35.
6. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. *Basic Clin Pharmacol Toxicol* 2010;106(2):86-94.
7. Sakshaug S (Ed). Drug Consumption in Norway 2006-2010. [Legemiddelforbruket i Norge 2006-2010] Oslo: Norwegian Institute of Public Health, 2011
8. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2011. Oslo, 2010.
9. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2011. Oslo 2010





2. Reseptregisteret 2006–2010

2.1 Utvalgte nøkkeltall fra Reseptregisteret

Reseptregisteret inneholder opplysninger fra alle landets apotek om utlevering av legemidler på resept til enkeltpersoner, til forskrivers egen praksis og til institusjoner. I 2010 ble 94 % av legemidlene i Reseptregisteret (målt i DDD) utlevert til enkeltpersoner. Leveransene til institusjoner (sykehus og sykehjem) utgjorde 4,9 % av det totale antall DDD og ca. 0,5 % av totalt antall DDD ble utlevert til bruk i forskrivers egen praksis. Salg av reseptfrie legemidler er ikke inkludert i Reseptregisteret. Reseptfritt salg utgjorde i 2010 16 % av totalt salg av legemidler i Norge målt i DDD (Kilde: Grossistbasert legemiddelstatistikk, Folkehelseinstituttet).

2. The Norwegian Prescription Database (NorPD) 2006–2010

2.1 Selected key figures from NorPD

NorPD contains information from all Norwegian pharmacies of prescriptions to individuals, to a prescriber's own practice and to institutions. In 2010, 94% of DDDs in NorPD were dispensed to individuals in ambulatory care. Deliveries to institutions (hospitals and nursing homes) amounted to 4.9% of the DDDs and about 0.5% of the DDDs were dispensed for use in the physician's practice. Sales of OTC medicines are not included in NorPD. OTC sales constitute 16% of total sales of pharmaceuticals in Norway in 2010, measured in DDDs (source: Norwegian Drug Wholesales Statistics, Norwegian Institute of Public Health).

Table 2.1.a: Number of individuals and one-year prevalence (%) of the population who had at least one prescription dispensed in Norway 2006–2010

	Women n (%)	Men n (%)	Both genders n (%)
2006	1 756 472 (74.8)	1 412 482 (61.0)	3 168 954 (68.0)
2007	1 774 921 (75.0)	1 440 496 (61.5)	3 215 417 (68.3)
2008	1 800 535 (75.3)	1 470 214 (61.8)	3 270 749 (68.6)
2009	1 839 944 (76.1)	1 523 054 (63.2)	3 362 998 (69.6)
2010	1 842 231 (75.3)	1 509 792 (61.8)	3 352 023 (68.6)




Figure 2.1: One-year prevalence (%) of the population who had at least one prescription dispensed in 2010 in Norway according to age and gender

Reseptregisteret ble opprettet 1. januar 2004, og i perioden 2004–2010 har mer enn 4,8 millioner individer blitt inkludert i NorPD med minst ett legemiddel utlevert på resept fra apotek. Antall legemiddelutleveringer etter resept til pasienter i samme periode er 248 millioner.

I 2010 fikk 69 % av den norske befolkningen utlevert minst ett legemiddel på resept, 75 % av kvinnene og 62 % av mennene (tabell 2.1.a). Krav om at pasientens fødselsnummer skal påføres resepten ble innført 1. oktober 2003. I 2004, det første driftsåret for NorPD, var andelen av resepter med ugyldig eller manglende 11-sifret fødselsnummer 3,7 %. I årene 2006–2007 lå denne andelen på rundt 2 %, og i 2008 og 2009 har den ligget på i underkant av 1,4 %. I 2010 var andelen uten gyldig fødselsnummer under 1 %. Andelen som har fått legemidler på resept gikk noe ned i 2010 (tabell 2.1.a).

Ettårsprevalensen for å få utlevert legemiddel etter resept i 2010 var lavest for begge kjønn i aldersgruppen 10–14 år (figur 2.1). Rundt 90 % av individene i alderen 70 år og eldre fikk utlevert medisiner etter resept. Hvis vi ekskluderer kvinner som kun fikk utlevert hormonelle prevensjonsmidler (ATC-kode G03A), blir prevalensen av legemiddelbruk redusert med ca 10–15 % hos kvinner i

Since January 2004 more than 4.8 million individuals have been included in NorPD with at least one prescription medication dispensed from a pharmacy. The number of prescriptions dispensed to patients in the same period (2004–2010) is 248 million.

In 2010, 69% of the Norwegian population had at least one prescription dispensed, 75% of women and 62% of men (Table 2.1.a). In 2004, the first operational year of NorPD, the proportion of prescriptions having invalid or missing personal identity number was 3.7%. In the period 2005–2007, the proportion was around 2%. The proportion of prescriptions with an invalid personal identity number has declined further to just below 1.4 % in 2008 and 2009. In 2010 the proportion was less than 1%. The annual total prevalence had a slight reduction in 2010 (see table 2.1.a).

The age-specific one year prevalence for having a drug dispensed in 2010 was lowest in both genders at about 10–14 years of age (figure 2.1). About 90 % of individuals aged 70 years and older received prescription medications. Excluding women who received only hormonal contraception for systemic use (ATC code G03A), the prevalence of drug use was reduced by about 10–15 % in women aged 15–29, although the

Table 2.1.b: One-year prevalence, or % of the population having at least one prescription dispensed, in Norway in 2010 according to the main ATC groups

ATC	Women %	Men %	Both genders %
A Alimentary tract and metabolism	16,3	12,4	14,4
B Blood and blood forming organs	11,7	12,0	11,9
C Cardiovascular system	20,6	19,3	19,9
D Dermatologicals	13,6	11,4	12,5
G Genito urinary system and sex hormones	24,2	5,3	14,8
H Systemic hormonal preparations, excl.sex hormones and insulins	10,7	5,1	7,9
J Anti-infectives for systemic use	30,5	20,7	25,6
L Anti-neoplastic and immunomodulating agents	1,7	1,4	1,6
M Musculo-skeletal system	21,1	15,8	18,4
N Nervous system	30,3	20,8	25,5
P Anti-parasitic products, insecticides and repellents	2,3	1,3	1,8
R Respiratory system	27,1	21,3	24,2
S Sensory organs	14,1	10,8	12,5
V Various	0,3	0,3	0,3

alderen 15–29 år, men fortsatt var andelen av legemiddelbrukere blant kvinner over 15 år høyere enn blant menn.

Tabell 2.1.b viser ettårsprevalens for hele befolkningen som har fått utlevert minst ett legemiddel etter resept innen hver av de 14 ATC-hovedgruppene, totalt og fordelt på kvinner og menn. De tre legemiddelgruppene som er mest brukt blant begge kjønn er midler mot infeksjoner til systemisk bruk (ATC-gruppe J), legemidler med virkning på nervesystemet (ATC-gruppe N) og legemidler som brukes for sykdommer i luftveiene (ATC-gruppe R).

Tabell 2.1.c viser en oversikt over legemidler med flest brukere i Norge i 2010.

proportion of drug users among women over 15 years of age was still higher than in men.

Table 2.1.b shows the one-year prevalence of the entire population, and among men and women, who received at least one prescription in each of the main ATC groups. The three drug groups most used in both men and women are anti-infectives (ATC group J), drugs affecting the nervous system (ATC group N) and drugs used for respiratory diseases (ATC group R).

Table 2.1.c lists the medicines with most users in Norway in 2010.

Table 2.1.c: Legemidler med flest brukere i Norge 2010 / Drugs with the highest number of users i Norway 2010

	ATC code	Active ingredient	Use	Number of individuals	Proportion (%) of the population
1	M01AB05	diclofenac	NSAID/analgesic	480 836	9.8
2	J01CE02	phenoxymethylpenicillin	Antibacterial	457 657	9.4
3	N02AA59	codeine, combinations excl. psycholeptics	Analgesic	387 362	7.9
4	B01AC06	acetylsalicylic acid	Antithrombotic	375 950	7.7
5	C10AA01	simvastatin	Cholesterol-lowering	349 727	7.2
6	N05CF01	zopiclone	Hypnotic	304 937	6.2
7	N02BE01	paracetamol	Analgesic	304 460	6.2
8	R06AE07	cetirizine	Antihistamine	282 251	5.8
9	C07AB02	metoprolol	Antihypertensive/cardiac disease	256 707	5.3
10	R05DA01	ethylmorphine	Cough suppressant	245 495	5.0
11	M01AE01	ibuprofen	Analgesic	215 577	4.4
12	R03AC02	salbutamol	Asthma/COPD	198 197	4.1
13	S01AA01	chloramphenicol	Antibacterial eyedrops	197 017	4.0
14	J01CA08	pivmecillinam	Antibacterial	185 907	3.8
15	H03AA01	levothyroxine sodium	Thyroxine supplement	176 895	3.6
16	H02AB06	prednisolone	Corticosteroid, systemic	152 176	3.1
17	R01AD09	mometasone	Anti-allergic nose spray	141 062	2.9
18	N05BA04	oxazepam	Anxiolytic	133 930	2.7
19	N05BA01	diazepam	Anxiolytic	132 542	2.7
20	J01AA02	doxycycline	Antibacterial	129 768	2.7
21	J01FA01	erythromycin	Antibacterial	129 093	2.6
22	R05CB01	acetylcysteine	Mucolytic	128 867	2.6
23	N02AX02	tramadol	Analgesic	127 881	2.6
24	J01CA04	amoxicillin	Antibacterial	127 477	2.6
25	C08CA01	amlodipine	Antihypertensive/angina pectoris	119 255	2.4
26	A02BC05	esomeprazole	Reflux oesophagitis	117 871	2.4
27	C10AA05	atorvastatin	Cholesterol-lowering	112 746	2.3
28	N06AB10	escitalopram	Antidepressant	102 602	2.1
29	A02BC02	pantoprazole	Reflux oesophagitis	102 195	2.1
30	A10BA02	metformin	Diabetes	101 623	2.1

2.2 Beskrivelse av hovedtabellene

Tabellene i del 2 i denne boken gir en oversikt over antall individer som har fått utlevert legemidler etter resept fra apotekene i Norge. Alle som har hentet ut minst ett legemiddel er inkludert, og opplysningene er fordelt på enkeltlegemidler og legemiddelgrupper. Selv om et individ har fått utlevert samme legemiddel flere ganger, telles vedkommende som bruker bare én gang. Det er kun utleveringer til individer med fullt fødselsnummer som er inkludert i tabellene i boken.

Tabellene inneholder tall for perioden 2006–2010. I tillegg er følgende opplysninger for 2010 inkludert:

- Andel kvinner (%) av totalt antall individer som har hentet ut minst én resept
- Antall individer som har hentet ut minst ett legemiddel etter resept fordelt på følgende aldersgrupper: <15, 15-44, 45-69, ≥70
- Salg i kroner fra apotek for utvalget i tabellen, dvs til individer med fullt fødselsnummer. Kronebeløpet tilsvarer reell utsalgspris fra apotek.

Tabellene er sortert i henhold til ATC-systemet (se nærmere beskrivelse på s. 15). De aller fleste ATC-grupper med legemidler på det norske markedet er inkludert. Legemidler til pasienter i sykehus eller sykehjem er ikke tilgjengelig på individnivå i Reseptregisteret. Det totale antall legemiddelbrukere vil derfor være høyere enn det som fremgår av tabellene for en del legemidler, og spesielt for legemidler som brukes mye i sykehus. Vi har valgt å utelate noen ATC-grupper. Dette er legemidler som hovedsaklig brukes i sykehus eller institusjoner. Følgende ATC-grupper er utelatt:

B05	Blodsubstitutter og infeksjonsløsninger
B06	Andre hematologiske midler
J06	Immunsera og immunoglobuliner
J07	Vaksiner
L01	Antineoplastiske midler
M03A	Perifert virkende muskelrelaxerende midler
N01	Anestetika
S01H	Lokalanestetika
S01J	Diagnostika
S01L	Midler ved okulær vaskulær sykdom
V	Varia (kun ATC-gruppe V01 <i>Allergener</i> er inkludert i tabellen)

Reseptfrie legemidler skrives i noen tilfeller også ut på resept, men i hovedsak vil salg av reseptfrie legemidler ikke være inkludert i denne boken. Salg av reseptfrie legemidler, både i og utenom apotek, er med i den grossistbaserte legemiddelstatistikken, hvor tallmaterialet blir publisert i publikasjonen Legemiddelforbruket i Norge (se også s. 15). I tabellene i del 2 i denne boken er

2.2 Description of the main tables

The tables in Section 2 of this book provide an overview of the number of individuals who have had prescriptions dispensed from pharmacies in Norway. Anyone who has had at least one prescription dispensed is included and the data are given for each medicinal substance and for groups of medicines. Even if an individual has been given the same medicine several times, he or she is counted as a user only once. Only dispensing data to individuals with a personal identification number are included in the tables.

The tables contain figures for the period 2006–2010. In addition, the following information for 2010 includes:

- Share of women (%) of the total number of individuals who have had at least one prescription dispensed
- The number of individuals who have had at least one prescription dispensed in the following age groups: <15, 15-44, 45-69, ≥ 70
- Sales in Norwegian kroner (NOK), i.e. for prescriptions dispensed to individuals with a personal identity number. The amount in NOK corresponds to the actual retail price from the pharmacy.

The tables are arranged according to the ATC system (see further description in p 15). The majority of ATC groups containing drugs on the Norwegian market are included. Drugs use by individuals in hospitals and nursing homes is not included at the individual level in the Norwegian Prescription Database. The total number of drug users will therefore be higher than the figures in the tables for a number of drugs, particularly for drugs that are frequently used in hospitals or institutions. We have chosen to exclude some ATC groups in this book that are mainly used in hospitals or institutions. The following ATC groups have been:

B05	Blood substitutes and perfusion solutions
B06	Other hematological agents
J06	Immune sera and immunoglobulins
J07	Vaccines
L01	Antineoplastic agents
M03A	Muscle relaxants, peripherally acting agents
N01	Anesthetics
S01H	Local anesthetics
S01J	Diagnostic agents
S01L	Ocular vascular disorder agents
V	Various (ATC group V01 Allergens is included in the table)

Non-prescription medicines are sometimes prescribed, but the majority of the OTC medicine sales will not be included in the tables in this book. Sales of OTC

Figure 2.2: The report generator at www.reseptregisteret.no (English version at www.norpd.no)

det tatt med en fotnote tilknyttet de ulike ATC-kodene hvor det i tillegg også selges reseptfrie pakninger. I 2010 utgjorde reseptfrie legemidler en andel på 16 % av totalt antall solgte doser (DDD). Disse andelene har holdt seg relativt konstant over tid.

De fleste legemidler som forskrives på resept, har godkjent markedsføringstillatelse i Norge. Leger har imidlertid anledning til å forskrive legemidler uten markedsføringstillatelse etter godkjenningssfritak fra Statens legemiddelverk. Det finnes også enkelte legemidler som inngår i en såkalt negativliste, og som bare kan utleveres etter spesiell tillatelse fra Legemiddelverket. Legemidler som er forskrevet på resept etter søknad om godkjenningssfritak eller etter spesiell tillatelse fra Legemiddelverket, er inkludert i tabellene i boken. Antall individer som behandles med disse legemidlene vil ofte være lavt. Dersom antall individer er lavere enn fem, angis <5 i tabellene.

Mange individer bruker flere legemidler. Vær derfor oppmerksom på at man ikke kan summere antall brukere av ulike legemidler, eller legemiddelgrupper i tabellene, for å finne totalt antall brukere av to eller flere legemidler. Statistikk på aggregert nivå i tabellene vil imidlertid inneholde brukere av minst ett av legemidlene i undernivåene. For eksempel viser tallene at totalt antall brukere av sovemidler (ATC-gruppe N05C) er lavere enn summen av antall brukere av de enkelte legemidlene som er klassifisert i N05C.

medicines are, however, included in the Norwegian Drug Wholesales Statistics database and the figures are published in "Drug Consumption in Norway" (see also page p 15). A footnote is used in the tables in part 2 of this book in the various ATC codes where OTC medicines are available in Norway. In 2010, OTC medicines had a share of 16% of total sales measured in DDDs. These shares have remained almost unchanged over time.

Most prescribed medicines have an approved marketing authorisation in Norway. However, physicians can prescribe drugs without approved marketing authorisation. There are also some medicines that are part of a so-called "negative list" which can only be prescribed by special permission from the Norwegian Medicines Agency. Drugs that are prescribed on licence or by special permission are included in the tables in the book. The number of individuals who are prescribed these medicines is often low. If the number of individuals is less than five, <5 is used in the tables.

Many individuals use more than one medicine. Please be aware that it is not possible to add together the number of users of various drugs or drug groups in the tables to find the total number of users of two or more drugs. Statistics on the aggregate level in the tables will, however, include the use of at least one of the drugs in the included drug groups. For example,

Det betyr at noen individer har fått utlevert mer enn en type sovemiddel i løpet av et år, enten ved bruk av flere sovemidler samtidig eller ved bytte fra ett middel til et annet.

Reseptregisterets nettsider: www.reseptregisteret.no
Reseptregisteret har eget nettsted som kan brukes sammen med tabellene i denne rapporten for å få kompletterende informasjon. På søkesidene (Figure 2.2) kan man selv lage rapporter over antall brukere av et bestemt legemiddel eller en legemiddelgruppe. Dette kan gjøres ved søk på forhåndsdefinerte legemiddelgrupper, via ATC systemet eller ved søk på virkestoff eller produktnavn.

Følgende data om legemiddelbruk kan hentes ut fra nettstedet:

- Antall brukere, eventuelt fordelt på kjønn, 10 års aldersgrupper, fylke eller helseregion
- Antall brukere per 1 000 innbyggere (prevalens per 1 000)
- Omsetning i kroner
- Omsetning i doser (DDD – definerte døgndoser)
- Befolningsgrunnlag i statistikken, eventuelt fordelt på kjønn, alder, fylke eller helseregion

Data er tilgjengelige fra 2004, og nettstedet oppdateres årlig med foregående års tall.

Tallene i denne rapporten kan avvike noe fra tallene som finnes på nettstedet. Årsaken er at uttrekket av data til boken er gjort på et noe senere tidspunkt enn datagrunnlaget for nettsiden. Rapporteringen av data fra apotek til Reseptregisteret er for en liten andel av reseptutleveringene forsinket. Forsinkelsen kan være på noen måneder, og dette innebærer at noen data fra foregående år blir rapportert på etterskudd. I tillegg er individer uten kjent bostedsadresse utelatt fra nettsiden, men inkludert i tabellene i denne rapporten. Nettstedet finnes også i engelsk versjon (www.norpd.no).

Utlevering av data fra Reseptregisteret

Det er mulig å søke om data fra Reseptregisteret til forskning eller til andre formål som er i henhold til formålet for Reseptregisteret. Søknadsskjema er tilgjengelige på nettstedet til FHI (www.fhi.no), og alle søknader om tilgang til data fra FHI skal sendes til datatilgang@fhi.no. Dataene er gratis, men kostnader i forbindelse med administrativ håndtering og filbehandling må påregnes.

the figures in the tables show that the total number of users of sleeping pills (ATC group N05C) is lower than the sum of the number of users of the individual medicines that are classified in N05C. This means that some individuals have been given more than one type of sleeping pill during a year, either through the use of more than one simultaneously or by switching from one agent to another.

The NorPD website: www.norpd.no

The Norwegian Prescription Database has its own website which can be used together with the tables in this report for complementary information. On the website (Figure 2.2), one can even create reports on the number of users of a particular drug or drug group. This can be done by searching for pre-defined drug groups, through the ATC system or by searching the active substance or product name.

The following data on drug use can be extracted from the website:

- Number of users, split by gender, 10-year age groups, county or health region
- Number of users per 1 000 population (prevalence per 1 000)
- Turnover in NOK (pharmacy retail price)
- Turnover in doses (DDD - defined daily doses)
- Population base for the statistics, split by gender, age, county or health region

Data are available from 2004 with an annual update for the preceding year.

The figures in this book may differ slightly from the numbers found on the website. This is because the data extraction for the book was made at a later date than the data on the website. Reporting of data from the pharmacy to NorPD is delayed for a minor number of prescriptions. The delay may be a few months, meaning that reports of data from a year can arrive the following year. Besides, individuals without known address are included in the tables in this book but not on the website.

Access to data from NorPD

It is possible to apply for data from the Norwegian Prescription Database for research or for other purposes which are according to the objectives of NorPD. Application forms are available on the website of NIPH (www.fhi.no) and all applications for access to data from NIPH should be sent to Datatilgang@fhi.no. The data is free of charge, but fees for administration and file processing will be required.

Beregning av prevalens per 1000 innbyggere
Prevalens er ofte definert som antall individer som har fått utlevert ett legemiddel per 1000 innbyggere. Antall individer oppgitt i tabellene kan benyttes til å beregne prevalens av legemiddelbruken i befolkningen. Hvordan dette kan gjøres er vist i eksemplet nedenfor.

Antall individer som fikk minst ett hjerte-/karmiddel (ATC-gruppe C) i Norge i 2010: 975 001

Antall innbyggere i Norge per 1. juli 2010: 4 888 946

Beregning av prevalens (per 1000) for brukere av hjerte-/karmidler i Norge i 2010:

$$\frac{\text{Antall individer} \times 1000}{\text{Antall innbyggere}} = \frac{975\,001 \times 1000}{4\,888\,946} = 199,4 \text{ individer per } 1000 \text{ innbyggere}$$

På s 95 finnes tabeller over befolkningstallet i Norge for årene 2006–2010. Befolkningstallet for de fire aldersgruppene i tabellene er også angitt. Det brukes middelfolkemengden for hvert år, dvs folketallet per 1. juli, beregnet ut fra Statistisk Sentralbyrås folketall 1.1 og 31.12. Alder er definert som den alder individet har ved slutten av året (utleveringsår minus fødselsår).

Calculation of prevalence per 1000 inhabitants
Prevalence is often defined as the number of individuals per 1000 inhabitants who have had at least one prescription dispensed in a pharmacy during a specific time period. The number of individuals listed in the tables can be used to calculate the prevalence of drug users in the population. Please read the following example:

The number of individuals who had at least one cardiovascular drug dispensed (ATC group C) in Norway in 2010: 975 001

The number of inhabitants in Norway as of 1st July 2010: 4 888 946

Calculation of the prevalence (per 1000) of users of cardiovascular drugs in Norway in 2010:

$$\frac{\text{The number of individuals} \times 1000}{\text{The number of inhabitants}} = \frac{975\,001 \times 1000}{4\,888\,946} = 199.4 \text{ individuals per } 1000 \text{ inhabitants}$$

The population in Norway for the years 2006–2010 is shown on p 95. The population of the four age groups in the tables is also provided. The population as of 1st July each year is used, calculated from the population figures by Statistics Norway from 1st January and 31st December. Age is defined as the age of the individual at the end of the year (year of dispensing minus birth year).

2.3 ATC main groups

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
A ALIMENTARY TRACT AND METABOLISM	570 945	610 748	647 819	678 398	702 259	57	19 933	160 673	313 032	208 621	1 357 565
B BLOOD AND BLOOD FORMING ORGANS	501 273	523 020	541 138	562 339	581 244	49	2 704	51 475	251 186	275 879	728 260
C CARDIOVASCULAR SYSTEM	849 724	883 033	917 223	945 882	975 001	52	4 987	92 581	506 802	370 631	1 979 042
D DERMATOLOGICALS	585 104	582 681	589 447	587 805	611 121	54	78 854	226 590	205 108	100 569	225 688
G GENITO URINARY SYSTEM AND SEX HORMONES	668 719	678 902	692 728	703 438	721 693	82	3 315	407 249	220 074	91 055	838 022
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	323 880	342 524	357 069	375 460	387 736	68	15 937	104 181	165 685	101 933	415 842
J ANTIINFECTIVES FOR SYSTEMIC USE	1 201 347	1 236 736	1 247 162	1 394 462	1 251 635	60	158 322	508 894	399 957	184 462	657 093
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	59 805	65 309	70 154	72 794	76 644	54	1 185	16 358	35 962	23 139	2 175 554
M MUSCULO-SKELETAL SYSTEM	906 519	915 414	907 359	891 118	901 482	57	12 992	328 664	407 600	152 226	291 165
N NERVOUS SYSTEM	1 143 324	1 181 693	1 208 793	1 230 906	1 248 124	59	30 059	396 661	536 511	284 893	2 607 070
P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	83 433	88 000	89 343	86 714	88 665	64	2 964	41 883	33 915	9 903	31 623
R RESPIRATORY SYSTEM	1 120 213	1 153 020	1 151 927	1 183 764	1 183 368	56	186 697	428 370	409 123	159 178	1 494 767
S SENSORY ORGANS	575 548	585 905	596 098	596 286	609 134	57	125 507	176 979	180 669	125 979	319 907
V VARIOUS	9 023	10 022	11 571	13 317	15 892	48	2 853	5 990	4 577	2 472	65 934

2.4 ATC group A – Alimentary tract and metabolism

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK	
	Number of individuals						Number of individuals per age group					
	<15	15–44	45–69	≥70								
A	ALIMENTARY TRACT AND METABOLISM	570 945	610 748	647 819	678 398	702 259	57	19 933	160 673	313 032	208 621	1 357 565
A01	STOMATOLOGICAL PREPARATIONS	17 449	18 366	18 177	11 204	6 460	58	322	2 207	2 420	1 511	994
A01A	STOMATOLOGICAL PREPARATIONS	17 449	18 366	18 177	11 204	6 460	58	322	2 207	2 420	1 511	994
A01AA	Caries prophylactic agents	557	601	618	665	776	66	<5	165	267	342	152
A01AA01	sodium fluoride ¹⁾	557	601	618	665	776	66	<5	165	267	342	152
A01AB	Antiinfectives and antiseptics for local oral treatment	9 383	8 913	8 944	8 998	4 087	56	187	1 300	1 627	973	416
A01AB02	hydrogen peroxide ¹⁾	287	53	<5	0	<5	67	<5	0	<5	<5	1
A01AB03	chlorhexidine ¹⁾	2 359	2 283	2 312	2 293	2 539	51	170	961	886	522	207
A01AB04	amphotericin B	6 667	6 514	6 554	6 690	1 529	64	14	331	737	447	196
A01AB09	miconazole	9	12	<5	5	<5	-	0	<5	0	0	10
A01AB11	various ¹⁾	16	11	18	22	26	50	<5	9	6	9	2
A01AB17	metronidazole	109	106	108	45	0	-	0	0	0	0	0
A01AC	Corticosteroids for local oral treatment	7 496	8 821	8 434	1 025	1 154	65	109	385	461	199	293
A01AC01	triamcinolone	7 496	8 821	8 434	1 025	1 154	65	109	385	461	199	293
A01AD	Other agents for local oral treatment	359	402	550	598	507	49	26	371	90	20	132
A01AD01	epinephrine	10	6	7	6	9	22	0	<5	5	<5	8
A01AD02	benzylamine	314	368	515	562	474	49	20	355	81	18	122
A01AD11	various	35	28	28	30	24	63	6	13	<5	<5	2
A02	DRUGS FOR ACID RELATED DISORDERS	255 223	277 446	298 394	316 608	338 590	54	5 787	74 201	162 232	96 370	373 801
A02A	ANTACIDS	4 587	4 499	4 296	4 537	4 689	43	148	1 077	1 614	1 850	5 540
A02AC	Calcium compounds	1 395	1 414	1 398	1 293	1 229	36	10	163	457	599	863
A02AC01	calcium carbonate ¹⁾	1 395	1 414	1 398	1 293	1 229	36	10	163	457	599	863
A02AD	Combinations and complexes of aluminium, calcium and magnesium compounds	1 859	1 547	1 240	1 495	1 484	60	69	680	437	298	214
A02AD01	ordinary salt combinations ¹⁾	1 859	1 547	1 240	1 495	1 484	60	69	680	437	298	214
A02AH	Antacids with sodium bicarbonate	1 935	2 107	2 166	2 187	2 340	34	34	269	879	1 158	4 248
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)	252 594	274 929	296 145	314 286	336 183	54	5 674	73 667	161 490	95 352	368 261
A02BA	H₂-receptor antagonists	59 044	60 233	59 188	58 629	57 782	58	1 071	15 515	26 444	14 752	19 603
A02BA01	cimetidine	8 509	6 270	356	56	46	59	0	<5	27	15	23
A02BA02	ranitidine ¹⁾	44 651	50 376	55 440	55 483	54 962	59	1 056	15 109	25 085	13 712	17 009

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
A02BA03 famotidine ¹⁾	4 459	3 920	3 448	2 878	2 546	54	10	319	1 242	975	2 477
A02BA07 ranitidine bismuth citrate	2 202	247	<5	0	0	-	0	0	0	0	0
A02BA53 famotidine, combinations ¹⁾	264	306	351	378	367	55	5	115	159	88	94
A02BB Prostaglandins	250	237	267	248	259	81	0	130	85	44	201
A02BB01 misoprostol	250	237	267	248	259	81	0	130	85	44	201
A02BC Proton pump inhibitors	205 954	227 639	250 318	269 753	292 680	53	4 708	61 901	142 139	83 932	347 920
A02BC01 omeprazole	27 017	40 041	44 880	46 873	47 040	54	2 917	9 243	20 886	13 994	49 901
A02BC02 pantoprazole ¹⁾	12 691	57 054	74 964	85 175	102 195	53	389	23 058	49 117	29 631	51 898
A02BC03 lansoprazole	37 108	48 545	50 409	50 018	48 794	51	389	9 410	24 647	14 348	33 242
A02BC05 esomeprazole	139 221	117 306	108 180	111 446	117 871	55	1 379	25 810	58 966	31 716	212 879
A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)	1 674	1 685	1 837	1 807	1 906	61	177	607	655	467	536
A02BX02 sucralfate	439	378	424	403	366	59	<5	97	146	119	278
A02BX13 alginic acid	1 243	1 312	1 424	1 414	1 546	62	173	513	509	351	258
A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS	52 588	54 609	58 680	60 447	62 461	71	1 702	21 266	23 307	16 186	13 455
A03A DRUGS FOR FUNCTIONAL BOWEL DISORDERS	3 522	3 420	3 325	3 435	3 562	58	191	822	1 152	1 397	1 405
A03AA Synthetic anticholinergics, esters with tertiary amino group	10	34	45	28	29	69	0	9	18	<5	42
A03AA04 mebeverine	10	34	42	27	29	69	0	9	18	<5	42
A03AA07 dicycloverine	0	0	<5	<5	0	-	0	0	0	0	0
A03AB Synthetic anticholinergics, quaternary ammonium compounds	36	41	32	112	130	47	<5	8	58	63	93
A03AB02 glycopyrronium	22	28	25	105	126	48	<5	6	56	63	90
A03AB05 propantheline	14	13	7	7	<5	-	0	<5	<5	0	3
A03AD Papaverine and derivatives	36	41	8	0	<5	100	0	<5	0	0	1
A03AD01 papaverine	36	41	8	0	<5	100	0	<5	0	0	1
A03AE Drugs acting on serotonin receptors	21	19	<5	0	0	-	0	0	0	0	0
A03AE02 tegaserod	21	19	<5	0	0	-	0	0	0	0	0
A03AX Other drugs for functional bowel disorders	3 426	3 290	3 239	3 302	3 401	58	190	802	1 077	1 332	1 270
A03AX13 silicones	3 426	3 290	3 239	3 302	3 401	58	190	802	1 077	1 332	1 270
A03B BELLADONNA AND DERIVATIVES, PLAIN	2 490	1 305	1 101	1 382	1 617	61	10	577	739	291	658
A03BA Belladonna alkaloids, tertiary amines	2 270	1 050	861	1 098	1 297	58	8	460	588	241	451

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
A03BA01 atropine	31	33	27	26	22	32	0	<5	12	7	25
A03BA03 hyoscyamine	2 243	1 017	834	1 072	1 276	59	8	457	577	234	426
A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds	231	259	242	285	321	71	<5	117	152	50	207
A03BB01 butylscopolamine	210	238	223	267	300	70	<5	106	143	49	190
A03BB03 methylscopolamine	21	21	19	18	23	83	0	11	11	<5	16
A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS	19	30	27	18	19	32	0	<5	12	5	21
A03CA Synthetic anticholinergic agents in combination with psycholeptics	19	30	27	18	19	32	0	<5	12	5	21
A03CA02 clidinium and psycholeptics	19	30	27	18	19	32	0	<5	12	5	21
A03F PROPULSIVES	47 358	50 518	54 797	56 319	58 069	72	1 512	20 049	21 727	14 781	11 371
A03FA Propulsives	47 358	50 518	54 797	56 319	58 069	72	1 512	20 049	21 727	14 781	11 371
A03FA01 metoclopramide	47 212	50 382	54 676	56 212	57 964	72	1 494	20 026	21 685	14 759	10 740
A03FA02 cisapride	148	134	116	93	83	61	18	22	32	11	531
A03FA03 domperidone	24	35	39	44	55	56	6	12	23	14	100
A04 ANTIEMETICS AND ANTINAUSEANTS	10 838	12 190	12 918	13 054	13 782	59	270	2 255	7 797	3 460	32 034
A04A ANTIEMETICS AND ANTINAUSEANTS	10 838	12 190	12 918	13 054	13 782	59	270	2 255	7 797	3 460	32 034
A04AA Serotonin (5HT₃) antagonists	9 243	9 738	10 498	10 867	11 426	58	204	1 403	6 693	3 126	27 116
A04AA01 ondansetron	8 328	9 013	10 010	10 437	11 142	58	204	1 383	6 513	3 042	25 720
A04AA02 granisetron	<5	<5	<5	<5	0	0	0	0	0	0	0
A04AA03 tropisetron	1 241	1 050	755	613	440	65	0	45	283	112	1 384
A04AA05 palonosetron	0	82	6	<5	5	100	0	<5	<5	<5	12
A04AD Other antiemetics	1 953	3 105	3 138	3 193	3 880	67	66	1 140	2 184	490	4 918
A04AD01 scopolamine	1 597	2 446	2 412	2 111	2 128	60	65	803	928	332	599
A04AD05 metopimazine	43	23	<5	0	0	-	0	0	0	0	0
A04AD10 dronabinol	0	<5	7	5	<5	100	0	0	<5	0	12
A04AD12 aprepitant	324	642	719	1 078	1 761	76	<5	339	1 262	159	4 308
A05 BILE AND LIVER THERAPY	1 254	1 457	1 752	1 913	2 020	72	92	676	940	312	8 638
A05A BILE THERAPY	1 254	1 457	1 752	1 913	2 020	72	92	676	940	312	8 638
A05AA Bile acid preparations	1 247	1 445	1 749	1 909	2 015	72	92	675	939	309	8 634
A05AA02 ursodeoxycholic acid	1 247	1 445	1 749	1 909	2 015	72	92	675	939	309	8 634
A05AX Other drugs for bile therapy	7	12	<5	<5	5	100	0	<5	<5	<5	3
A06 LAXATIVES	23 664	26 332	28 855	31 408	44 190	55	3 694	6 712	15 999	17 785	20 355

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
A06A LAXATIVES	23 664	26 332	28 855	31 408	44 190	55	3 694	6 712	15 999	17 785	20 355
A06AA Softeners, emollients	79	88	69	105	112	42	18	14	42	38	50
A06AA01 liquid paraffin ¹⁾	79	88	69	105	112	42	18	14	42	38	50
A06AB Contact laxatives	10 692	11 940	12 341	13 383	15 045	54	287	1 645	5 250	7 863	3 032
A06AB02 bisacodyl ¹⁾	3 612	3 842	3 847	3 858	4 054	57	62	522	1 202	2 268	692
A06AB06 senna glycosides ¹⁾	2 049	2 138	2 002	2 020	2 119	50	43	191	623	1 262	404
A06AB08 sodium picosulfate ¹⁾	5 966	7 092	7 574	8 584	10 072	54	186	1 022	3 860	5 004	1 915
A06AB20 contact laxatives in combination ¹⁾	<5	11	6	<5	6	100	0	0	<5	<5	3
A06AB53 dantron, combinations	<5	<5	<5	<5	<5	0	0	0	<5	0	2
A06AB56 senna glycosides, combinations ¹⁾	15	10	17	17	10	70	0	<5	<5	<5	2
A06AB58 sodium picosulfate, combinations ¹⁾	0	0	0	0	31	55	0	5	21	5	14
A06AC Bulk producers	1 680	1 586	1 508	1 772	1 994	60	42	529	755	668	541
A06AC01 ispaghula (psylla seeds) ¹⁾	1 665	1 575	1 505	1 772	1 994	60	42	529	755	668	541
A06AC51 ispaghula, combinations ¹⁾	16	11	<5	0	0	-	0	0	0	0	0
A06AD Osmotically acting laxatives	12 281	14 700	17 176	18 687	30 413	54	3 205	4 389	11 636	11 183	9 227
A06AD11 lactulose ¹⁾	10 145	12 320	13 475	13 507	14 461	51	760	1 707	5 194	6 800	3 519
A06AD12 lactitol	86	58	68	78	59	58	42	13	<5	<5	55
A06AD15 macrogol	0	0	0	0	45	60	43	<5	0	0	29
A06AD17 sodium phosphate ¹⁾	901	602	923	847	9 638	57	10	1 783	5 245	2 600	1 972
A06AD65 macrogol, combinations ¹⁾	1 395	2 086	3 327	4 947	7 271	56	2 446	986	1 624	2 215	3 653
A06AG Enemas	4 310	4 453	4 522	4 649	4 891	48	521	1 061	1 613	1 696	6 197
A06AG02 bisacodyl ¹⁾	1 523	1 574	1 468	1 475	1 409	46	35	398	549	427	706
A06AG04 glycerol ¹⁾	652	649	689	772	827	47	218	189	220	200	2 553
A06AG10 docusate sodium, incl. combinations ¹⁾	1 155	1 137	1 213	1 217	1 394	46	81	296	474	543	1 556
A06AG11 laurilsulfate, incl. combinations ¹⁾	1 324	1 475	1 511	1 567	1 647	49	207	261	523	656	1 382
A06AH Peripheral opioid receptor antagonists	0	0	18	164	197	47	0	10	122	65	1 307
A06AH01 methylnaltrexone bromide	0	0	18	164	197	47	0	10	122	65	1 307
A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS	54 523	55 436	60 675	62 567	69 743	58	6 692	19 478	28 119	15 454	115 398
A07A INTESTINAL ANTIINFECTIVES	21 600	21 049	24 718	25 617	31 177	64	6 181	7 712	10 589	6 695	11 904
A07AA Antibiotics	21 600	21 049	24 718	25 617	31 177	64	6 181	7 712	10 589	6 695	11 904

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
A07AA02 nystatin	21 449	20 894	24 493	25 375	30 708	64	6 172	7 508	10 416	6 612	10 721
A07AA06 paromomycin	44	49	90	81	154	75	6	86	59	<5	358
A07AA09 vancomycin	113	123	158	177	182	55	<5	31	63	84	585
A07AA11 rifaximin	0	0	0	<5	184	72	0	107	73	<5	240
A07B INTESTINAL ADSORBENTS	121	134	146	95	80	43	12	32	17	19	10
A07BA Charcoal preparations	121	134	146	95	80	43	12	32	17	19	10
A07BA01 medicinal charcoal ¹⁾	121	134	146	95	80	43	12	32	17	19	10
A07C ELECTROLYTES WITH CARBOHYDRATES	407	281	118	182	259	52	139	64	37	19	171
A07CA Oral rehydration salt formulations ¹⁾	407	281	118	182	259	52	139	64	37	19	171
A07D ANTIPROPULSIVES	14 084	15 085	15 925	16 123	16 720	56	145	3 607	7 280	5 688	6 504
A07DA Antipropulsives	14 084	15 085	15 925	16 123	16 720	56	145	3 607	7 280	5 688	6 504
A07DA01 diphenoxylate	<5	<5	<5	<5	<5	-	0	0	<5	0	18
A07DA02 opium	51	41	99	94	124	58	0	14	59	51	243
A07DA03 loperamide ¹⁾	14 056	15 017	15 718	15 828	16 449	56	145	3 524	7 157	5 623	6 180
A07DA53 loperamide, combinations ¹⁾	0	76	221	326	294	51	0	88	136	70	63
A07E INTESTINAL ANTIINFLAMMATORY AGENTS	19 924	20 618	21 364	21 914	22 738	52	213	8 117	10 905	3 503	93 649
A07EA Corticosteroids acting locally	4 093	4 407	4 806	5 014	5 209	59	59	1 882	2 399	869	14 458
A07EA01 prednisolone	1 041	975	1 002	1 011	1 173	48	14	473	523	163	1 123
A07EA02 hydrocortisone	1 078	1 159	1 195	1 233	1 154	60	9	501	514	130	1 206
A07EA06 budesonide	2 176	2 480	2 820	2 972	3 187	61	41	1 070	1 464	612	12 129
A07EB Antiallergic agents, excl. corticosteroids	69	71	63	54	53	70	17	13	22	<5	335
A07EB01 cromoglicic acid	69	71	63	54	53	70	17	13	22	<5	335
A07EC Aminosalicylic acid and similar agents	18 078	18 442	18 949	19 275	19 902	49	171	7 287	9 572	2 872	78 856
A07EC01 sulfasalazine	6 854	6 613	6 461	6 194	6 104	53	5	1 554	3 419	1 126	7 431
A07EC02 mesalazine	10 754	11 301	11 965	12 549	13 314	48	165	5 534	5 947	1 668	66 468
A07EC03 olsalazine	476	463	494	488	494	46	<5	181	227	82	1 711
A07EC04 balsalazide	862	890	858	809	750	46	<5	331	333	84	3 246
A07F ANTIDIARRHEAL MICROORGANISMS	66	63	302	694	1 252	74	29	668	475	80	2 574
A07FA Antidiarrheal microorganisms	66	63	302	694	1 252	74	29	668	475	80	2 574
A07FA01 lactic acid producing organisms	0	0	204	581	918	74	11	527	362	18	2 015
A07FA02 saccharomyces boulardii	66	63	98	116	283	71	9	112	105	57	195

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
A08 ANTI OBESITY PREPARATIONS, EXCL. DIET PRODUCTS	33 419	36 776	37 873	38 343	19 166	78	6	8 974	9 115	1 071	27 433
A08A ANTI OBESITY PREPARATIONS, EXCL. DIET PRODUCTS	33 419	36 776	37 873	38 343	19 166	78	6	8 974	9 115	1 071	27 433
A08AA Centrally acting antiobesity products	16 358	17 850	22 024	25 710	5 782	83	<5	3 446	2 198	137	1 766
A08AA10 sibutramine	16 358	17 850	22 024	25 710	5 782	83	<5	3 446	2 198	137	1 766
A08AB Peripherally acting antiobesity products	18 083	16 710	14 563	14 540	14 571	77	5	6 195	7 401	970	25 666
A08AB01 orlistat ¹⁾	18 083	16 710	14 563	14 540	14 571	77	5	6 195	7 401	970	25 666
A08AX Other antiobesity drugs	1 033	5 242	4 206	<5	<5	100	0	<5	0	0	1
A08AX01 rimonabant	1 033	5 242	4 206	<5	<5	100	0	<5	0	0	1
A09 DIGESTIVES, INCL. ENZYMES	5 173	5 027	5 053	5 126	5 479	57	132	894	2 642	1 811	16 531
A09A DIGESTIVES, INCL. ENZYMES	5 173	5 027	5 053	5 126	5 479	57	132	894	2 642	1 811	16 531
A09AA Enzyme preparations	5 120	4 962	4 965	5 070	5 441	57	132	889	2 628	1 792	16 493
A09AA02 multienzymes (lipase, protease etc.)	5 120	4 962	4 965	5 070	5 441	57	132	889	2 628	1 792	16 493
A09AB Acid preparations	78	76	104	65	50	76	0	6	21	23	22
A09AB01 glutamic acid hydrochloride ¹⁾	71	58	66	52	44	80	0	5	18	21	22
A09AB03 hydrochloric acid ¹⁾	7	<5	<5	<5	6	50	0	<5	<5	<5	0
A09AB04 citric acid	0	15	35	10	0	0	0	0	0	0	0
A09AC Enzyme and acid preparations, combinations	0	0	0	0	15	80	0	11	<5	0	15
A09AC02 multienzymes and acid preparations	0	0	0	0	15	80	0	11	<5	0	15
A10 DRUGS USED IN DIABETES	124 659	131 977	139 100	145 677	152 050	45	1 840	22 765	77 015	50 430	516 924
A10A INSULINS AND ANALOGUES	48 126	49 356	51 156	52 603	54 008	44	1 819	13 865	24 062	14 262	359 919
A10AB Insulins and analogues for injection, fast-acting	29 765	30 993	32 514	33 562	34 869	43	1 811	12 592	14 934	5 532	128 749
A10AB01 insulin (human)	4 558	2 536	2 184	1 823	1 604	41	26	345	835	398	3 726
A10AB03 insulin (pork)	16	<5	<5	0	0	-	0	0	0	0	0
A10AB04 insulin lispro	8 749	8 632	8 672	8 615	8 834	42	151	4 181	3 688	814	37 683
A10AB05 insulin aspart	19 283	21 086	22 740	23 900	25 153	43	1 693	8 381	10 691	4 388	86 102
A10AB06 insulin glulisine	0	<5	145	270	375	47	<5	154	179	39	1 238
A10AC Insulins and analogues for injection, intermediate-acting	35 491	34 030	33 505	33 129	32 511	43	753	6 466	15 181	10 111	112 063
A10AC01 insulin (human)	35 482	34 025	33 503	33 129	32 511	43	753	6 466	15 181	10 111	112 063

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
A10AC03 insulin (pork)	19	7	<5	0	0	-	0	0	0	0	0
A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting	10 379	10 253	10 261	9 736	9 112	44	10	723	4 430	3 949	45 326
A10AD01 insulin (human)	940	43	33	17	<5	0	0	0	0	<5	33
A10AD04 Insulin lispro	803	763	750	672	647	43	<5	118	337	189	3 100
A10AD05 insulin aspart	9 389	9 482	9 506	9 075	8 476	44	7	605	4 100	3 764	42 193
A10AE Insulins and analogues for injection, long-acting	6 221	8 144	9 845	11 310	13 694	46	691	5 830	5 709	1 464	73 781
A10AE03 insulin (pork)	0	0	<5	<5	<5	0	0	<5	0	0	11
A10AE04 insulin glargine	4 025	5 137	6 167	6 958	8 431	46	247	3 706	3 540	938	41 432
A10AE05 insulin detemir	2 300	3 102	3 802	4 493	5 526	46	464	2 249	2 272	541	32 338
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	91 944	98 919	105 412	111 436	117 281	45	24	10 455	64 147	42 655	157 006
A10BA Biguanides	74 126	81 208	88 638	95 537	101 623	46	14	9 719	57 534	34 356	54 499
A10BA02 metformin	74 126	81 208	88 638	95 537	101 623	46	14	9 719	57 534	34 356	54 499
A10BB Sulfonamides, urea derivatives	45 398	46 457	47 056	47 349	46 107	42	11	2 314	23 613	20 169	21 271
A10BB01 glibenclamide	2 377	2 127	1 912	1 738	1 539	45	10	56	669	804	833
A10BB02 chlorpropamide	<5	<5	<5	<5	<5	50	0	0	<5	0	4
A10BB07 glipizide	6 522	6 094	5 707	5 229	4 806	43	0	133	2 034	2 639	2 869
A10BB12 glimepiride	36 989	38 632	39 866	40 684	40 023	42	<5	2 133	21 042	16 847	17 566
A10BD Combinations of oral blood glucose lowering drugs	1 940	2 680	2 652	3 852	8 217	37	0	714	5 589	1 914	30 925
A10BD03 metformin and rosiglitazone	1 940	2 680	2 641	2 575	2 284	37	0	128	1 504	652	7 381
A10BD04 glimepiride and rosiglitazone	0	0	<5	<5	0	-	0	0	0	0	0
A10BD05 metformin and pioglitazone	0	0	<5	27	32	34	0	<5	25	5	168
A10BD07 metformin and sitagliptin	0	0	0	318	2 185	36	0	176	1 524	485	7 033
A10BD08 metformin and vildagliptin	0	0	10	1 068	4 790	37	0	460	3 277	1 053	16 343
A10BF Alpha glucosidase inhibitors	1 232	1 100	988	922	813	45	<5	37	410	365	1 235
A10BF01 acarbose	1 232	1 100	988	922	813	45	<5	37	410	365	1 235
A10BG Thiazolidinediones	6 437	6 461	5 719	5 401	4 671	42	0	296	2 919	1 456	18 824
A10BG02 rosiglitazone	5 053	5 008	4 193	3 798	3 103	43	0	173	1 855	1 075	11 004
A10BG03 pioglitazone	1 431	1 515	1 568	1 641	1 779	38	0	139	1 197	443	7 820
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors	0	143	798	1 752	6 467	42	0	604	4 200	1 663	21 749
A10BH01 sitagliptin	0	143	793	1 491	4 796	42	0	453	3 121	1 222	17 469
A10BH02 vildagliptin	0	0	6	288	935	45	0	74	607	254	2 175

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
A10BH03 saxagliptin	0	0	0	0	846	42	0	88	545	213	2 106
A10BX Other blood glucose lowering drugs, excl. insulins	464	530	725	847	1 334	46	0	202	930	202	8 502
A10BX02 repaglinide	455	435	399	330	283	37	0	12	163	108	572
A10BX03 nateglinide	9	12	13	13	11	9	0	<5	6	<5	24
A10BX04 exenatide	0	85	314	491	554	48	0	98	415	41	4 150
A10BX07 liraglutide	0	0	0	19	534	49	0	104	380	50	3 756
A11 VITAMINS	66 745	75 652	79 346	91 051	93 032	61	603	20 729	34 515	37 185	56 609
A11B MULTIVITAMINS, PLAIN	25	31	39	78	100	69	48	52	0	0	65
A11BA Multivitamins, plain	25	31	39	78	100	69	48	52	0	0	65
A11C VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO	5 863	6 742	7 961	9 836	11 359	56	174	3 400	4 621	3 164	11 661
A11CA Vitamin A, plain	24	31	38	29	30	63	<5	9	17	0	124
A11CA01 retinol (vit A)	15	18	22	13	14	57	0	<5	10	0	15
A11CA02 betacarotene	9	13	16	16	16	69	<5	5	7	0	109
A11CC Vitamin D and analogues	5 841	6 714	7 930	9 815	11 336	56	170	3 393	4 609	3 164	11 537
A11CC01 ergocalciferol	1 098	1 477	2 034	3 096	4 250	68	43	2 036	1 751	420	2 092
A11CC03 alfacalcidol	3 034	3 190	3 525	3 790	3 883	45	100	599	1 502	1 682	6 097
A11CC04 calcitriol	1 657	1 911	2 085	2 297	2 396	45	7	360	1 008	1 021	3 149
A11CC05 colecalciferol	93	221	367	753	939	77	20	440	410	69	200
A11D VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 ¹⁾	574	624	697	762	790	35	<5	119	485	183	519
A11DA Vitamin B1, plain	574	624	677	745	782	34	<5	117	483	179	514
A11DA01 thiamine (vit B1) ¹⁾	574	624	677	745	782	34	<5	117	483	179	514
A11DB Vitamin B1 in combination with vitamin B6 and/or vitamin B12	0	0	20	17	8	63	0	<5	<5	<5	5
A11E VITAMIN B-COMPLEX, INCL. COMBINATIONS	57 811	65 855	68 574	78 386	78 339	61	239	16 470	29 220	32 410	41 900
A11EA Vitamin B-complex, plain ¹⁾	57 217	65 084	67 559	77 312	77 132	61	194	16 261	28 769	31 908	40 828
A11EB Vitamin B-complex with vitamin C	0	0	58	114	92	55	<5	16	37	35	30
A11EX Vitamin B-complex, other combinations	610	793	986	1 008	1 154	41	41	202	426	485	1 043
A11G ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS	3 045	3 307	3 410	3 507	3 676	68	14	346	744	2 572	1 004
A11GA Ascorbic acid (vitamin C), plain	3 045	3 307	3 410	3 507	3 676	68	14	346	744	2 572	1 004
A11GA01 ascorbic acid (vit C) ¹⁾	3 045	3 307	3 410	3 507	3 676	68	14	346	744	2 572	1 004

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group A

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
A11H OTHER PLAIN VITAMIN PREPARATIONS	1 262	1 249	1 181	1 462	1 604	62	161	710	467	266	856
A11HA Other plain vitamin preparations	1 262	1 249	1 181	1 462	1 604	62	161	710	467	266	856
A11HA01 nicotinamide	21	14	14	5	13	54	<5	<5	7	<5	8
A11HA02 pyridoxine (vit B6) ¹⁾	554	574	568	871	1 072	64	65	563	321	123	416
A11HA03 tocopherol (vit E) ¹⁾	695	650	590	572	442	55	88	112	105	137	404
A11HA04 riboflavin (vit B2)	0	14	13	16	12	50	5	<5	<5	<5	4
A11HA06 pyridoxal phosphate	0	0	0	0	66	76	<5	30	33	<5	23
A11J OTHER VITAMIN PRODUCTS, COMBINATIONS	37	51	63	59	61	57	38	19	<5	0	79
A11JA Combinations of vitamins	37	51	63	59	48	48	37	10	<5	0	71
A11JB Vitamins with minerals	0	0	0	0	13	92	<5	9	<5	0	7
A12 MINERAL SUPPLEMENTS	69 327	76 580	83 209	91 599	100 930	79	383	7 913	39 606	53 028	64 429
A12A CALCIUM	50 059	56 470	62 611	70 986	80 549	83	183	6 777	32 865	40 724	49 223
A12AA Calcium	1 499	1 449	1 515	1 467	1 415	69	70	222	507	616	1 230
A12AA02 calcium glubionate	5	<5	<5	8	7	29	6	0	<5	0	38
A12AA04 calcium carbonate ¹⁾	390	371	397	371	412	72	8	57	127	220	154
A12AA06 calcium lactate gluconate ¹⁾	1 100	1 078	1 123	1 090	982	69	55	165	375	387	1 012
A12AA12 calcium acetate anhydrous	18	11	22	12	28	46	<5	5	9	13	25
A12AX Calcium, combinations with other drugs	48 745	55 193	61 293	69 722	79 333	83	116	6 574	32 448	40 195	47 994
A12B POTASSIUM	18 555	19 749	20 402	20 533	20 532	66	93	977	6 520	12 942	12 801
A12BA Potassium	18 555	19 749	20 402	20 533	20 532	66	93	977	6 520	12 942	12 801
A12BA01 potassium chloride	17 142	18 225	18 833	18 968	18 790	66	13	798	5 965	12 014	10 394
A12BA02 potassium citrate	1 650	1 799	1 860	1 828	2 052	63	83	210	663	1 096	2 387
A12BA30 combinations	<5	5	5	<5	<5	33	0	<5	<5	0	20
A12C OTHER MINERAL SUPPLEMENTS	3 405	3 345	3 628	3 773	4 002	60	113	427	1 432	2 030	2 184
A12CA Sodium	283	379	464	622	715	70	5	41	228	441	377
A12CA01 sodium chloride ¹⁾	283	379	464	622	715	70	5	41	228	441	377
A12CB Zinc	879	904	909	865	767	63	68	140	213	346	314
A12CB01 zinc sulfate	879	904	909	865	767	63	68	140	213	346	314
A12CC Magnesium	2 272	2 096	2 292	2 338	2 589	58	40	252	1 017	1 280	1 494
A12CC04 magnesium citrate	17	24	19	<5	0	-	0	0	0	0	0
A12CC10 magnesium oxide	0	0	9	13	18	72	<5	0	10	7	15
A12CC30 magnesium (different salts in combination) ¹⁾	2 262	2 077	2 272	2 328	2 571	58	36	252	1 008	1 275	1 405

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
A14 ANABOLIC AGENTS FOR SYSTEMIC USE	803	710	660	728	847	82	0	243	545	59	514
A14A ANABOLIC STEROIDS	803	710	660	728	847	82	0	243	545	59	514
A14AA Androstan derivatives	686	595	561	645	827	83	0	236	537	54	448
A14AA07 prasterone	684	593	560	644	827	83	0	236	537	54	448
A14AA08 oxandrolone	<5	<5	<5	<5	0	-	0	0	0	0	0
A14AB Estren derivatives	119	117	100	84	21	24	0	7	9	5	67
A14AB01 nandrolone	119	117	100	84	21	24	0	7	9	5	67
A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	158	197	329	293	548	62	86	246	189	27	110 042
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS	158	197	329	293	317	50	76	108	109	24	109 854
A16AA Amino acids and derivatives	63	73	93	107	123	41	60	37	20	6	2 411
A16AA01 levocarnitine	52	56	63	73	87	38	49	22	10	6	1 050
A16AA03 glutamine	<5	<5	13	17	12	42	0	<5	9	0	11
A16AA04 mercaptamine	7	8	8	7	10	50	7	<5	0	0	685
A16AA06 betaine	0	6	10	11	16	50	5	10	<5	0	665
A16AB Enzymes	40	44	44	51	50	36	<5	24	21	<5	95 861
A16AB02 imiglucerase	8	9	9	10	7	57	0	<5	<5	0	9 175
A16AB03 agalsidase alfa	17	17	17	16	32	34	<5	14	14	<5	57 678
A16AB04 agalsidase beta	16	19	19	23	18	44	0	7	10	<5	12 001
A16AB05 laronidase	0	0	0	0	<5	100	0	<5	0	0	2 476
A16AB07 alglucosidase alfa	0	0	<5	<5	<5	0	0	0	<5	0	3 026
A16AB09 idursulfase	0	0	0	<5	<5	0	<5	<5	0	0	11 505
A16AX Various alimentary tract and metabolism products	56	81	198	139	149	62	15	48	71	15	11 582
A16AX01 thioctic acid	44	66	180	122	121	69	<5	36	69	15	118
A16AX03 sodium phenylbutyrate	<5	<5	<5	<5	<5	0	<5	0	0	0	260
A16AX04 nitisinone	11	11	12	12	13	23	10	<5	0	0	9 453
A16AX05 zinc acetate	0	<5	<5	<5	7	43	0	6	<5	0	43
A16AX06 miglustat	0	<5	0	0	<5	0	0	0	<5	0	228
A16AX07 sapropterin	0	0	0	0	5	80	<5	<5	0	0	1 481

2.5 ATC group B – Blood and bloodforming organs

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15–44	45–69	≥70							
B BLOOD AND BLOOD FORMING ORGANS	501 273	523 020	541 138	562 339	581 244	49	2 704	51 475	251 186	275 879	728 260
B01 ANTITHROMBOTIC AGENTS	418 431	437 916	455 764	472 405	485 703	45	403	20 214	211 796	253 290	428 109
B01A ANTITHROMBOTIC AGENTS	418 431	437 916	455 764	472 405	485 703	45	403	20 214	211 796	253 290	428 109
B01AA Vitamin K antagonists	79 159	82 072	84 246	86 426	88 712	40	53	3 436	27 059	58 164	76 512
B01AA01 dicoumarol	67	70	88	93	90	49	0	11	39	40	449
B01AA02 phenindione	43	45	33	27	24	54	0	<5	12	8	318
B01AA03 warfarin	79 057	81 969	84 154	86 321	88 613	40	53	3 421	27 016	58 123	75 744
B01AB Heparin group	21 803	25 390	28 157	32 040	36 923	58	191	7 939	16 351	12 442	86 848
B01AB01 heparin	649	748	789	826	925	56	123	177	448	177	2 216
B01AB02 antithrombin III	0	0	<5	<5	<5	100	0	<5	0	0	304
B01AB04 dalteparin	10 754	13 379	15 439	15 917	21 232	59	42	4 428	9 528	7 234	50 222
B01AB05 enoxaparin	10 700	11 591	12 275	15 743	15 353	57	28	3 417	6 703	5 205	34 106
B01AB10 tinzaparin	<5	0	0	0	0	-	0	0	0	0	0
B01AC Platelet aggregation inhibitors excl. heparin	337 675	353 151	368 204	380 879	390 022	44	179	10 494	179 491	199 858	262 664
B01AC04 clopidogrel	22 541	23 296	25 178	26 429	28 362	34	5	992	14 624	12 741	89 058
B01AC05 ticlopidine	454	432	429	420	327	43	0	<5	143	181	902
B01AC06 acetylsalicylic acid	329 617	344 984	359 576	370 129	375 950	44	178	10 179	173 588	192 005	112 711
B01AC07 dipyridamole	12 870	15 554	18 072	18 755	19 306	44	0	327	7 314	11 665	22 204
B01AC09 epoprostenol	9	7	9	7	<5	50	0	<5	<5	0	4 673
B01AC11 iloprost	10	5	<5	<5	<5	75	0	0	<5	<5	1 786
B01AC21 treprostinil	0	8	9	9	9	78	0	<5	6	0	19 520
B01AC22 prasugrel	0	0	0	31	214	32	0	16	124	74	977
B01AC30 combinations	1 440	1 331	2 230	5 557	8 785	44	0	201	3 729	4 855	10 834
B01AD Enzymes	0	0	<5	<5	<5	100	<5	0	0	0	646
B01AD02 alteplase	0	0	<5	<5	<5	100	<5	0	0	0	646
B01AE Direct thrombin inhibitors	166	0	<5	9	186	43	0	6	85	95	1 007
B01AE05 ximelagatran	166	0	0	0	0	-	0	0	0	0	0
B01AE07 dabigatran etexilate	0	0	<5	9	186	43	0	6	85	95	1 007
B01AX Other antithrombotic agents	<5	7	7	61	208	65	0	19	112	77	431
B01AX05 fondaparinux	<5	7	7	16	17	59	0	<5	5	8	114
B01AX06 rivaroxaban	0	0	0	45	191	65	0	15	107	69	317
B02 ANTIHEMORRHAGICS	11 795	12 236	12 621	12 470	12 234	92	253	5 964	5 448	569	153 370
B02A ANTIFIBRINOLYTICS	11 501	11 882	12 227	12 065	11 870	94	178	5 812	5 370	510	14 597
B02AA Amino acids	11 480	11 858	12 204	12 033	11 839	94	176	5 797	5 358	508	4 350
B02AA02 tranexamic acid	11 480	11 858	12 204	12 033	11 839	94	176	5 797	5 358	508	4 350

ATC group B

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
B02AB Proteinase inhibitors	30	33	30	40	38	58	<5	19	14	<5	10 246
B02AB02 alfa1 antitrypsin	<5	<5	<5	<5	<5	100	0	<5	0	0	399
B02AB03 c1-inhibitor	29	32	29	39	37	57	<5	18	14	<5	9 847
B02B VITAMIN K AND OTHER HEMOSTATICS	348	398	451	468	419	38	84	177	96	62	138 773
B02BA Vitamin K	195	226	263	275	212	65	51	73	39	49	136
B02BA01 phytomenadione	195	226	263	275	212	65	51	73	39	49	136
B02BD Blood coagulation factors	153	172	188	187	189	7	33	101	49	6	133 685
B02BD01 coagulation factor IX, II, VII and X in combination	0	0	<5	<5	<5	100	0	<5	0	0	450
B02BD02 coagulation factor VIII	115	122	138	129	134	1	23	75	34	<5	94 893
B02BD03 factor VIII inhibitor bypassing activity	8	7	8	6	6	0	0	<5	<5	<5	14 344
B02BD04 coagulation factor IX	17	26	23	30	28	0	8	14	<5	<5	11 806
B02BD06 von Willebrand factor and coagulation factor VIII in combination	7	8	14	15	12	50	<5	5	5	<5	6 827
B02BD08 eptacog alfa (activated)	6	9	<5	7	7	43	<5	<5	<5	0	2 830
B02BD09 nonacog alfa	0	0	0	0	<5	0	0	0	<5	0	591
B02BX Other systemic hemostatics	0	0	0	6	18	56	0	<5	8	7	4 952
B02BX04 romiplostim	0	0	0	6	14	57	0	<5	7	<5	4 598
B02BX05 eltrombopag	0	0	0	0	<5	50	0	0	<5	<5	354
B03 ANTIANEMIC PREPARATIONS	108 864	112 845	113 445	120 950	129 288	65	1 954	27 239	46 304	53 791	130 779
B03A IRON PREPARATIONS	17 568	18 685	20 056	22 178	24 006	68	1 274	6 153	5 024	11 555	6 804
B03AA Iron bivalent, oral preparations	16 456	17 495	18 752	20 801	22 575	66	1 268	5 404	4 566	11 337	5 099
B03AA01 ferrous glycine sulfate ¹⁾	1 412	1 708	2 024	2 892	3 573	69	47	1 037	883	1 606	1 788
B03AA02 ferrous fumarate ¹⁾	1 292	1 208	1 337	1 333	1 320	49	982	159	56	123	184
B03AA03 ferrous gluconate	0	0	10	112	101	69	14	35	23	29	28
B03AA07 ferrous sulfate ¹⁾	13 828	14 691	15 542	16 693	17 755	67	233	4 204	3 636	9 682	3 100
B03AC Iron trivalent, parenteral preparations	1 181	1 257	1 395	1 461	1 524	87	6	784	482	252	1 705
B03AC02 saccharated iron oxide	301	302	297	288	280	82	<5	141	81	56	407
B03AC06 ferric oxide dextran complexes	886	965	1 113	1 189	1 254	88	<5	649	403	198	1 297
B03B VITAMIN B12 AND FOLIC ACID	92 285	95 348	94 766	100 602	107 693	65	749	22 034	41 403	43 507	29 272
B03BA Vitamin B12 (cyanocobalamin and analogues)	66 003	67 011	65 577	69 156	76 073	66	143	15 670	26 739	33 521	17 451
B03BA01 cyanocobalamin	5 819	5 378	5 696	6 558	7 389	68	18	2 115	2 664	2 592	1 608

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group B

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
B03BA02 cyanocobalamin tannin complex	34 867	35 668	34 254	36 404	39 764	66	46	8 394	13 709	17 615	8 778
B03BA03 hydroxocobalamin	27 326	27 756	27 457	28 055	31 117	66	84	5 696	11 170	14 167	6 996
B03BA05 mecobalamin	19	26	26	16	38	76	<5	25	9	<5	69
B03BB Folic acid and derivatives	31 752	33 592	34 058	36 595	36 308	61	618	7 012	16 141	12 537	11 822
B03BB01 folic acid ¹⁾	31 752	33 592	34 058	36 595	36 308	61	618	7 012	16 141	12 537	11 822
B03X OTHER ANTIANEMIC PREPARATIONS	3 318	3 511	3 520	3 639	3 485	38	17	341	1 221	1 906	94 703
B03XA Other antianemic preparations	3 318	3 511	3 520	3 639	3 485	38	17	341	1 221	1 906	94 703
B03XA01 erythropoietin	902	867	681	470	334	38	<5	32	114	185	8 802
B03XA02 darbepoetin alfa	2 473	2 683	2 716	2 785	2 714	39	14	272	949	1 479	74 071
B03XA03 methoxy polyethylene glycol-epoetin beta	0	7	230	452	475	36	0	41	177	257	11 831

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.6 ATC group C – Cardiovascular system

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15–44	45–69	≥70							
C CARDIOVASCULAR SYSTEM	849 724	883 033	917 223	945 882	975 001	52	4 987	92 581	506 802	370 631	1 979 042
C01 CARDIAC THERAPY	134 611	130 333	129 655	124 934	122 945	48	3 226	7 134	40 097	72 488	80 013
C01A CARDIAC GLYCOSIDES	29 466	28 141	27 042	25 818	24 742	49	40	175	4 567	19 960	3 803
C01AA Digitalis glycosides	29 466	28 141	27 042	25 818	24 742	49	40	175	4 567	19 960	3 803
C01AA04 digitoxin	28 149	26 937	25 925	24 734	23 702	49	<5	132	4 361	19 208	3 620
C01AA05 digoxin	1 342	1 223	1 144	1 123	1 068	49	39	43	214	772	183
C01B ANTIARRHYTHMICS, CLASS I AND III	8 536	9 190	9 879	10 321	11 684	34	32	553	6 411	4 688	22 722
C01BA Antiarrhythmics, class Ia	228	202	184	173	159	52	0	7	65	87	393
C01BA01 quinidine	18	9	5	<5	<5	100	0	0	0	<5	25
C01BA03 disopyramide	210	193	179	170	156	51	0	7	65	84	369
C01BB Antiarrhythmics, class Ib	31	33	26	23	17	41	0	7	5	5	146
C01BB02 mexiletine	31	33	26	23	17	41	0	7	5	5	146
C01BC Antiarrhythmics, class Ic	4 708	5 112	5 517	5 783	6 391	38	30	425	4 083	1 853	14 924
C01BC03 propafenone	<5	<5	<5	<5	<5	75	0	<5	<5	<5	19
C01BC04 flecainide	4 707	5 111	5 515	5 780	6 388	38	30	425	4 081	1 852	14 905
C01BD Antiarrhythmics, class III	3 696	3 967	4 273	4 475	5 430	29	<5	130	2 482	2 816	7 259
C01BD01 amiodarone	3 696	3 967	4 273	4 475	4 852	28	<5	109	2 094	2 647	3 995
C01BD07 dronedarone	0	0	0	0	764	33	0	26	510	228	3 264
C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES	9 688	9 479	12 191	12 217	14 119	59	3 152	5 138	4 847	982	9 183
C01CA Adrenergic and dopaminergic agents	9 688	9 479	12 191	12 217	14 119	59	3 152	5 138	4 847	982	9 183
C01CA01 etilefrine	148	131	115	114	95	63	0	28	39	28	218
C01CA03 norepinephrine	0	0	<5	0	0	0	0	0	0	0	0
C01CA17 midodrine	10	18	14	14	16	69	0	10	<5	<5	184
C01CA24 epinephrine	9 524	9 322	12 058	12 082	14 004	59	3 152	5 100	4 801	951	8 759
C01CA26 ephedrine	10	11	6	7	6	17	0	<5	<5	<5	22
C01D VASODILATORS USED IN CARDIAC DISEASES	95 771	91 790	88 486	83 929	79 423	48	0	1 279	25 682	52 462	42 213
C01DA Organic nitrates	95 771	91 790	88 486	83 929	79 423	48	0	1 279	25 682	52 462	42 213
C01DA02 glyceryl trinitrate	73 624	70 701	68 610	65 059	60 655	47	0	1 206	22 234	37 215	11 909
C01DA08 isosorbide dinitrate	4 592	3 820	3 257	2 787	2 310	53	0	9	318	1 983	1 941
C01DA14 isosorbide mononitrate	42 502	40 190	38 045	35 904	34 136	52	0	151	6 930	27 055	28 363
C01E OTHER CARDIAC PREPARATIONS	99	145	133	144	151	68	<5	31	96	20	2 092
C01EB Other cardiac preparations	99	145	133	144	151	68	<5	31	96	20	2 092
C01EB09 ubidecarenone	92	132	123	129	125	66	<5	18	84	19	261
C01EB15 trimetazidine	7	13	10	9	10	60	0	<5	7	0	14

ATC group C

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
C01EB19 icatibant	0	0	0	6	14	79	0	10	<5	<5	1 816
C02 ANTIHYPERTENSIVES	17 921	17 295	17 795	17 689	17 440	27	13	657	8 281	8 489	55 035
C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTING	6 563	6 879	7 114	6 702	6 467	42	0	370	3 665	2 432	6 408
C02AB Methyldopa	1 154	1 130	1 084	410	141	79	0	75	36	30	322
C02AB01 methyldopa (levorotatory)	1 154	1 130	1 084	410	141	79	0	75	36	30	322
C02AC Imidazoline receptor agonists	5 465	5 817	6 119	6 347	6 338	41	0	296	3 636	2 406	6 086
C02AC01 clonidine	74	72	74	78	63	51	0	15	39	9	140
C02AC05 moxonidine	5 393	5 746	6 045	6 269	6 275	41	0	281	3 597	2 397	5 946
C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING	11 497	10 575	10 920	11 234	11 221	17	0	270	4 832	6 119	14 440
C02CA Alpha-adrenoreceptor antagonists	11 497	10 575	10 920	11 233	11 221	17	0	270	4 832	6 119	14 440
C02CA04 doxazosin	11 497	10 575	10 920	11 233	11 221	17	0	270	4 832	6 119	14 440
C02CC Guanidine derivatives	0	0	0	<5	0	-	0	0	0	0	0
C02CC02 guanethidine	0	0	0	<5	0	-	0	0	0	0	0
C02D ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON	320	339	331	319	301	33	<5	17	133	149	333
C02DB Hydrazinophthalazine derivatives	283	302	300	285	270	35	<5	12	109	148	194
C02DB02 hydralazine	283	302	300	285	270	35	<5	12	109	148	194
C02DC Pyrimidine derivatives	37	40	31	34	32	16	<5	6	24	<5	139
C02DC01 minoxidil	37	40	31	34	32	16	<5	6	24	<5	139
C02K OTHER ANTIHYPERTENSIVES	94	89	106	119	142	69	11	40	63	28	33 854
C02KD Serotonin antagonists	24	21	22	18	19	89	0	6	11	<5	473
C02KD01 ketanserin	24	21	22	18	19	89	0	6	11	<5	473
C02KX Other antihypertensives	72	69	85	102	124	66	11	35	52	26	33 380
C02KX01 bosentan	72	69	83	91	103	63	11	33	35	24	27 541
C02KX02 ambrisentan	0	0	<5	12	19	79	0	<5	15	<5	5 334
C02KX03 sitaxentan	0	0	<5	0	<5	67	0	0	<5	<5	506
C03 DIURETICS	218 253	225 203	233 970	235 551	223 776	61	188	10 578	88 404	124 606	88 986
C03A LOW-CEILING DIURETICS, THIAZIDES	53 824	61 870	71 860	74 215	65 993	60	7	3 685	34 960	27 341	27 145
C03AA Thiazides, plain	33 187	38 198	44 488	45 270	36 358	57	<5	2 074	19 841	14 439	8 347
C03AA01 bendroflumethiazide	22 567	26 172	30 790	31 709	22 807	58	<5	1 234	12 588	8 984	4 062
C03AA03 hydrochlorothiazide	10 702	12 097	13 765	13 625	16 719	58	<5	968	8 994	6 754	4 285
C03AB Thiazides and potassium in combination	21 624	24 868	28 814	30 363	41 614	61	<5	2 158	21 694	17 759	18 798
C03AB01 bendroflumethiazide and potassium	21 624	24 868	28 814	30 363	41 614	61	<5	2 158	21 694	17 759	18 798

ATC group C

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
C03B LOW-CEILING DIURETICS, EXCL. THIAZIDES	5	5	6	6	5	60	0	0	<5	<5	22
C03BA Sulfonamides, plain	5	5	6	6	5	60	0	0	<5	<5	22
C03BA04 chlortalidone	<5	5	6	6	5	60	0	0	<5	<5	22
C03BA08 metolazone	<5	0	0	0	0	-	0	0	0	0	0
C03C HIGH-CEILING DIURETICS	129 819	128 628	128 682	127 994	127 330	60	171	5 479	38 215	83 465	44 894
C03CA Sulfonamides, plain	129 645	128 628	128 682	127 994	127 330	60	171	5 479	38 215	83 465	44 894
C03CA01 furosemide	110 811	106 983	104 724	101 618	98 961	62	170	4 747	31 129	62 915	22 694
C03CA02 bumetanide	23 653	26 396	28 833	31 193	33 426	54	<5	843	8 214	24 367	22 187
C03CA04 torasemide	<5	<5	<5	<5	<5	100	0	0	0	<5	13
C03CB Sulfonamides and potassium in combination	498	<5	0	0	0	-	0	0	0	0	0
C03CB02 bumetanide and potassium	498	<5	0	0	0	-	0	0	0	0	0
C03D POTASSIUM-SPARING AGENTS	16 419	16 818	17 302	17 602	17 625	50	17	861	6 676	10 071	11 216
C03DA Aldosterone antagonists	16 404	16 805	17 287	17 589	17 612	50	16	859	6 671	10 066	11 077
C03DA01 spironolactone	16 145	16 399	16 795	17 028	17 027	51	16	818	6 312	9 881	7 017
C03DA02 potassium canrenoate	0	<5	0	0	<5	100	0	0	<5	0	2
C03DA04 eplerenone	321	453	579	658	678	16	0	50	408	220	4 058
C03DB Other potassium-sparing agents	17	16	15	18	18	33	<5	<5	9	5	139
C03DB01 amiloride	17	16	15	18	18	33	<5	<5	9	5	139
C03E DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION	36 326	36 317	35 388	34 026	31 689	66	7	1 092	14 835	15 755	5 580
C03EA Low-ceiling diuretics and potassium-sparing agents	36 326	36 317	35 388	34 026	31 689	66	7	1 092	14 835	15 755	5 580
C03EA01 hydrochlorothiazide and potassium-sparing agents	36 326	36 317	35 388	34 026	31 689	66	7	1 092	14 835	15 755	5 580
C03X OTHER DIURETICS	0	0	0	0	<5	67	0	0	<5	<5	129
C03XA Vasopressin antagonists	0	0	0	0	<5	67	0	0	<5	<5	129
C03XA01 tolvaptan	0	0	0	0	<5	67	0	0	<5	<5	129
C04 PERIPHERAL VASODILATORS	1 825	1 719	1 524	1 340	1 165	45	0	19	299	847	1 273
C04A PERIPHERAL VASODILATORS	1 825	1 719	1 524	1 340	1 165	45	0	19	299	847	1 273
C04AD Purine derivatives	1 819	1 715	1 520	1 334	1 160	45	0	18	296	846	1 248
C04AD03 pentoxifylline	1 819	1 715	1 520	1 334	1 160	45	0	18	296	846	1 248
C04AX Other peripheral vasodilators	6	<5	<5	6	5	80	0	<5	<5	<5	25
C04AX01 cyclandelate	<5	<5	0	0	0	-	0	0	0	0	0
C04AX02 phenoxybenzamine	<5	<5	<5	6	5	80	0	<5	<5	<5	25

ATC group C

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
C05 VASOPROTECTIVES	54 946	54 309	55 015	56 622	59 318	57	836	24 186	23 614	10 682	10 773
C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE	48 902	48 819	49 681	51 350	54 265	56	802	23 271	21 579	8 613	9 019
C05AA Corticosteroids	48 227	48 021	48 507	49 667	52 337	56	764	22 338	20 857	8 378	6 781
C05AA01 hydrocortisone	14 664	11 920	9 924	9 649	9 740	56	272	3 886	3 963	1 619	1 906
C05AA04 prednisolone	35 198	38 325	40 337	41 682	44 262	56	508	19 224	17 531	6 999	4 875
C05AE Muscle relaxants	440	663	1 360	2 137	2 732	50	24	1 381	1 091	236	2 077
C05AE01 glyceryl trinitrate	440	663	1 360	2 137	2 732	50	24	1 381	1 091	236	2 077
C05AX Other agents for treatment of hemorrhoids and anal fissures for topical use	805	992	993	901	825	49	19	393	276	137	162
C05AX03 other preparations, combinations	783	973	963	885	806	49	19	383	268	136	129
C05B ANTIVARICOSE THERAPY	6 256	5 656	5 555	5 490	5 246	69	34	958	2 105	2 149	1 754
C05BA Heparins or heparinoids for topical use	6 250	5 647	5 551	5 486	5 241	69	34	958	2 100	2 149	1 743
C05BA01 organo-heparinoid ¹⁾	6 226	5 620	5 525	5 462	5 207	68	34	954	2 084	2 135	631
C05BA04 pentosan polysulfate sodium	25	27	26	25	34	97	0	<5	16	14	1 112
C05BB Sclerosing agents for local injection	6	9	<5	<5	5	60	0	0	5	0	10
C05BB02 polidocanol	6	9	<5	<5	5	60	0	0	5	0	10
C07 BETA BLOCKING AGENTS	334 519	343 799	351 979	356 307	361 018	50	355	19 679	164 499	176 485	181 383
C07A BETA BLOCKING AGENTS	329 995	338 456	346 541	350 742	355 592	49	355	19 321	161 164	174 752	177 502
C07AA Beta blocking agents, non-selective	29 264	28 174	27 359	25 833	24 960	58	128	4 253	10 863	9 716	11 347
C07AA03 pindolol	38	35	31	28	28	71	0	<5	15	12	62
C07AA05 propranolol	15 955	15 992	16 403	16 540	16 851	64	120	4 038	7 882	4 811	6 308
C07AA06 timolol	1 625	1 462	1 337	636	13	62	0	<5	9	<5	25
C07AA07 sotalol	11 731	10 750	9 646	8 818	8 080	46	7	205	2 968	4 900	4 923
C07AA12 nadolol	5	8	12	13	17	47	<5	13	<5	0	29
C07AB Beta blocking agents, selective	280 632	290 513	299 222	305 469	311 096	49	213	13 113	140 530	157 240	148 061
C07AB02 metoprolol	224 298	235 349	244 331	250 948	256 707	48	186	10 852	116 613	129 056	124 714
C07AB03 atenolol	51 208	46 631	42 913	39 561	36 747	58	22	1 563	15 939	19 223	11 094
C07AB07 bisoprolol	8 800	12 020	15 502	18 387	21 000	46	5	847	9 486	10 662	12 253
C07AG Alpha and beta blocking agents	25 223	24 757	24 682	24 389	23 885	46	21	2 274	11 731	9 859	18 094
C07AG01 labetalol	2 033	2 158	2 173	2 324	2 391	79	<5	1 424	583	382	2 348
C07AG02 carvedilol	23 216	22 634	22 529	22 092	21 524	42	19	857	11 165	9 483	15 746

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
C07B BETA BLOCKING AGENTS AND THIAZIDES	5 092	5 875	5 991	6 057	5 815	54	0	376	3 540	1 899	3 881
C07BB Beta blocking agents, selective, and thiazides	5 092	5 875	5 991	6 057	5 815	54	0	376	3 540	1 899	3 881
C07BB07 bisoprolol and thiazides	5 092	5 875	5 991	6 057	5 815	54	0	376	3 540	1 899	3 881
C08 CALCIUM CHANNEL BLOCKERS	193 590	200 902	208 609	214 670	221 221	49	64	8 754	105 505	106 898	174 338
C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	166 946	176 033	185 199	192 741	200 591	48	56	7 966	97 855	94 714	151 932
C08CA Dihydropyridine derivatives	166 946	176 033	185 199	192 741	200 591	48	56	7 966	97 855	94 714	151 932
C08CA01 amlodipine	109 225	111 182	113 649	115 249	119 255	47	31	3 954	57 681	57 589	55 066
C08CA02 felodipine	18 315	17 749	17 106	16 692	16 308	51	0	396	7 159	8 753	12 122
C08CA03 isradipine	742	693	683	664	620	55	<5	13	269	337	1 178
C08CA05 nifedipine	24 845	26 450	28 302	29 940	31 644	48	25	2 412	15 409	13 798	44 215
C08CA06 nimodipine	30	35	36	32	44	52	0	11	30	<5	31
C08CA13 lercanidipine	16 906	23 469	28 958	33 491	36 035	51	0	1 333	18 937	15 765	39 320
C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS	28 031	26 226	24 756	23 260	21 850	55	8	810	8 119	12 913	22 405
C08DA Phenylalkylamine derivatives	20 251	19 138	18 203	17 237	16 443	56	8	723	5 972	9 740	11 807
C08DA01 verapamil	20 251	19 138	18 203	17 237	16 443	56	8	723	5 972	9 740	11 807
C08DB Benzothiazepine derivatives	7 858	7 157	6 633	6 091	5 473	54	0	90	2 168	3 215	10 598
C08DB01 diltiazem	7 858	7 157	6 633	6 091	5 473	54	0	90	2 168	3 215	10 598
C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	406 896	430 122	452 971	473 385	498 435	49	453	27 822	268 789	201 371	850 019
C09A ACE INHIBITORS, PLAIN	118 918	120 705	123 582	125 436	130 225	42	406	7 031	59 474	63 314	67 677
C09AA ACE inhibitors, plain	118 918	120 705	123 582	125 436	130 225	42	406	7 031	59 474	63 314	67 677
C09AA01 captopril	4 458	3 988	3 500	3 233	2 858	45	197	113	984	1 564	4 302
C09AA02 enalapril	41 746	41 791	42 622	43 093	45 421	47	210	2 849	21 140	21 222	18 779
C09AA03 lisinopril	29 324	28 417	27 936	27 083	26 746	47	<5	1 596	12 848	12 298	15 857
C09AA05 ramipril	44 003	47 159	50 152	52 684	55 797	36	5	2 517	24 724	28 551	28 519
C09AA10 trandolapril	117	117	119	111	92	24	0	<5	53	36	219
C09B ACE INHIBITORS, COMBINATIONS	36 041	35 749	35 756	35 260	35 973	50	<5	1 303	18 299	16 370	27 956
C09BA ACE inhibitors and diuretics	36 041	35 749	35 756	35 023	35 181	50	<5	1 250	17 839	16 091	27 049
C09BA02 enalapril and diuretics	19 795	19 816	20 160	20 154	20 510	50	<5	796	10 432	9 281	15 931
C09BA03 lisinopril and diuretics	16 266	15 959	15 625	14 889	14 695	50	0	456	7 421	6 818	11 117

ATC group C

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
C09BB ACE inhibitors and calcium channel blockers	0	0	0	259	820	47	0	56	476	288	907
C09BB02 enalapril and lercanidipine	0	0	0	259	820	47	0	56	476	288	907
C09C ANGIOTENSIN II ANTAGONISTS, PLAIN	143 706	153 235	162 375	168 742	180 106	51	69	13 557	101 027	65 453	321 522
C09CA Angiotensin II antagonists, plain	143 706	153 235	162 375	168 742	180 106	51	69	13 557	101 027	65 453	321 522
C09CA01 losartan	43 824	44 600	44 127	42 955	51 864	52	31	3 151	27 787	20 895	46 580
C09CA02 eprosartan	1 757	2 213	2 386	2 322	2 063	52	0	96	983	984	4 081
C09CA03 valsartan	19 186	19 497	20 016	20 380	20 740	48	0	1 282	11 936	7 522	38 855
C09CA04 irbesartan	24 329	23 786	23 422	22 328	21 416	50	<5	1 145	12 380	7 889	51 145
C09CA06 candesartan	53 496	60 248	67 536	74 704	78 219	53	33	7 451	44 342	26 393	163 748
C09CA07 telmisartan	2 476	3 810	5 222	5 866	5 987	44	0	422	3 625	1 940	13 526
C09CA08 olmesartan medoxomil	399	1 093	1 539	1 751	1 680	51	<5	167	1 037	473	3 588
C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS	144 654	158 621	172 489	184 232	195 532	50	<5	8 539	114 229	72 763	432 605
C09DA Angiotensin II antagonists and diuretics	144 654	157 769	168 660	174 848	179 874	51	<5	7 372	104 392	68 109	382 665
C09DA01 losartan and diuretics	61 126	63 364	64 598	63 952	66 079	53	0	2 256	36 499	27 324	79 766
C09DA02 eprosartan and diuretics	889	1 428	1 840	2 042	1 924	48	0	95	1 066	763	4 311
C09DA03 valsartan and diuretics	21 180	23 363	24 767	25 424	25 641	49	0	1 082	15 170	9 389	72 285
C09DA04 irbesartan and diuretics	27 940	29 862	31 288	31 418	30 814	50	0	1 108	17 982	11 724	87 864
C09DA06 candesartan and diuretics	34 109	39 096	43 908	48 685	51 645	51	<5	2 643	31 287	17 714	126 091
C09DA07 telmisartan and diuretics	1 461	2 415	3 320	3 724	3 991	42	0	204	2 490	1 297	10 056
C09DA08 olmesartan medoxomil and diuretics	0	349	813	1 144	1 124	50	0	70	696	358	2 293
C09DB Angiotensin II antagonists and calcium channel blockers	0	1 356	5 351	11 764	16 483	41	0	1 188	10 352	4 943	42 223
C09DB01 valsartan and amlodipine	0	1 356	5 351	11 764	16 482	41	0	1 188	10 351	4 943	42 222
C09DB02 olmesartan medoxomil and amlodipine	0	0	0	0	<5	0	0	0	<5	0	0
C09DX Angiotensin II antagonists, other combinations	0	0	0	0	4 017	40	0	297	2 569	1 151	7 718
C09DX01 valsartan, amlodipine and hydrochlorothiazide	0	0	0	0	4 017	40	0	297	2 569	1 151	7 718
C09X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	0	0	47	93	93	34	0	9	62	22	259
C09XA Renin-inhibitors	0	0	47	93	93	34	0	9	62	22	259
C09XA02 aliskiren	0	0	47	93	92	35	0	9	61	22	254
C09XA52 aliskiren and hydrochlorothiazide	0	0	0	0	<5	0	0	0	<5	0	5

ATC group C

ATC level		2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
		Number of individuals						Number of individuals per age group				
								<15	15-44	45-69	≥70	
C10	LIPID MODIFYING AGENTS	363 077	398 211	426 023	452 787	478 281	47	91	21 713	264 732	191 745	537 224
C10A	LIPID MODIFYING AGENTS, PLAIN	363 076	397 850	425 411	452 087	477 559	47	91	21 681	264 251	191 536	535 037
C10AA	HMG CoA reductase inhibitors	360 919	395 295	421 813	447 807	472 779	47	81	21 013	261 532	190 153	449 925
C10AA01	simvastatin	254 972	321 003	348 045	356 766	349 727	47	34	13 821	186 468	149 404	237 131
C10AA02	lovastatin	2 107	1 884	1 715	1 424	1 260	58	0	17	528	715	2 099
C10AA03	pravastatin	28 113	24 230	23 056	22 329	21 334	49	6	541	10 358	10 429	25 007
C10AA04	fluvastatin	7 173	7 097	7 268	7 465	7 508	48	0	552	4 436	2 520	12 720
C10AA05	atorvastatin	103 389	85 847	59 209	79 685	112 746	45	43	7 042	72 409	33 252	167 417
C10AA07	rosuvastatin	22	234	355	571	2 114	45	<5	297	1 495	318	5 550
C10AB	Fibrates	322	320	328	317	331	31	0	67	241	23	1 790
C10AB02	bezafibrate	80	76	70	64	58	40	0	6	46	6	222
C10AB04	gemfibrozil	93	102	105	101	104	26	0	22	74	8	978
C10AB05	fenofibrate	151	143	156	154	170	32	0	39	122	9	591
C10AC	Bile acid sequestrants	2 153	2 087	2 134	2 090	2 238	54	8	477	1 170	583	6 924
C10AC01	colestyramine	1 535	1 486	1 563	1 566	1 686	58	6	416	815	449	2 406
C10AC02	colestipol	439	430	384	308	292	46	<5	22	162	107	795
C10AC04	colesevelam	197	184	204	237	280	44	<5	44	202	33	3 723
C10AD	Nicotinic acid and derivatives	175	231	234	285	396	28	<5	47	315	33	978
C10AD02	nicotinic acid	154	212	216	218	153	29	<5	19	113	20	382
C10AD06	acipimox	22	19	20	11	12	33	0	0	11	<5	69
C10AD52	nicotinic acid, combinations	0	0	0	69	249	27	0	28	207	14	527
C10AX	Other lipid modifying agents	4 534	7 997	12 591	14 589	16 503	43	<5	1 437	11 353	3 710	75 421
C10AX06	omega-3-triglycerides incl. other esters and acids	2 039	2 194	2 417	2 754	3 037	29	<5	456	2 199	381	23 450
C10AX09	ezetimibe	2 586	5 967	10 425	12 126	13 817	46	<5	1 013	9 434	3 368	51 971
C10B	LIPID MODIFYING AGENTS, COMBINATIONS	<5	<5	<5	0	81	40	0	<5	50	27	107
C10BA	HMG CoA reductase inhibitors in combination with other lipid modifying agents	<5	<5	<5	0	81	40	0	<5	50	27	107
C10BA02	simvastatin and ezetimibe	<5	<5	<5	0	81	40	0	<5	50	27	107

2.7 ATC group D – Dermatologicals

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15–44	45–69	≥70							
D DERMATOLOGICALS	585 104	582 681	589 447	587 805	611 121	54	78 854	226 590	205 108	100 569	225 688
D01 ANTIFUNGALS FOR DERMATOLOGICAL USE	106 214	109 784	113 854	111 682	116 630	48	11 639	42 934	42 081	19 976	29 355
D01A ANTIFUNGALS FOR TOPICAL USE	92 865	95 467	98 958	96 750	101 017	49	11 439	36 881	34 501	18 196	15 768
D01AA Antibiotics	2 786	3 201	3 467	219	54	83	6	33	9	6	12
D01AA01 nystatin	2 786	3 201	3 467	219	54	83	6	33	9	6	12
D01AC Imidazole and triazole derivatives	68 172	70 653	73 508	74 998	79 180	50	9 585	28 156	26 519	14 920	9 956
D01AC01 clotrimazole ¹⁾	7 979	8 182	8 369	8 811	9 506	53	1 246	3 423	2 526	2 311	1 289
D01AC02 miconazole ¹⁾	2 247	2 082	1 927	1 880	2 118	50	305	805	673	335	365
D01AC03 econazole ¹⁾	2 326	2 230	2 197	2 177	1 119	53	81	330	383	325	149
D01AC08 ketoconazole ¹⁾	15 123	15 366	15 005	14 992	15 116	41	980	6 630	5 551	1 955	2 429
D01AC20 combinations ¹⁾	44 009	46 252	49 639	50 909	55 165	51	7 395	18 330	18 654	10 786	5 723
D01AC60 bifonazole, combinations	<5	0	<5	0	0	-	0	0	0	0	0
D01AE Other antifungals for topical use	24 779	24 522	24 966	24 330	24 664	47	2 161	9 764	8 929	3 810	5 801
D01AE02 methyrosaniline ¹⁾	645	663	716	696	694	54	221	160	173	140	73
D01AE14 ciclopirox ¹⁾	33	52	14	<5	<5	0	0	<5	0	0	0
D01AE15 terbinafine ¹⁾	17 149	17 201	17 148	16 909	17 510	44	1 725	7 511	5 634	2 640	3 029
D01AE16 amorolfine	7 353	6 973	7 481	7 081	6 826	55	239	2 239	3 261	1 087	2 699
D01B ANTIFUNGALS FOR SYSTEMIC USE	16 706	17 544	18 326	18 300	19 223	39	326	7 553	9 152	2 192	13 587
D01BA Antifungals for systemic use	16 706	17 544	18 326	18 300	19 223	39	326	7 553	9 152	2 192	13 587
D01BA01 griseofulvin	26	14	16	19	15	53	15	0	0	0	6
D01BA02 terbinafine	16 686	17 535	18 314	18 285	19 213	39	316	7 553	9 152	2 192	13 581
D02 EMOLLIENTS AND PROTECTIVES	1 361	1 572	1 750	1 841	2 219	52	377	591	737	514	647
D02A EMOLLIENTS AND PROTECTIVES	1 361	1 572	1 750	1 841	2 219	52	377	591	737	514	647
D02AB Zinc products ¹⁾	16	8	10	6	9	67	0	<5	<5	5	2
D02AE Carbamide products	44	222	459	670	858	53	153	236	227	242	368
D02AE01 carbamide ¹⁾	44	222	459	670	858	53	153	236	227	242	368
D02AF Salicylic acid preparations	1 298	1 274	1 197	1 048	1 227	51	169	322	487	249	198
D02AX Other emollients and protectives	<5	76	93	125	148	41	66	34	24	24	79
D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS	172	120	143	91	60	48	<5	12	30	17	12
D03A CICATRIZANTS	172	120	143	91	60	48	<5	12	30	17	12

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group D

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
D03AA Cod-liver oil ointments	91	38	54	7	0	0	0	0	0	0	0
D03AX Other cicatrizants	81	82	89	84	60	48	<5	12	30	17	12
D03AX03 dexpanthenol	81	82	89	84	60	48	<5	12	30	17	12
D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.	2 978	2 996	3 195	3 676	3 866	65	452	1 423	1 015	976	670
D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.	2 978	2 996	3 195	3 676	3 866	65	452	1 423	1 015	976	670
D04AA Antihistamines for topical use	6	5	<5	<5	0	-	0	0	0	0	0
D04AA02 mepyramine	<5	0	<5	0	0	-	0	0	0	0	0
D04AA13 dimetindene	5	5	<5	<5	0	-	0	0	0	0	0
D04AB Anesthetics for topical use	1 878	1 936	2 094	2 637	2 795	69	276	1 193	761	565	541
D04AB01 lidocaine ¹⁾	1 878	1 935	2 094	2 637	2 795	69	276	1 193	761	565	541
D04AB06 tetracaine ¹⁾	0	<5	0	0	0	-	0	0	0	0	0
D04AX Other antipruritics	1 105	1 080	1 119	1 052	1 091	54	177	235	261	418	129
D05 ANTIPSORIATICS	24 550	25 466	26 570	27 496	29 914	45	452	9 282	15 308	4 872	49 960
D05A ANTIPSORIATICS FOR TOPICAL USE	23 417	24 289	25 328	26 164	28 637	45	445	9 035	14 498	4 659	43 036
D05AA Tars ¹⁾	934	954	1 007	980	1 042	59	84	340	366	252	257
D05AC Antracen derivatives	167	109	15	11	9	22	0	<5	6	<5	4
D05AC01 dithranol	167	109	15	11	9	22	0	<5	6	<5	4
D05AD Psoralens for topical use	10	11	10	6	<5	100	0	0	<5	0	3
D05AD01 trioxysalen	10	11	10	6	<5	100	0	0	<5	0	3
D05AX Other antipsoriatics for topical use	22 576	23 431	24 515	25 358	27 788	44	364	8 768	14 225	4 431	42 772
D05AX02 calcipotriol	13 495	11 694	9 932	8 743	8 025	45	119	2 448	4 101	1 357	7 440
D05AX03 calcitriol	872	929	1 125	1 084	1 127	50	26	351	603	147	858
D05AX52 calcipotriol, combinations	13 188	15 373	17 660	19 311	22 327	44	262	7 165	11 439	3 461	34 474
D05B ANTIPSORIATICS FOR SYSTEMIC USE	1 637	1 669	1 765	1 886	1 880	43	8	420	1 157	295	6 924
D05BA Psoralens for systemic use	68	59	35	34	40	48	0	11	19	10	36
D05BA02 methoxsalen	58	55	29	33	35	46	0	9	19	7	25
D05BA03 bergapten	10	<5	7	<5	5	60	0	<5	0	<5	11
D05BB Retinoids for treatment of psoriasis	1 568	1 603	1 709	1 819	1 808	43	8	398	1 118	284	5 248
D05BB02 acitretin	1 568	1 603	1 709	1 819	1 808	43	8	398	1 118	284	5 248
D05BX Other antipsoriatics for systemic use	12	15	25	41	42	36	0	16	23	<5	1 640

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group D

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
D05BX51 fumaric acid derivatives, combinations	12	15	25	41	42	36	0	16	23	<5	1 640
D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE	118 080	110 305	108 179	105 181	111 153	59	14 667	46 756	33 510	16 220	20 180
D06A ANTIBIOTICS FOR TOPICAL USE	57 847	55 472	57 269	54 025	58 794	55	12 154	18 466	17 603	10 571	5 107
D06AA Tetracycline and derivatives	3 025	3 004	2 844	2 682	2 729	56	399	744	993	593	311
D06AA02 chlortetracycline	33	26	16	23	19	47	<5	6	6	6	5
D06AA03 oxytetracycline	2 992	2 978	2 828	2 659	2 710	56	398	738	987	587	306
D06AX Other antibiotics for topical use	54 993	52 622	54 594	51 498	56 204	55	11 775	17 753	16 656	10 020	4 796
D06AX01 fusidic acid	53 087	50 936	52 409	49 106	53 649	56	10 757	17 018	16 233	9 641	4 418
D06AX05 bacitracin	2 044	1 819	1 972	1 802	1 739	49	562	527	324	326	212
D06AX07 gentamicin	0	<5	0	0	0	0	0	0	0	0	0
D06AX09 mupirocin	13	8	19	17	14	64	<5	7	5	<5	3
D06AX13 retapamulin	0	7	374	745	1 008	54	528	253	141	86	163
D06B CHEMOTHERAPEUTICS FOR TOPICAL USE	62 469	56 907	52 801	53 024	54 386	62	2 675	29 170	16 536	6 005	15 073
D06BA Sulfonamides	3 447	3 472	3 491	3 202	3 371	53	618	1 131	1 027	595	537
D06BA01 silver sulfadiazine	3 447	3 472	3 491	3 202	3 371	53	618	1 131	1 027	595	537
D06BB Antivirals	52 220	46 096	41 381	41 307	41 865	62	1 932	24 815	11 132	3 986	13 038
D06BB03 aciclovir ¹⁾	28 218	24 069	20 673	20 098	19 684	72	1 357	9 703	6 959	1 665	2 766
D06BB04 podophyllotoxin	11 403	12 249	13 170	13 402	13 562	48	153	12 291	1 057	61	2 964
D06BB06 penciclovir ¹⁾	11 808	8 457	5 031	4 000	3 347	70	162	1 475	1 335	375	709
D06BB10 imiquimod	1 853	2 226	3 407	4 705	6 195	57	275	2 108	1 888	1 924	6 599
D06BB11 docosanol	0	0	6	<5	0	-	0	0	0	0	0
D06BX Other chemotherapeutics	7 061	7 572	8 151	8 721	9 420	67	130	3 330	4 502	1 458	1 498
D06BX01 metronidazole	7 061	7 572	8 151	8 721	9 420	67	130	3 330	4 502	1 458	1 498
D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	347 435	345 383	349 458	347 211	358 914	54	52 310	108 712	128 657	69 235	85 426
D07A CORTICOSTEROIDS, PLAIN	270 409	275 450	285 572	286 429	298 825	54	45 173	90 193	105 877	57 582	64 729
D07AA Corticosteroids, weak (group I)	28 271	27 000	27 438	26 763	28 336	54	13 341	6 937	4 647	3 411	3 418
D07AA02 hydrocortisone ¹⁾	28 271	27 000	27 438	26 763	28 336	54	13 341	6 937	4 647	3 411	3 418
D07AB Corticosteroids, moderately potent (group II)	88 549	91 249	95 779	96 510	102 022	54	23 433	30 048	30 339	18 202	14 579
D07AB02 hydrocortisone butyrate	59 837	62 168	64 610	64 887	67 869	55	16 480	20 141	19 345	11 903	9 853
D07AB08 desonide	29 909	30 353	32 620	33 079	35 672	54	7 467	10 286	11 371	6 548	4 726

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group D

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
D07AC Corticosteroids, potent (group III)	148 931	151 115	154 909	153 607	158 001	54	16 224	50 231	58 821	32 725	35 233
D07AC01 betamethasone	48 814	50 713	52 700	50 084	52 391	54	3 094	16 607	21 189	11 501	7 459
D07AC03 desoximetasone	14 160	13 759	13 814	13 853	13 694	53	524	3 802	5 960	3 408	5 239
D07AC04 flucinolone acetonide	7 549	7 294	7 162	6 572	6 491	53	224	1 350	2 944	1 973	1 171
D07AC08 fluocinonide	1 173	991	872	792	724	54	10	165	362	187	122
D07AC13 mometasone	66 965	69 044	71 674	74 342	78 888	54	10 785	26 127	26 848	15 128	17 613
D07AC17 fluticasone	17 853	16 868	16 949	15 468	13 071	54	2 185	4 423	4 139	2 324	3 629
D07AD Corticosteroids, very potent (group IV)	43 658	45 615	48 233	49 945	52 800	56	1 623	15 990	25 032	10 155	11 499
D07AD01 clobetasol	43 658	45 615	48 233	49 945	52 800	56	1 623	15 990	25 032	10 155	11 499
D07B CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS	57 672	48 610	41 193	37 064	36 036	49	4 937	10 642	13 154	7 303	4 865
D07BB Corticosteroids, moderately potent, combinations with antiseptics	38 422	28 430	29 399	17 785	15 440	50	3 081	4 166	5 204	2 989	2 610
D07BB02 desonide and antiseptics	10 643	14 113	13 954	17 619	15 440	50	3 081	4 166	5 204	2 989	2 610
D07BB03 triamcinolone and antiseptics	19 576	351	<5	0	0	0	0	0	0	0	0
D07BB04 hydrocortisone butyrate and antiseptics	9 295	14 438	15 968	193	0	0	0	0	0	0	0
D07BC Corticosteroids, potent, combinations with antiseptics	20 868	21 617	13 184	20 114	21 356	49	2 088	6 685	8 148	4 435	2 256
D07BC01 betamethasone and antiseptics	18 661	18 726	9 686	17 301	18 848	49	1 887	5 991	7 079	3 891	1 984
D07BC02 flucinolone acetonide and antiseptics	2 274	3 218	3 872	2 918	2 600	48	208	720	1 105	567	271
D07C CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS	24 256	23 925	26 606	26 357	26 756	54	5 708	7 827	8 406	4 815	3 282
D07CA Corticosteroids, weak, combinations with antibiotics	24 256	23 925	25 877	26 351	26 755	54	5 708	7 826	8 406	4 815	3 282
D07CA01 hydrocortisone and antibiotics	24 256	23 925	25 877	26 351	26 755	54	5 708	7 826	8 406	4 815	3 282
D07CC Corticosteroids, potent, combinations with antibiotics	0	0	768	6	<5	0	0	<5	0	0	0
D07CC01 betamethasone and antibiotics	0	0	768	6	<5	0	0	<5	0	0	0
D07X CORTICOSTEROIDS, OTHER COMBINATIONS	30 421	30 467	27 135	26 626	26 427	48	869	8 772	11 747	5 039	12 549
D07XA Corticosteroids, weak, other combinations	0	<5	0	0	0	-	0	0	0	0	0

ATC group D

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
D07XA01 hydrocortisone	0	<5	0	0	0	-	0	0	0	0	0
D07XB Corticosteroids, moderately potent, other combinations	4 007	3 998	556	0	0	-	0	0	0	0	0
D07XB02 triamcinolone	4 007	3 998	556	0	0	-	0	0	0	0	0
D07XC Corticosteroids, potent, other combinations	26 597	26 629	26 672	26 626	26 427	48	869	8 772	11 747	5 039	12 549
D07XC01 betamethasone	26 597	26 629	26 672	26 626	26 427	48	869	8 772	11 747	5 039	12 549
D08 ANTISEPTICS AND DISINFECTANTS	17 934	17 778	18 290	18 621	19 268	59	3 080	7 759	6 203	2 226	2 517
D08A ANTISEPTICS AND DISINFECTANTS ¹⁾	17 934	17 778	18 290	18 621	19 268	59	3 080	7 759	6 203	2 226	2 517
D08AB Aluminium agents	211	266	265	285	278	46	120	73	54	31	39
D08AC Biguanides and amidines	13 980	13 937	14 688	15 171	15 900	60	2 099	6 782	5 424	1 595	1 922
D08AC01 dibrompropamide ¹⁾	5 781	5 256	5 342	5 115	5 278	51	1 628	1 640	1 107	903	630
D08AC02 chlorhexidine ¹⁾	8 445	8 934	9 594	10 315	10 877	64	552	5 246	4 356	723	1 292
D08AG Iodine products	54	56	53	54	74	42	13	17	21	23	13
D08AG01 iodine/octylphenoxyglycol ether ¹⁾	16	12	15	5	<5	0	0	0	<5	0	0
D08AG02 povidone-iodine	<5	<5	0	20	31	55	<5	6	7	17	6
D08AG03 iodine ¹⁾	37	44	38	29	42	33	12	11	13	6	6
D08AJ Quaternary ammonium compounds	109	136	147	135	151	58	22	37	41	51	125
D08AJ03 cetylpyridinium ¹⁾	109	136	147	135	151	58	22	37	41	51	125
D08AL Silver compounds	0	0	0	0	<5	0	0	<5	0	0	0
D08AL01 silver nitrate	0	0	0	0	<5	0	0	<5	0	0	0
D08AX Other antiseptics and disinfectants	3 798	3 564	3 292	3 131	3 020	51	890	882	701	547	417
D08AX01 hydrogen peroxide ¹⁾	2 646	2 462	2 223	2 059	1 829	53	575	549	374	331	208
D08AX06 potassium permanganate ¹⁾	1 179	1 123	1 090	1 095	1 205	47	321	337	331	216	209
D09 MEDICATED DRESSINGS	2 203	2 203	2 077	1 936	1 910	55	164	412	578	756	245
D09A MEDICATED DRESSINGS	2 203	2 203	2 077	1 936	1 910	55	164	412	578	756	245
D09AA Medicated dressings with antiinfectives	2 203	2 203	2 077	1 936	1 910	55	164	412	578	756	245
D09AA02 fusidic acid	2 203	2 203	2 077	1 936	1 910	55	164	412	578	756	245
D10 ANTI-ACNE PREPARATIONS	44 309	47 760	48 261	51 472	54 303	64	3 253	39 768	8 994	2 288	25 216
D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE	42 397	45 425	45 378	47 904	50 376	66	3 175	36 095	8 821	2 285	13 437
D10AD Retinoids for topical use in acne	18 653	21 386	21 578	24 388	27 045	66	1 869	20 005	3 872	1 299	6 732
D10AD01 tretinoin	7 855	9 767	9 451	9 888	10 546	76	410	5 860	3 157	1 119	1 107

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
D10AD02 retinol	57	44	97	117	170	62	11	41	100	18	49
D10AD03 adapalene	11 166	12 028	10 560	8 449	7 111	63	616	5 919	431	145	1 672
D10AD53 adapalene, combinations	0	0	2 247	7 081	10 271	59	935	9 069	249	18	3 903
D10AE Peroxides	2 052	2 359	2 001	2 245	2 265	51	258	1 907	93	7	388
D10AE01 benzoyl peroxide ¹⁾	2 052	2 359	2 001	2 245	2 265	51	258	1 907	93	7	388
D10AF Antiinfectives for treatment of acne	16 977	17 353	16 763	16 046	16 071	64	1 146	12 341	2 218	366	3 547
D10AF01 clindamycin	16 932	17 305	16 729	16 009	16 049	64	1 144	12 324	2 215	366	3 535
D10AF02 erythromycin	46	54	39	41	24	63	<5	19	<5	0	12
D10AX Other anti-acne preparations for topical use	13 135	13 442	13 521	13 292	13 285	68	649	9 035	2 972	629	2 769
D10AX03 azelaic acid	13 122	13 428	13 516	13 286	13 276	68	649	9 033	2 968	626	2 768
D10AX30 various combinations	15	14	7	7	11	73	<5	<5	<5	<5	1
D10B ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE	2 744	3 424	4 227	5 153	5 748	44	144	5 366	233	5	11 779
D10BA Retinoids for treatment of acne	2 744	3 424	4 227	5 153	5 748	44	144	5 366	233	5	11 779
D10BA01 isotretinoin	2 744	3 424	4 227	5 153	5 748	44	144	5 366	233	5	11 779
D11 OTHER DERMATOLOGICAL PREPARATIONS	13 351	13 633	14 730	15 690	16 767	54	2 643	7 285	4 783	2 056	11 060
D11A OTHER DERMATOLOGICAL PREPARATIONS	13 351	13 633	14 730	15 690	16 767	54	2 643	7 285	4 783	2 056	11 060
D11AC Medicated shampoos	1 127	1 017	1 027	974	1 058	52	91	660	228	79	125
D11AC03 selenium compounds ¹⁾	1 127	1 017	1 027	974	1 058	52	91	660	228	79	125
D11AF Wart and anti-corn preparations ¹⁾	1 468	1 415	1 375	1 498	1 924	51	787	726	309	102	233
D11AH Agents for atopic dermatitis, excluding corticosteroids	7 516	8 117	9 500	10 323	10 808	56	1 758	4 814	3 347	889	6 076
D11AH01 tacrolimus	3 949	4 344	6 175	6 804	7 491	56	1 180	3 375	2 330	606	4 232
D11AH02 pimecrolimus	3 697	3 907	3 511	3 712	3 530	57	622	1 535	1 078	295	1 843
D11AX Other dermatologicals	3 273	3 116	2 868	2 940	3 036	47	11	1 112	913	1 000	4 626
D11AX01 minoxidil	196	172	192	175	202	58	<5	125	65	10	137
D11AX10 finasteride	810	766	815	797	742	1	0	592	147	<5	3 642
D11AX16 eflornithine	0	0	0	0	<5	100	0	<5	0	0	1
D11AX18 diclofenac	2 120	2 070	1 697	1 702	1 604	53	5	51	580	968	676

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.8 ATC group G – Genito urinary system and sex hormones

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15–44	45–69	≥70							
G GENITO URINARY SYSTEM AND SEX HORMONES	668 719	678 902	692 728	703 438	721 693	82	3 315	407 249	220 074	91 055	838 022
G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS	29 769	30 233	30 558	30 699	32 037	100	127	23 391	7 043	1 476	6 898
G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS	29 769	30 233	30 558	30 699	32 037	100	127	23 391	7 043	1 476	6 898
G01AA Antibiotics	14 683	14 367	14 416	15 244	20 684	100	66	15 224	4 716	678	4 898
G01AA10 clindamycin	14 683	14 367	14 416	15 244	20 684	100	66	15 224	4 716	678	4 898
G01AF Imidazole derivatives	16 166	17 083	17 328	16 777	12 777	99	62	9 277	2 586	852	1 997
G01AF01 metronidazole	8 844	9 944	10 346	9 685	5 464	100	8	4 086	1 204	166	627
G01AF02 clotrimazole ¹⁾	5 230	5 254	5 028	5 326	5 608	99	36	3 970	1 031	571	1 034
G01AF04 miconazole ¹⁾	823	790	960	768	633	100	<5	468	127	34	113
G01AF05 econazole ¹⁾	1 646	1 490	1 407	1 324	1 334	97	15	960	265	94	223
G01AX Other antiinfectives and antiseptics	12	12	18	6	<5	67	0	0	<5	0	3
G01AX03 policresulen	12	12	18	6	<5	67	0	0	<5	0	3
G02 OTHER GYNECOLOGICALS	38 157	41 330	42 936	44 047	45 225	99	<5	40 089	4 984	148	46 267
G02A OXYTOCICS	35	31	26	12	15	100	0	13	<5	0	2
G02AB Ergot alkaloids	34	31	26	12	15	100	0	13	<5	0	2
G02AB01 methylergometrine	34	31	26	12	15	100	0	13	<5	0	2
G02AD Prostaglandins	<5	0	0	0	0	0	0	0	0	0	0
G02AD02 dinoprostone	<5	0	0	0	0	0	0	0	0	0	0
G02B CONTRACEPTIVES FOR TOPICAL USE	35 777	39 043	40 634	41 674	42 935	100	<5	38 607	4 318	6	43 199
G02BA Intrauterine contraceptives	23 093	24 831	24 795	24 803	24 840	100	0	20 923	3 913	<5	28 781
G02BA03 plastic IUD with progestogen	23 093	24 831	24 795	24 803	24 840	100	0	20 923	3 913	<5	28 781
G02BB Intravaginal contraceptives	12 805	14 337	16 010	17 064	18 256	100	<5	17 836	414	<5	14 418
G02BB01 vaginal ring with progestogen and estrogen	12 805	14 337	16 010	17 064	18 256	100	<5	17 836	414	<5	14 418
G02C OTHER GYNECOLOGICALS	2 428	2 342	2 381	2 458	2 367	80	0	1 557	668	142	3 066
G02CB Prolactine inhibitors	2 428	2 342	2 381	2 458	2 367	80	0	1 557	668	142	3 066
G02CB01 bromocriptine	1 360	1 260	1 247	1 312	1 226	90	0	928	241	57	785
G02CB03 cabergoline	904	915	987	943	921	68	0	523	327	71	1 245
G02CB04 quinagolide	211	214	189	302	284	78	0	154	113	17	1 036
G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	511 143	510 107	512 606	515 229	525 567	99	2 572	350 831	135 796	36 368	400 214
G03A HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE	300 971	301 407	304 422	307 262	315 314	100	1 231	303 370	10 687	26	173 746
G03AA Progestogens and estrogens, fixed combinations	145 430	211 548	212 575	214 962	221 389	100	1 027	216 445	3 907	10	130 840

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
G03AA06 norgestrel and estrogen	<5	0	0	0	0	0	0	0	0	0	0
G03AA07 levonorgestrel and estrogen	47 622	83 628	88 668	87 148	90 234	100	404	88 259	1 565	6	46 731
G03AA09 desogestrel and estrogen	10 862	40 384	48 475	55 278	61 018	100	412	59 665	940	<5	20 691
G03AA12 drospirenone and estrogen	84 140	97 495	79 229	74 740	72 591	100	268	71 071	1 249	<5	57 087
G03AA13 norelgestromin and estrogen	9 260	9 019	9 016	8 924	8 978	100	10	8 779	189	0	6 331
G03AB Progestogens and estrogens, sequential preparations	112 814	29 232	22 034	18 862	17 638	100	48	16 944	645	<5	5 535
G03AB03 levonorgestrel and estrogen	102 583	5 340	<5	<5	0	0	0	0	0	0	0
G03AB04 norethisterone and estrogen	12 073	24 611	22 031	18 546	16 057	100	41	15 422	593	<5	4 356
G03AB08 dienogest and estrogen	0	0	0	326	1 624	100	7	1 563	54	0	1 180
G03AC Progestogens	77 768	85 546	87 693	89 490	92 531	100	207	85 996	6 313	15	37 331
G03AC01 norethisterone	12 892	10 481	9 195	8 182	7 397	100	<5	6 439	953	<5	1 682
G03AC03 levonorgestrel	261	265	193	141	115	100	<5	110	<5	0	149
G03AC06 medroxyprogesterone	23 401	22 512	21 186	19 971	19 601	100	57	16 580	2 955	9	4 707
G03AC08 etonogestrel	2 063	2 600	2 683	2 807	3 292	100	9	3 201	82	0	4 227
G03AC09 desogestrel	41 479	51 995	56 589	60 277	64 120	100	138	61 575	2 402	5	26 565
G03AD Emergency contraceptives	163	143	119	100	159	99	<5	151	6	0	39
G03AD01 levonorgestrel ¹⁾	163	143	119	99	79	99	<5	77	<5	0	17
G03AD02 ulipristal	0	0	0	<5	80	99	<5	74	5	0	23
G03B ANDROGENS	3 999	4 291	4 801	5 234	5 550	6	51	1 655	3 124	720	20 654
G03BA 3-oxoandrogen (4) derivatives	3 999	4 291	4 801	5 231	5 548	6	51	1 653	3 124	720	20 635
G03BA03 testosterone	3 999	4 291	4 801	5 231	5 548	6	51	1 653	3 124	720	20 635
G03BB 5-androstanon (3) derivatives	0	0	0	<5	<5	0	0	<5	<5	0	18
G03BB01 mesterolone	0	0	0	<5	<5	0	0	<5	<5	0	18
G03C ESTROGENS	101 563	105 541	109 009	112 831	116 536	100	199	5 149	79 240	31 948	74 204
G03CA Natural and semisynthetic estrogens, plain	90 033	95 288	99 840	104 463	108 511	100	199	4 933	72 088	31 291	61 722
G03CA01 ethinylestradiol	165	159	146	140	127	83	73	39	15	0	652
G03CA03 estradiol	68 866	76 472	83 236	89 792	95 178	100	26	4 636	68 544	21 972	54 377
G03CA04 estriol ¹⁾	22 781	20 430	18 208	16 213	14 802	100	101	302	4 250	10 149	6 691
G03CA53 estradiol, combinations	0	0	0	<5	0	0	0	0	0	0	0
G03CA57 conjugated estrogens	<5	<5	5	<5	<5	100	0	<5	<5	0	2
G03CX Other estrogens	12 561	11 193	10 007	9 183	8 838	100	0	260	7 856	722	12 482
G03CX01 tibolone	12 561	11 193	10 007	9 183	8 838	100	0	260	7 856	722	12 482
G03D PROGESTOGENS	39 386	39 348	40 529	37 790	38 777	100	1 148	28 724	8 755	150	16 101
G03DA Pregnen (4) derivatives	12 156	12 456	13 004	13 106	12 987	100	78	9 723	3 055	131	13 839

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group G

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
G03DA02 medroxyprogesterone	7 539	7 338	7 504	7 215	6 867	100	78	3 705	2 955	129	1 261
G03DA04 progesterone	4 703	5 202	5 588	5 987	6 239	100	0	6 134	103	<5	12 578
G03DC Estren derivatives	27 931	27 603	28 284	25 413	26 527	100	1 076	19 564	5 866	21	2 262
G03DC02 norethisterone	27 931	27 603	28 284	25 413	26 527	100	1 076	19 564	5 866	21	2 262
G03F PROGESTOGENS AND ESTROGENS IN COMBINATION	56 823	50 987	47 395	45 758	44 080	100	8	2 562	38 276	3 234	33 022
G03FA Progestogens and estrogens, fixed combinations	44 108	40 064	37 409	36 195	35 049	100	<5	815	31 148	3 085	26 781
G03FA01 norethisterone and estrogen	43 324	39 329	36 729	35 628	34 519	100	<5	795	30 658	3 065	26 098
G03FA12 medroxyprogesterone and estrogen	521	500	474	527	715	100	0	23	660	32	683
G03FA15 dienogest and estrogen	361	314	280	233	<5	100	0	0	<5	0	1
G03FB Progestogens and estrogens, sequential preparations	14 549	12 441	11 369	10 851	10 322	100	7	1 837	8 313	165	6 241
G03FB01 norgestrel and estrogen	820	5	0	0	0	0	0	0	0	0	0
G03FB05 norethisterone and estrogen	13 910	12 437	11 369	10 851	10 322	100	7	1 837	8 313	165	6 241
G03G GONADOTROPINS AND OTHER OVULATION STIMULANTS	9 748	10 113	10 938	11 093	10 341	95	<5	10 150	187	0	72 091
G03GA Gonadotropins	5 263	5 552	5 884	6 013	6 137	98	<5	6 070	64	0	70 526
G03GA01 chorionic gonadotrophin	1 299	1 391	1 667	1 277	1 476	92	<5	1 449	24	0	653
G03GA02 human menopausal gonadotrophin	864	1 092	1 405	1 601	1 540	100	0	1 526	14	0	11 711
G03GA04 urofollitropin	0	0	0	0	85	100	0	84	<5	0	638
G03GA05 follitropin alfa	1 595	1 624	1 631	1 770	1 743	99	0	1 721	22	0	22 315
G03GA06 follitropin beta	2 787	2 878	3 052	2 916	3 016	100	0	2 995	21	0	31 644
G03GA07 lutropin alfa	81	82	62	65	26	100	0	26	0	0	105
G03GA08 choriogonadotropin alfa	3 717	4 040	4 179	4 556	4 538	100	0	4 506	32	0	2 497
G03GA09 corifollitropin alfa	0	0	0	0	132	100	0	132	0	0	900
G03GA30 combinations	0	0	<5	8	<5	100	0	<5	0	0	63
G03GB Ovulation stimulants, synthetic	5 647	5 846	6 453	6 483	5 385	93	<5	5 246	138	0	1 565
G03GB02 clomifene	5 647	5 846	6 453	6 483	5 385	93	<5	5 246	138	0	1 565
G03H ANTIANDROGENS	19 127	19 573	16 970	16 171	16 759	99	80	16 234	334	111	6 964
G03HA Antiandrogens, plain	236	232	189	181	205	5	0	22	73	110	463
G03HA01 cyproterone	236	232	189	181	205	5	0	22	73	110	463
G03HB Antiandrogens and estrogens	18 899	19 346	16 791	15 999	16 560	100	80	16 217	262	<5	6 500
G03HB01 cyproterone and estrogen	18 899	19 346	16 791	15 999	16 560	100	80	16 217	262	<5	6 500

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
G03X OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	1 958	1 720	1 507	1 298	1 142	97	<5	18	422	701	3 433
G03XA Antigonadotropins and similar agents	43	52	51	50	49	39	0	15	27	7	189
G03XA01 danazol	43	52	51	50	49	39	0	15	27	7	189
G03XB Antiprogestogens	0	<5	<5	0	<5	100	0	<5	0	0	1
G03XB01 mifepristone	0	<5	<5	0	<5	100	0	<5	0	0	1
G03XC Selective estrogen receptor modulators	1 915	1 666	1 452	1 248	1 092	100	<5	<5	395	694	3 243
G03XC01 raloxifene	1 915	1 666	1 452	1 248	1 092	100	<5	<5	395	694	3 243
G04 UROLOGICALS	122 746	131 477	141 649	148 780	156 056	21	625	15 348	81 824	58 259	384 644
G04B OTHER UROLOGICALS, INCL. ANTISPASMODICS	95 657	100 732	106 596	109 835	113 499	28	624	13 559	64 979	34 337	327 166
G04BA Acidifiers	<5	<5	<5	<5	0	0	0	0	0	0	0
G04BA01 ammonium chloride	<5	<5	<5	<5	0	-	0	0	0	0	0
G04BD Urinary antispasmodics	39 293	40 928	42 828	44 578	46 170	69	615	3 513	20 059	21 983	163 285
G04BD04 oxybutynin	2 060	2 054	1 690	1 480	1 504	71	139	250	617	498	10 056
G04BD07 tolterodine	27 135	23 747	21 577	18 355	15 675	71	426	855	6 005	8 389	56 729
G04BD08 solifenacin	11 237	13 975	15 757	17 349	19 874	68	64	1 658	9 070	9 082	61 002
G04BD10 darifenacin	2 185	4 336	5 430	5 630	5 125	71	<5	367	2 328	2 429	15 416
G04BD11 fesoterodine	0	0	1 818	5 380	7 638	66	13	668	3 666	3 291	20 082
G04BE Drugs used in erectile dysfunction	57 442	61 028	65 137	66 657	68 785	0	9	10 135	45 799	12 842	163 859
G04BE01 alprostadil	1 941	2 039	2 335	2 180	2 543	0	0	138	1 735	670	4 539
G04BE02 papaverine	30	30	40	37	55	0	0	<5	45	9	112
G04BE03 sildenafil	32 054	33 267	34 776	34 734	34 371	1	9	4 890	22 251	7 221	75 802
G04BE04 yohimbine	23	20	13	19	15	0	0	<5	8	6	16
G04BE07 apomorphine	160	6	0	0	0	-	0	0	0	0	0
G04BE08 tadalafil	18 471	21 276	23 981	26 821	29 880	0	0	4 904	20 507	4 469	65 591
G04BE09 vardenafil	11 727	11 625	11 561	10 376	9 933	0	0	1 346	6 821	1 766	16 707
G04BE30 combinations	573	599	537	616	495	0	0	26	358	111	1 093
G04BX Other urologicals	13	10	10	10	11	45	0	8	<5	0	22
G04BX01 magnesium hydroxide	13	10	10	10	11	45	0	8	<5	0	22
G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY	31 539	35 865	41 018	45 439	49 905	1	<5	1 958	20 474	27 472	57 478
G04CA Alpha-adrenoreceptor antagonists	23 708	27 133	31 502	34 944	38 354	1	<5	1 008	17 136	20 209	34 932
G04CA01 alfuzosin	972	937	777	536	497	2	0	28	216	253	743
G04CA02 tamsulosin	21 924	25 399	30 169	33 876	37 375	1	0	910	16 732	19 733	33 598

ATC group G

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
G04CA03 terazosin	984	987	898	744	649	1	<5	79	262	307	588
G04CA52 tamsulosin and dutasteride	0	0	0	0	<5	0	0	0	<5	<5	3
G04CB Testosterone-5-alpha reductase inhibitors	10 300	11 657	13 253	14 939	16 979	0	0	958	5 402	10 619	22 546
G04CB01 finasteride	5 915	5 804	10 194	12 852	15 189	0	0	921	4 857	9 411	17 164
G04CB02 dutasteride	4 492	5 943	4 054	2 331	1 939	0	0	42	601	1 296	5 382

2.9 ATC group H – Systemic hormonal preparations, excl. sex hormones and insulins

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15–44	45–69	≥70							
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	323 880	342 524	357 069	375 460	387 736	68	15 937	104 181	165 685	101 933	415 842
H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES	22 932	23 659	24 310	24 490	24 826	66	9 220	12 890	1 666	1 050	285 504
H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES	1 395	1 441	1 485	1 577	1 656	44	911	450	281	14	159 667
H01AA ACTH	<5	<5	<5	<5	<5	0	0	0	<5	0	2
H01AA02 tetracosactide	<5	<5	<5	<5	<5	0	0	0	<5	0	2
H01AC Somatropin and somatropin agonists	1 383	1 429	1 470	1 555	1 631	44	911	439	267	14	151 943
H01AC01 somatropin	1 383	1 429	1 470	1 555	1 631	44	911	439	267	14	151 943
H01AX Other anterior pituitary lobe hormones and analogues	10	10	13	21	24	38	0	11	13	0	7 723
H01AX01 pegvisomant	10	10	13	21	24	38	0	11	13	0	7 723
H01B POSTERIOR PITUITARY LOBE HORMONES	18 267	18 541	18 859	18 807	18 976	62	8 343	8 716	1 091	826	39 311
H01BA Vasopressin and analogues	11 606	11 706	11 623	11 288	11 247	36	8 307	1 058	1 056	826	37 858
H01BA02 desmopressin	11 606	11 706	11 623	11 288	11 247	36	8 307	1 058	1 056	826	37 858
H01BB Oxytocin and analogues	6 661	6 837	7 237	7 522	7 731	100	36	7 660	35	0	1 453
H01BB02 oxytocin	6 661	6 837	7 237	7 522	7 731	100	36	7 660	35	0	1 453
H01C HYPOTHALAMIC HORMONES	3 444	3 847	4 147	4 315	4 430	93	7	3 854	357	212	86 526
H01CA Gonadotropin-releasing hormones	2 748	3 021	3 101	2 829	2 314	100	0	2 294	20	0	5 827
H01CA02 nafarelin	2 748	3 021	3 101	2 829	2 314	100	0	2 294	20	0	5 827
H01CB Antigrowth hormones	415	460	494	498	593	51	7	59	315	212	74 987
H01CB02 octreotide	358	385	406	398	472	53	6	52	257	157	57 855
H01CB03 lanreotide	67	89	118	118	137	46	<5	9	63	64	17 132
H01CC Anti-gonadotropin-releasing hormones	344	459	675	1 246	1 887	100	0	1 865	22	0	5 713
H01CC01 ganirelix	261	351	555	975	1 513	100	0	1 495	18	0	4 479
H01CC02 cetorelix	93	120	149	298	481	100	0	475	6	0	1 233
H02 CORTICOSTEROIDS FOR SYSTEMIC USE	156 732	169 704	177 573	190 385	197 194	56	4 600	58 285	81 187	53 122	49 622
H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	156 596	169 577	177 454	190 241	197 010	56	4 600	58 243	81 085	53 082	49 545
H02AA Mineralocorticoids	1 121	1 145	1 160	1 178	1 223	56	84	386	534	219	335
H02AA02 fludrocortisone	1 121	1 145	1 160	1 178	1 223	56	84	386	534	219	335
H02AB Glucocorticoids	156 455	169 433	177 308	190 107	196 875	56	4 591	58 216	81 038	53 030	49 210

ATC group H

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
H02AB01 betamethasone	2 867	1 907	1 736	1 700	1 637	48	613	342	509	173	538
H02AB02 dexamethasone	1 716	1 799	1 931	2 118	2 551	49	97	276	1 488	690	2 649
H02AB04 methylprednisolone	9 139	9 582	10 159	10 745	10 810	53	69	2 972	5 452	2 317	3 940
H02AB06 prednisolone	121 169	129 018	136 459	143 521	152 176	58	3 085	35 080	64 893	49 118	31 261
H02AB07 prednisone	5	<5	<5	<5	82	72	0	8	49	25	54
H02AB08 triamcinolone	23 347	29 129	29 048	34 538	32 177	49	616	20 110	9 938	1 513	4 220
H02AB09 hydrocortisone	447	429	422	437	481	64	59	192	189	41	920
H02AB10 cortisone	2 375	2 453	2 510	2 593	2 662	52	131	693	1 286	552	5 553
H02AB13 deflazacort	13	18	17	18	17	59	6	<5	7	<5	74
H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS	344	359	340	332	372	62	0	69	202	101	77
H02BX Corticosteroids for systemic use, combinations	344	359	340	332	372	62	0	69	202	101	77
H02BX01 methylprednisolone, combinations	344	359	340	332	372	62	0	69	202	101	77
H03 THYROID THERAPY	154 303	160 934	167 745	174 352	180 831	82	1 320	34 273	90 436	54 802	57 067
H03A THYROID PREPARATIONS	150 758	157 372	164 071	170 770	177 246	82	1 294	33 281	88 891	53 780	54 317
H03AA Thyroid hormones	150 758	157 372	164 071	170 770	177 246	82	1 294	33 281	88 891	53 780	54 317
H03AA01 levothyroxine sodium	150 521	157 115	163 750	170 482	176 895	82	1 287	33 156	88 706	53 746	50 462
H03AA02 liothyronine sodium	3 643	3 867	3 986	4 095	4 142	91	20	1 329	2 491	302	3 236
H03AA03 combinations of levothyroxine and liothyronine	257	295	404	429	328	89	0	120	195	13	304
H03AA05 thyroid gland preparations	0	0	0	0	182	91	0	83	96	<5	316
H03B ANTITHYROID PREPARATIONS	4 951	4 985	5 130	5 019	5 123	80	47	1 660	2 243	1 173	2 750
H03BA Thiouracils	453	470	552	552	521	87	<5	310	154	55	440
H03BA02 propylthiouracil	453	470	552	552	521	87	<5	310	154	55	440
H03BB Sulfur-containing imidazole derivatives	4 621	4 624	4 740	4 590	4 725	80	46	1 429	2 122	1 128	2 310
H03BB01 carbimazole	4 621	4 624	4 740	4 590	4 725	80	46	1 429	2 122	1 128	2 310
H04 PANCREATIC HORMONES	5 018	4 775	5 265	5 336	5 485	46	1 144	2 702	1 350	289	2 607
H04A GLYCOGENOLYTIC HORMONES	5 018	4 775	5 265	5 336	5 485	46	1 144	2 702	1 350	289	2 607
H04AA Glycogenolytic hormones	5 018	4 775	5 265	5 336	5 485	46	1 144	2 702	1 350	289	2 607
H04AA01 glucagon	5 018	4 775	5 265	5 336	5 485	46	1 144	2 702	1 350	289	2 607
H05 CALCIUM HOMEOSTASIS	532	603	644	748	802	59	<5	103	369	329	21 042
H05A PARATHYROID HORMONES AND ANALOGUES	152	194	225	237	263	81	0	29	141	93	8 433
H05AA Parathyroid hormones and analogues	152	194	225	237	263	81	0	29	141	93	8 433

ATC group H

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
H05AA02 teriparatide	152	174	201	213	253	81	0	29	135	89	7 966
H05AA03 parathyroid hormone	0	22	25	25	12	83	0	0	7	5	467
H05B ANTI-PARATHYROID AGENTS	383	411	421	511	540	49	<5	74	228	237	12 609
H05BA Calcitonin preparations	194	156	110	86	80	85	<5	5	14	60	462
H05BA01 calcitonin (salmon synthetic)	194	156	110	86	80	85	<5	5	14	60	462
H05BX Other anti-parathyroid agents	189	255	313	425	460	42	0	69	214	177	12 147
H05BX01 cinacalcet	189	255	304	391	417	43	0	62	195	160	11 300
H05BX02 paricalcitol	0	0	11	44	59	51	0	10	27	22	847

2.10 ATC group J – Antiinfectives for systemic use

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15–44	45–69	≥70							
J ANTIINFECTIVES FOR SYSTEMIC USE	1 201 347	1 236 736	1 247 162	1 394 462	1 251 635	60	158 322	508 894	399 957	184 462	657 093
J01 ANTIBACTERIALS FOR SYSTEMIC USE	1 136 906	1 168 650	1 181 343	1 138 196	1 179 714	59	154 049	472 507	375 537	177 621	284 808
J01A TETRACYCLINES	176 511	180 466	172 668	161 072	166 971	57	1 627	69 102	67 858	28 384	30 876
J01AA Tetracyclines	176 511	180 466	172 668	161 072	166 971	57	1 627	69 102	67 858	28 384	30 876
J01AA02 doxycycline	141 390	144 575	135 973	124 471	129 768	58	680	43 453	59 090	26 545	17 481
J01AA04 lymecycline	11 474	12 328	12 748	13 528	14 767	56	376	10 391	3 354	646	7 356
J01AA06 oxytetracycline	6 065	5 785	5 605	5 244	5 163	52	105	3 144	1 477	437	995
J01AA07 tetracycline	20 131	20 344	20 731	20 086	19 705	54	504	13 649	4 617	935	4 920
J01AA08 minocycline	5	<5	8	16	58	69	0	37	20	<5	30
J01AA12 tigecycline	<5	<5	6	<5	<5	0	0	<5	0	0	94
J01B AMPHENICOLS	0	0	<5	0	<5	0	0	<5	0	0	1
J01BA Amphenicols	0	0	<5	0	<5	0	0	<5	0	0	1
J01BA01 chloramphenicol	0	0	<5	0	<5	0	0	<5	0	0	1
J01C BETA-LACTAM ANTI-BACTERIALS, PENICILLINS	701 490	731 232	764 656	744 430	775 844	60	116 140	303 846	237 153	118 705	119 045
J01CA Penicillins with extended spectrum	245 173	262 484	281 586	283 578	301 145	74	37 066	98 560	95 108	70 411	46 769
J01CA01 ampicillin	33	32	35	19	39	38	<5	<5	7	28	30
J01CA02 pivampicillin	4 102	1 288	<5	0	0	0	0	0	0	0	0
J01CA04 amoxicillin	104 508	114 670	123 464	118 112	127 477	56	32 468	31 062	39 897	24 050	16 662
J01CA08 pivmecillinam	146 365	156 916	169 587	176 709	185 907	87	4 968	70 782	59 204	50 953	30 074
J01CA11 mecillinam	11	12	8	<5	<5	100	0	0	<5	0	3
J01CE Beta-lactamase sensitive penicillins	450 099	460 871	475 189	444 685	457 770	54	83 307	192 712	134 039	47 712	43 787
J01CE01 benzylpenicillin	63	53	54	58	52	33	<5	9	18	22	30
J01CE02 phenoxymethylpenicillin	450 008	460 792	475 113	444 618	457 657	54	83 305	192 653	134 003	47 696	43 534
J01CE08 benzathine benzylpenicillin	61	50	46	40	99	26	<5	63	29	6	223
J01CF Beta-lactamase resistant penicillins	65 522	73 745	79 411	85 870	92 635	48	5 533	40 076	31 406	15 620	28 097
J01CF01 dicloxacillin	62 593	71 515	77 178	84 083	91 037	49	5 446	39 471	30 843	15 277	26 912
J01CF02 cloxacillin	3 496	2 687	2 683	2 153	1 924	48	88	701	705	430	1 133
J01CF05 flucloxacillin	<5	6	19	32	22	32	17	<5	0	<5	52
J01CR Combinations of penicillins, incl. beta-lactamase inhibitors	48	31	52	120	135	61	68	16	20	31	392
J01CR02 amoxicillin and enzyme inhibitor	30	15	38	101	118	59	67	9	15	27	192
J01CR05 piperacillin and enzyme inhibitor	18	16	14	19	17	71	<5	7	5	<5	200

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
J01D OTHER BETA-LACTAM ANTIBACTERIALS	29 322	28 996	27 210	24 295	23 474	59	3 173	8 449	7 893	3 959	7 488
J01DB First-generation cephalosporins	29 105	28 757	26 924	23 974	23 101	59	3 093	8 326	7 804	3 878	3 333
J01DB01 cefalexin	29 093	28 733	26 914	23 952	23 084	59	3 093	8 324	7 798	3 869	3 318
J01DB03 cefalotin	14	24	10	23	17	35	0	<5	6	9	15
J01DC Second-generation cephalosporins	46	58	67	63	71	46	<5	13	19	38	62
J01DC02 cefuroxime	46	58	67	63	71	46	<5	13	19	38	62
J01DD Third-generation cephalosporins	173	198	232	263	310	44	87	104	72	47	2 207
J01DD01 cefotaxime	16	17	30	39	42	50	<5	7	16	17	65
J01DD02 ceftazidime	54	66	57	71	80	45	21	40	12	7	1 445
J01DD04 ceftriaxone	103	115	148	155	190	43	64	58	45	23	697
J01DF Monobactams	12	12	12	11	13	38	0	11	<5	<5	461
J01DF01 aztreonam	12	12	12	11	13	38	0	11	<5	<5	461
J01DH Carbapenems	34	29	31	56	43	49	8	26	<5	5	1 425
J01DH02 meropenem	34	27	30	46	39	51	8	25	<5	<5	1 208
J01DH03 ertapenem	0	<5	<5	8	<5	33	0	0	<5	<5	108
J01DH51 imipenem and enzyme inhibitor	0	<5	<5	<5	<5	50	0	<5	0	<5	108
J01E SULFONAMIDES AND TRIMETHOPRIM	131 645	125 977	123 868	118 486	117 017	78	13 983	32 052	37 177	33 805	11 197
J01EA Trimethoprim and derivatives	102 072	96 543	93 084	88 501	86 061	86	8 423	24 438	26 751	26 449	7 031
J01EA01 trimethoprim	102 072	96 543	93 084	88 501	86 061	86	8 423	24 438	26 751	26 449	7 031
J01EE Combinations of sulfonamides and trimethoprim, incl. derivatives	33 887	33 487	34 914	34 026	34 949	57	6 083	8 364	11 610	8 892	4 166
J01EE01 sulfamethoxazole and trimethoprim	33 887	33 487	34 914	34 026	34 949	57	6 083	8 364	11 610	8 892	4 166
J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS	317 051	326 229	310 374	283 337	300 921	57	41 064	141 391	92 187	26 279	53 451
J01FA Macrolides	285 966	292 195	272 328	244 678	257 800	58	37 240	123 274	76 896	20 390	39 932
J01FA01 erythromycin	161 948	158 396	142 942	123 140	129 093	58	29 408	51 330	37 364	10 991	16 502
J01FA02 spiramycin	4 149	4 368	3 575	3 033	2 794	62	44	1 109	1 309	332	473
J01FA09 clarithromycin	50 845	51 608	44 208	36 958	37 818	57	4 214	13 816	14 758	5 030	7 124
J01FA10 azithromycin	81 225	90 880	92 794	90 850	98 373	59	4 653	62 115	26 860	4 745	15 833
J01FF Lincosamides	37 935	41 699	46 064	45 847	51 130	54	4 669	21 988	17 824	6 649	13 519
J01FF01 clindamycin	37 935	41 699	46 064	45 847	51 130	54	4 669	21 988	17 824	6 649	13 519
J01G AMINOGLYCOSIDE ANTIBACTERIALS	257	282	278	289	273	44	98	105	49	21	11 420

ATC group J

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
J01GA Streptomycins	<5	0	<5	0	0	-	0	0	0	0	0
J01GA01 streptomycin	<5	0	<5	0	0	-	0	0	0	0	0
J01GB Other aminoglycosides	256	282	277	289	273	44	98	105	49	21	11 420
J01GB01 tobramycin	229	253	245	258	250	44	95	96	43	16	10 650
J01GB03 gentamicin	23	25	28	26	16	44	<5	6	<5	5	95
J01GB06 amikacin	<5	5	6	5	10	60	<5	6	<5	0	675
J01GB07 netilmicin	<5	0	0	0	0	-	0	0	0	0	0
J01M QUINOLONE ANTIBACTERIALS	51 286	55 879	59 957	60 651	64 658	50	502	16 674	27 097	20 385	15 360
J01MA Fluoroquinolones	51 285	55 879	59 957	60 651	64 658	50	502	16 674	27 097	20 385	15 360
J01MA01 ofloxacin	3 199	3 002	3 012	2 717	2 515	45	<5	759	1 038	715	868
J01MA02 ciprofloxacin	48 526	53 263	57 335	58 298	62 401	50	500	15 857	26 223	19 821	13 992
J01MA12 levofloxacin	<5	5	5	15	21	33	0	<5	13	<5	168
J01MA14 moxifloxacin	0	36	65	71	142	47	0	128	12	<5	332
J01MB Other quinolones	<5	0	0	0	0	-	0	0	0	0	0
J01MB02 nalidixic acid	<5	0	0	0	0	-	0	0	0	0	0
J01X OTHER ANTIBACTERIALS	45 044	46 625	47 875	51 068	54 600	84	1 571	11 273	17 850	23 906	35 970
J01XA Glycopeptide antibacterials	14	23	29	27	23	48	6	<5	8	6	472
J01XA01 vancomycin	11	21	23	26	21	52	6	<5	8	<5	353
J01XA02 teicoplanin	<5	<5	6	<5	<5	0	0	0	0	<5	119
J01XB Polymyxins	79	66	60	64	55	58	16	27	8	<5	2 036
J01XB01 colistin	79	66	60	64	55	58	16	27	8	<5	2 036
J01XC Steroid antibacterials	868	866	865	711	757	53	38	240	275	204	514
J01XC01 fusidic acid	868	866	865	711	757	53	38	240	275	204	514
J01XD Imidazole derivatives	12	16	17	23	24	67	<5	<5	9	9	83
J01XD01 metronidazole	12	16	17	23	24	67	<5	<5	9	9	83
J01XE Nitrofurantoin derivatives	29 181	29 388	29 536	31 295	33 566	85	1 433	8 635	10 939	12 559	3 758
J01XE01 nitrofurantoin	29 181	29 388	29 536	31 295	33 566	85	1 433	8 635	10 939	12 559	3 758
J01XX Other antibacterials	18 203	19 854	21 193	23 185	24 874	83	127	2 978	8 096	13 673	29 105
J01XX05 methenamine	18 078	19 711	21 023	22 969	24 631	83	126	2 934	7 985	13 586	19 329
J01XX08 linezolid	128	146	177	223	252	39	<5	44	115	92	9 776
J02 ANTIMYCOTICS FOR SYSTEMIC USE	36 874	39 045	40 785	42 646	45 311	87	443	28 768	12 964	3 136	21 935
J02A ANTIMYCOTICS FOR SYSTEMIC USE	36 874	39 045	40 785	42 646	45 311	87	443	28 768	12 964	3 136	21 935
J02AA Antibiotics	7	<5	<5	<5	0	-	0	0	0	0	0
J02AA01 amphotericin B	7	<5	<5	<5	0	-	0	0	0	0	0
J02AB Imidazole derivatives	2 317	2 325	2 294	2 262	2 163	45	20	1 439	626	78	631
J02AB02 ketoconazole	2 317	2 325	2 294	2 262	2 163	45	20	1 439	626	78	631

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
J02AC Triazole derivatives	34 664	36 794	38 599	40 488	43 264	89	425	27 406	12 369	3 064	19 261
J02AC01 fluconazole	34 357	36 547	38 354	40 227	42 948	89	420	27 264	12 230	3 034	12 169
J02AC02 itraconazole	403	316	307	526	471	77	6	269	171	25	555
J02AC03 voriconazole	62	59	66	65	80	46	<5	23	43	13	5 309
J02AC04 posaconazole	0	<5	7	9	22	32	0	7	14	<5	1 228
J02AX Other antimycotics for systemic use	<5	<5	<5	<5	<5	100	0	0	<5	<5	2 043
J02AX04 caspofungin	<5	<5	<5	<5	<5	100	0	0	<5	<5	2 043
J02AX06 anidulafungin	0	0	0	<5	0	-	0	0	0	0	0
J04 ANTIMYCOBACTERIALS	887	913	917	1 336	1 573	47	92	650	498	333	4 473
J04A DRUGS FOR TREATMENT OF TUBERCULOSIS	448	479	486	931	1 126	50	83	559	290	194	4 104
J04AB Antibiotics	267	314	318	401	444	47	39	96	148	161	1 359
J04AB02 rifampicin	245	296	303	377	422	46	38	85	138	161	858
J04AB04 rifabutin	24	17	16	25	24	63	<5	12	11	0	500
J04AB30 capreomycin	0	<5	<5	0	0	-	0	0	0	0	0
J04AC Hydrazides	55	47	38	64	75	57	5	51	16	<5	91
J04AC01 isoniazid	55	47	38	64	75	57	5	51	16	<5	91
J04AD Thiocarbamide derivatives	0	<5	<5	<5	0	0	0	0	0	0	0
J04AD01 protionamide	0	<5	<5	<5	0	-	0	0	0	0	0
J04AK Other drugs for treatment of tuberculosis	155	127	99	126	203	52	7	110	69	17	678
J04AK01 pyrazinamide	40	25	13	20	28	50	<5	19	8	0	49
J04AK02 ethambutol	139	123	97	115	198	51	7	106	68	17	629
J04AM Combinations of drugs for treatment of tuberculosis	115	96	112	493	645	51	45	441	127	32	1 976
J04AM02 rifampicin and isoniazid	82	70	82	433	578	52	44	401	107	26	1 540
J04AM05 rifampicin, pyrazinamide and isoniazid	50	34	36	76	138	49	<5	94	30	12	324
J04AM06 rifampicin, pyrazinamide, ethambutol and isoniazid	0	<5	13	58	47	53	<5	29	10	5	111
J04B DRUGS FOR TREATMENT OF LEPRO	439	437	433	405	449	37	9	93	208	139	370
J04BA Drugs for treatment of lepra	439	437	433	405	449	37	9	93	208	139	370
J04BA01 clofazimine	0	0	<5	0	0	0	0	0	0	0	0
J04BA02 dapson	439	437	432	405	449	37	9	93	208	139	370
J05 ANTIVIRALS FOR SYSTEMIC USE	24 139	24 510	24 594	304 687	31 018	60	719	15 489	11 206	3 604	281 523
J05A DIRECT ACTING ANTIVIRALS	24 139	24 510	24 594	304 687	31 018	60	719	15 489	11 206	3 604	281 523

ATC group J

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors	18 391	19 845	21 808	23 038	24 874	64	472	12 411	8 715	3 276	49 763
J05AB01 aciclovir	8 359	8 787	9 892	10 264	11 310	67	299	5 651	3 703	1 657	4 450
J05AB04 ribavirin	662	728	803	770	705	36	8	418	276	<5	17 989
J05AB06 ganciclovir	<5	0	<5	0	<5	33	<5	0	<5	0	45
J05AB11 valaciclovir	9 532	10 466	11 347	12 244	13 087	64	162	6 590	4 713	1 622	16 398
J05AB12 cidofovir	<5	0	<5	0	0	-	0	0	0	0	0
J05AB14 valganciclovir	191	197	223	246	283	33	<5	70	179	31	10 882
J05AD Phosphonic acid derivatives	<5	<5	0	0	0	0	0	0	0	0	0
J05AD01 foscarnet	<5	<5	0	0	0	0	0	0	0	0	0
J05AE Protease inhibitors	819	961	1 108	1 238	1 347	40	11	726	588	22	57 679
J05AE01 saquinavir	16	19	17	11	9	33	0	<5	5	0	376
J05AE02 indinavir	30	21	11	6	<5	33	0	<5	0	<5	81
J05AE03 ritonavir	260	310	379	499	604	34	<5	317	277	8	2 304
J05AE04 nelfinavir	68	51	0	0	0	-	0	0	0	0	0
J05AE06 lopinavir	410	525	582	583	551	53	9	346	188	8	18 427
J05AE07 fosamprenavir	6	5	<5	<5	<5	33	0	<5	<5	<5	106
J05AE08 atazanavir	353	425	517	660	780	34	<5	403	360	14	31 939
J05AE09 tipranavir	6	7	<5	<5	0	-	0	0	0	0	0
J05AE10 darunavir	0	25	48	55	70	21	0	16	54	0	4 446
J05AF Nucleoside and nucleotide reverse transcriptase inhibitors	450	400	394	388	399	34	18	190	182	9	15 693
J05AF01 zidovudine	69	61	55	41	34	41	5	20	8	<5	618
J05AF02 didanosine	131	102	77	53	37	43	<5	17	18	<5	664
J05AF04 stavudine	69	47	28	13	13	62	<5	8	<5	0	211
J05AF05 lamivudine	209	174	145	117	100	48	12	39	47	<5	1 110
J05AF06 abacavir	51	52	46	48	51	39	8	17	25	<5	1 156
J05AF07 tenofovir disoproxil	191	155	148	158	163	30	<5	86	71	<5	5 839
J05AF08 adefovir dipivoxil	32	36	38	33	22	36	0	8	13	<5	1 009
J05AF09 emtricitabine	47	20	13	11	11	36	0	6	<5	<5	172
J05AF10 entecavir	<5	23	56	87	106	31	0	52	50	<5	4 775
J05AF11 telbivudine	0	<5	6	8	5	20	0	<5	<5	0	139
J05AG Non-nucleoside reverse transcriptase inhibitors	514	573	633	573	529	39	16	248	255	10	12 491
J05AG01 nevirapine	176	179	183	186	191	41	7	89	92	<5	4 191
J05AG03 efavirenz	342	398	455	382	321	39	9	158	147	7	7 434
J05AG04 etravirine	0	0	0	12	23	26	<5	<5	18	0	866

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
J05AH Neuraminidase inhibitors	4 584	3 266	1 088	282 089	3 859	50	221	1 876	1 470	292	1 014
J05AH01 zanamivir	0	<5	109	2 542	35	69	<5	18	14	<5	11
J05AH02 oseltamivir	4 584	3 264	981	279 940	3 828	50	220	1 861	1 457	290	1 004
J05AR Antivirals for treatment of HIV infections, combinations	1 054	1 299	1 563	1 886	2 149	36	9	1 130	979	31	132 480
J05AR01 zidovudine and lamivudine	676	684	648	606	514	51	<5	289	211	11	16 089
J05AR02 lamivudine and abacavir	125	161	230	258	279	35	<5	133	136	6	11 808
J05AR03 tenofovir disoproxil and emtricitabine	315	518	738	890	1 065	35	<5	564	484	15	57 039
J05AR04 zidovudine, lamivudine and abacavir	38	39	37	36	35	49	0	13	22	0	2 004
J05AR06 emtricitabine, tenofovir disoproxil and efavirenz	0	0	130	362	514	26	<5	276	231	6	45 540
J05AX Other antivirals	7	8	50	97	179	44	0	82	95	<5	12 404
J05AX05 inosine pranobex	<5	<5	<5	<5	31	81	0	22	8	<5	83
J05AX07 enfuvirtide	6	7	6	<5	0	-	0	0	0	0	0
J05AX08 raltegravir	0	0	48	96	148	36	0	60	87	<5	11 711
J05AX09 maraviroc	0	0	5	5	7	0	0	0	7	0	610

2.11 ATC group L – Antineoplastic and immunomodulating agents

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	59 805	65 309	70 154	72 794	76 644	54	1 185	16 358	35 962	23 139	2 175 554
L02 ENDOCRINE THERAPY	22 457	23 657	24 557	24 456	24 884	50	183	2 565	8 685	13 451	247 172
L02A HORMONES AND RELATED AGENTS	10 195	10 633	10 787	10 787	11 008	22	179	1 923	1 970	6 936	112 779
L02AA Estrogens	79	75	48	25	17	18	0	0	5	12	28
L02AA02 polyestradiol phosphate	79	75	48	25	17	18	0	0	5	12	28
L02AB Progestogens	313	294	223	188	177	82	0	7	90	80	372
L02AB01 meggestrol	227	216	186	178	177	82	0	7	90	80	372
L02AB02 medroxyprogesterone	90	79	44	12	0	-	0	0	0	0	0
L02AE Gonadotropin releasing hormone analogues	9 841	10 299	10 547	10 589	10 827	21	179	1 917	1 879	6 852	112 378
L02AE01 buserelin	1 370	1 364	1 337	1 282	1 474	99	0	1 457	9	8	2 368
L02AE02 leuprorelin	3 467	3 546	3 804	3 886	3 891	11	178	246	544	2 923	44 679
L02AE03 goserelin	5 171	5 511	5 557	5 601	5 619	6	<5	243	1 375	4 000	65 318
L02AE04 triptorelin	<5	<5	<5	8	<5	100	0	<5	0	0	13
L02B HORMONE ANTAGONISTS AND RELATED AGENTS	14 905	16 023	16 898	16 799	17 126	60	5	680	7 719	8 722	134 393
L02BA Anti-estrogens	5 842	5 565	5 502	4 959	4 108	98	<5	575	2 399	1 132	12 696
L02BA01 tamoxifen	5 603	5 314	5 251	4 716	3 892	97	<5	571	2 270	1 049	3 514
L02BA03 fulvestrant	257	272	270	267	242	98	0	<5	142	96	9 182
L02BB Anti-androgens	5 512	6 006	6 370	6 379	6 641	0	0	5	1 604	5 032	45 458
L02BB01 flutamide	481	431	389	351	305	1	0	<5	55	246	1 374
L02BB03 bicalutamide	5 058	5 597	6 003	6 058	6 362	0	0	<5	1 558	4 803	44 083
L02BG Enzyme inhibitors	4 610	5 521	5 968	6 601	7 219	99	<5	113	4 245	2 858	75 541
L02BG03 anastrozole	2 741	3 254	3 444	3 276	2 901	99	0	21	1 732	1 148	27 307
L02BG04 letrozole	994	1 180	1 396	2 360	3 478	99	<5	77	2 049	1 349	36 406
L02BG06 exemestane	1 074	1 272	1 363	1 200	1 108	99	0	19	641	448	11 828
L02BX Other hormone antagonists and related agents	0	0	0	0	89	1	0	0	34	55	699
L02BX02 degarelix	0	0	0	0	89	1	0	0	34	55	699
L03 IMMUNOSTIMULANTS	4 355	4 890	5 353	5 663	5 883	62	56	2 353	3 008	466	373 929
L03A IMMUNOSTIMULANTS	4 355	4 890	5 353	5 663	5 883	62	56	2 353	3 008	466	373 929
L03AA Colony stimulating factors	1 417	1 714	1 928	2 085	2 222	59	40	400	1 363	419	86 149
L03AA02 filgrastim	366	378	364	362	415	49	37	97	236	45	9 449
L03AA13 pegfilgrastim	1 137	1 431	1 649	1 815	1 919	61	<5	328	1 207	381	76 700
L03AB Interferons	2 487	2 602	2 667	2 666	2 649	58	16	1 414	1 182	37	202 360
L03AB01 interferon alfa natural	0	0	<5	5	11	45	0	<5	6	<5	1 466
L03AB03 interferon gamma	10	11	11	9	9	44	5	<5	0	0	1 417

ATC group L

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK	
	Number of individuals						Number of individuals per age group					
	<15	15-44	45-69	≥70								
L03AB04	interferon alfa-2a	57	20	5	14	19	26	0	<5	12	<5	473
L03AB05	interferon alfa-2b	158	113	80	62	74	43	0	12	46	16	2 165
L03AB07	interferon beta-1a	1 207	1 311	1 335	1 348	1 217	70	<5	651	560	<5	128 661
L03AB08	interferon beta-1b	334	336	363	372	533	67	0	280	251	<5	35 423
L03AB10	peginterferon alfa-2b	446	504	465	416	310	38	8	169	124	9	13 075
L03AB11	peginterferon alfa-2a	299	324	424	468	503	37	0	307	194	<5	19 680
L03AC	Interleukins	<5	<5	<5	0	0	-	0	0	0	0	0
L03AC01	aldesleukin	<5	<5	<5	0	0	-	0	0	0	0	0
L03AX	Other immunostimulants	506	670	862	1 023	1 148	74	0	625	513	10	85 420
L03AX03	BCG vaccine	8	5	<5	7	13	38	0	0	5	8	87
L03AX13	glatiramer acetate	498	665	858	1 016	1 135	75	0	625	508	<5	85 333
L04	IMMUNOSUPPRESSANTS	29 180	32 317	35 076	37 221	39 922	56	840	10 857	21 124	7 101	1 257 151
L04A	IMMUNOSUPPRESSANTS	29 180	32 317	35 076	37 221	39 922	56	840	10 857	21 124	7 101	1 257 151
L04AA	Selective immunosuppressants	3 295	3 796	4 317	4 619	4 910	49	67	1 087	2 942	814	112 512
L04AA06	mycophenolic acid	1 925	2 296	2 647	2 965	3 266	39	65	863	1 907	431	74 949
L04AA10	sirolimus	76	68	68	70	101	37	<5	18	72	9	3 974
L04AA13	leflunomide	1 214	1 264	1 318	1 362	1 458	72	0	169	925	364	8 270
L04AA18	everolimus	147	228	253	263	294	27	<5	42	203	48	17 514
L04AA21	efalizumab	85	127	196	118	0	0	0	0	0	0	0
L04AA23	natalizumab	0	0	42	58	49	63	0	33	16	0	860
L04AA24	abatacept	0	17	16	<5	<5	100	0	0	0	<5	7
L04AA25	eculizumab	0	0	0	<5	<5	75	0	<5	<5	0	6 938
L04AB	Tumor necrosis factor alpha (TNF-α) inhibitors	5 536	6 569	7 626	8 409	9 648	53	178	3 545	5 136	789	926 224
L04AB01	etanercept	4 122	4 565	5 280	5 162	5 078	55	126	1 574	2 893	485	466 587
L04AB02	infliximab	20	426	278	83	<5	100	0	<5	0	0	120
L04AB04	adalimumab	1 631	1 791	2 329	3 519	3 992	51	58	1 755	1 926	253	395 325
L04AB05	certolizumab pegol	0	0	0	0	135	78	0	46	80	9	6 893
L04AB06	golimumab	0	0	0	0	1 038	53	0	417	561	60	57 299
L04AC	Interleukin inhibitors	55	61	58	69	127	47	9	48	62	8	12 016
L04AC03	anakinra	55	61	58	68	75	52	8	28	35	<5	5 513
L04AC05	ustekinumab	0	0	0	<5	50	40	0	19	27	<5	5 375
L04AC08	canakinumab	0	0	0	0	<5	50	<5	<5	0	0	1 128
L04AD	Calcineurin inhibitors	4 166	4 328	4 388	4 578	4 797	38	122	1 333	2 713	629	144 436
L04AD01	ciclosporin	3 445	3 424	3 306	3 289	3 306	37	39	763	1 960	544	82 465
L04AD02	tacrolimus	769	976	1 161	1 349	1 569	40	86	598	794	91	61 972

ATC group L

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
L04AX Other immunosuppressants	22 043	24 138	25 770	26 861	28 376	59	592	7 038	14 940	5 806	61 962
L04AX01 azathioprine	5 661	5 954	6 028	6 197	6 388	52	174	2 898	2 661	655	5 640
L04AX02 thalidomide	274	357	340	330	348	46	6	13	118	211	12 891
L04AX03 methotrexate	16 203	17 921	19 466	20 348	21 618	62	416	4 160	12 143	4 899	9 512
L04AX04 lenalidomide	0	<5	60	106	157	41	0	8	85	64	33 919

2.12 ATC group M – Musculo-skeletal system

ATC level		2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
		Number of individuals						Number of individuals per age group				
								<15	15–44	45–69	≥70	
M	MUSCULO-SKELETAL SYSTEM	906 519	915 414	907 359	891 118	901 482	57	12 992	328 664	407 600	152 226	291 165
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	803 676	822 755	829 545	815 413	823 781	57	12 192	324 097	380 364	107 128	199 862
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS	803 492	822 620	829 405	815 292	823 694	57	12 192	324 089	380 319	107 094	198 468
M01AA	Butylpyrazolidines	<5	0	<5	0	0	-	0	0	0	0	0
M01AA01	phenylbutazone	<5	0	<5	0	0	-	0	0	0	0	0
M01AB	Acetic acid derivatives and related substances	389 185	436 431	498 631	491 567	505 137	55	7 102	211 688	231 779	54 568	68 188
M01AB01	indometacin	13 002	12 784	12 154	11 675	2 710	54	19	753	1 449	489	678
M01AB02	sulindac	750	752	600	386	16	63	0	0	10	6	8
M01AB05	diclofenac	360 628	408 801	471 691	464 455	480 836	55	7 067	206 672	218 902	48 195	51 795
M01AB15	ketorolac	8	7	7	11	27	52	0	6	14	7	6
M01AB16	aceclofenac	360	0	0	0	0	-	0	0	0	0	0
M01AB55	diclofenac, combinations	21 109	21 650	22 250	23 266	29 220	63	23	6 326	15 635	7 236	15 700
M01AC	Oxicams	201 065	167 590	88 227	81 319	76 283	55	271	24 366	40 159	11 487	22 158
M01AC01	piroxicam	172 211	140 318	60 698	55 461	51 607	52	209	19 025	26 981	5 392	14 529
M01AC06	meloxicam	31 158	29 448	28 570	26 731	25 431	62	62	5 548	13 623	6 198	7 629
M01AE	Propionic acid derivatives	251 811	262 707	278 524	273 808	275 804	61	5 026	110 750	124 605	35 423	64 100
M01AE01	ibuprofen ¹⁾	183 565	193 933	208 791	211 639	215 577	62	4 270	92 027	95 319	23 961	39 119
M01AE02	naproxen ¹⁾	64 992	64 457	66 541	59 487	58 325	58	783	19 044	27 908	10 590	21 524
M01AE03	ketoprofen	8 282	8 799	8 541	7 912	7 475	60	13	1 705	4 176	1 581	3 244
M01AE14	dexibuprofen	1 223	2 180	2 124	1 417	1 025	56	<5	462	460	102	214
M01AG	Fenamates	918	849	827	669	106	85	<5	66	38	<5	60
M01AG02	tolfenamic acid	918	849	827	669	106	85	<5	66	38	<5	60
M01AH	Coxibs	34 414	37 251	36 485	35 851	35 986	55	58	12 101	18 376	5 451	18 040
M01AH01	celecoxib	11 194	9 398	8 315	8 030	7 841	61	17	2 240	4 174	1 410	6 700
M01AH02	rofecoxib	0	<5	0	0	0	-	0	0	0	0	0
M01AH03	valdecoxib	6	<5	0	0	0	-	0	0	0	0	0
M01AH04	parecoxib	0	0	<5	<5	0	-	0	0	0	0	0
M01AH05	etoricoxib	23 505	28 099	28 365	28 047	28 362	54	41	9 918	14 331	4 072	11 340
M01AX	Other antiinflammatory and antirheumatic agents, non-steroids	71 124	64 418	55 088	51 313	48 127	67	25	4 032	27 503	16 567	25 922
M01AX01	nabumetone	12 722	12 759	11 261	9 107	7 343	67	12	1 587	3 891	1 853	4 851
M01AX05	glucosamine ¹⁾	58 712	51 520	43 576	41 918	40 400	67	11	2 391	23 397	14 601	19 548
M01C	SPECIFIC ANTIRHEUMATIC AGENTS	444	360	325	285	242	77	0	30	152	60	1 394

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group M

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
M01CB Gold preparations	383	308	267	241	199	81	0	23	126	50	520
M01CB01 sodium aurothiomalate	188	109	97	74	36	81	0	0	22	14	77
M01CB03 auranofin	196	200	171	167	163	81	0	23	104	36	443
M01CC Penicillamine and similar agents	17	15	15	12	14	43	0	<5	10	<5	79
M01CC01 penicillamine	17	15	15	12	14	43	0	<5	10	<5	79
M01CX Other specific antirheumatic agents	44	37	43	32	30	67	0	<5	17	9	796
M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	41 869	37 832	31 768	27 100	24 377	56	941	8 005	9 423	6 008	3 647
M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN	41 869	37 832	31 768	27 100	24 377	56	941	8 005	9 423	6 008	3 647
M02AA Antiinflammatory preparations, non-steroids for topical use	41 735	37 721	31 675	27 031	24 183	56	937	7 937	9 359	5 950	3 628
M02AA10 ketoprofen ¹⁾	37 836	33 758	27 552	23 095	20 113	56	761	6 723	7 860	4 769	2 951
M02AA13 ibuprofen ¹⁾	3 936	3 958	4 040	3 852	3 990	58	177	1 195	1 446	1 172	634
M02AA15 diclofenac	66	127	173	160	167	65	<5	38	79	49	43
M02AB Capsaicin and similar agents	14	13	8	5	6	67	0	0	<5	<5	2
M02AB01 capsaicin	14	13	8	5	6	67	0	0	<5	<5	2
M02AC Preparations with salicylic acid derivatives	129	106	89	69	189	60	<5	74	60	51	15
M02AX Other topical products for joint and muscular pain	10	21	7	11	13	85	0	0	<5	9	2
M02AX10 various	10	21	7	11	13	85	0	0	<5	9	2
M03 MUSCLE RELAXANTS	78 565	51 832	12 875	5 592	5 917	56	123	1 571	3 516	707	12 544
M03B MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS	78 407	51 658	12 660	5 388	5 656	55	122	1 423	3 410	701	10 458
M03BA Carbamic acid esters	75 167	48 187	8 594	1 087	1 096	67	0	304	701	91	3 183
M03BA02 carisoprodol	75 148	48 173	8 583	1 087	1 096	67	0	304	701	91	3 182
M03BA52 carisoprodol, combinations excl. psycholeptics	33	25	30	<5	0	-	0	0	0	0	0
M03BB Oxazol, thiazine, and triazine derivatives	7	<5	<5	0	0	-	0	0	0	0	0
M03BB03 chlorzoxazone	<5	<5	<5	0	0	-	0	0	0	0	0
M03BB53 chlorzoxazone, combinations excl. psycholeptics	5	0	0	0	0	-	0	0	0	0	0
M03BC Ethers, chemically close to antihistamines	<5	<5	<5	<5	<5	100	0	0	<5	0	5
M03BC51 orphenadrine, combinations	<5	<5	<5	<5	<5	100	0	0	<5	0	5

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
M03BX Other centrally acting agents	3 500	3 836	4 236	4 318	4 583	52	122	1 129	2 722	610	7 133
M03BX01 baclofen	3 469	3 804	4 195	4 277	4 544	52	122	1 114	2 698	610	6 805
M03BX02 tizanidine	59	60	72	59	59	47	0	21	37	<5	328
M03C MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS	<5	<5	<5	0	0	-	0	0	0	0	0
M03CA Dantrolene and derivatives	<5	<5	<5	0	0	-	0	0	0	0	0
M03CA01 dantrolene	<5	<5	<5	0	0	-	0	0	0	0	0
M04 ANTIGOUT PREPARATIONS	35 899	36 456	37 887	39 432	40 872	29	20	2 506	17 295	21 051	16 354
M04A ANTIGOUT PREPARATIONS	35 899	36 456	37 887	39 432	40 872	29	20	2 506	17 295	21 051	16 354
M04AA Preparations inhibiting uric acid production	33 327	33 756	34 952	36 396	37 660	29	7	2 194	15 914	19 545	13 034
M04AA01 allopurinol	33 327	33 756	34 952	36 396	37 651	29	7	2 193	15 909	19 542	12 898
M04AA03 febuxostat	0	0	0	0	9	33	0	<5	5	<5	136
M04AB Preparations increasing uric acid excretion	2 063	2 062	2 099	2 123	2 061	30	<5	152	932	973	2 169
M04AB01 probenecid	2 063	2 062	2 099	2 123	2 061	30	<5	152	932	973	2 169
M04AC Preparations with no effect on uric acid metabolism	1 906	2 069	2 373	2 597	3 070	23	9	318	1 348	1 395	1 151
M04AC01 colchicine	1 906	2 069	2 373	2 597	3 070	23	9	318	1 348	1 395	1 151
M05 DRUGS FOR TREATMENT OF BONE DISEASES	56 100	56 742	56 634	56 744	57 590	89	8	612	19 549	37 421	57 896
M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION	56 100	56 742	56 634	56 744	57 590	89	8	612	19 549	37 421	57 896
M05BA Bisphosphonates	52 815	53 894	54 146	54 669	55 778	89	8	602	19 194	35 974	53 384
M05BA01 etidronic acid	567	442	372	297	240	92	0	<5	29	210	260
M05BA02 clodronic acid	40	44	48	44	48	50	0	0	27	21	752
M05BA03 pamidronic acid	<5	<5	10	13	21	33	0	0	16	5	128
M05BA04 alendronic acid	48 337	51 588	51 829	52 053	52 696	89	8	553	17 900	34 235	39 282
M05BA06 ibandronic acid	1 424	719	704	704	696	93	0	8	298	390	2 833
M05BA07 risedronic acid	6 033	1 971	1 405	1 214	1 097	92	0	16	404	677	3 325
M05BA08 zoledronic acid	32	47	221	835	1 583	87	0	34	807	742	6 804
M05BB Bisphosphonates, combinations	3 865	3 235	2 745	2 267	1 950	94	0	9	396	1 545	4 430
M05BB01 etidronic acid and calcium, sequential	3 860	3 234	2 745	2 267	1 950	94	0	9	396	1 545	4 430
M05BB03 alendronic acid and colecalciferol	5	<5	0	0	0	0	0	0	0	0	0
M05BX Other drugs affecting bone structure and mineralization	0	0	0	0	27	93	0	<5	9	17	83

ATC group M

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
M05BX04 denosumab	0	0	0	0	27	93	0	<5	9	17	83
M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	<5	<5	<5	<5	0	-	0	0	0	0	0
M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	<5	<5	<5	<5	0	-	0	0	0	0	0
M09AX Other drugs for disorders of the musculo-skeletal system	<5	<5	<5	<5	0	-	0	0	0	0	0
M09AX01 hyaluronic acid	<5	<5	<5	<5	0	-	0	0	0	0	0

2.13 ATC group N – Nervous system

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15–44	45–69	≥70							
N NERVOUS SYSTEM	1 143 324	1 181 693	1 208 793	1 230 906	1 248 124	59	30 059	396 661	536 511	284 893	2 607 070
N02 ANALGESICS	618 379	647 981	676 886	693 682	710 229	60	8 545	233 491	309 878	158 315	660 585
N02A OPIOIDS	456 190	470 928	484 768	487 514	491 735	57	4 566	163 044	215 273	108 852	362 655
N02AA Natural opium alkaloids	401 151	406 407	409 141	405 617	401 791	56	4 436	138 473	176 320	82 562	237 719
N02AA01 morphine	6 608	6 768	6 995	7 048	6 993	47	15	1 029	3 326	2 623	20 749
N02AA03 hydromorphone	90	65	53	41	40	60	<5	7	25	7	411
N02AA05 oxycodone	10 843	12 637	14 983	16 910	19 063	53	11	2 908	8 799	7 345	54 853
N02AA08 dihydrocodeine	35	38	40	49	47	70	0	9	32	6	234
N02AA55 oxycodone, combinations	0	0	5	228	1 000	57	<5	96	440	461	4 743
N02AA59 codeine, combinations excl. psycholeptics	392 195	396 326	397 626	392 734	387 362	56	4 414	136 575	169 744	76 629	156 730
N02AB Phenylpiperidine derivatives	9 740	10 091	10 253	10 451	11 157	59	9	1 988	4 790	4 370	37 265
N02AB01 ketobemidone	3 753	3 743	3 738	3 729	3 991	55	<5	1 186	1 918	883	4 130
N02AB02 pethidine	1 466	1 403	1 377	1 340	1 342	62	<5	406	730	203	2 062
N02AB03 fentanyl	5 101	5 500	5 657	5 857	6 323	61	<5	511	2 392	3 418	31 074
N02AC Diphenylpropylamine derivatives	10 161	9 262	8 523	7 442	4 700	61	0	680	2 183	1 837	2 499
N02AC54 dextropropoxyphene, comb. excl. psycholeptics	10 161	9 262	8 523	7 442	4 700	61	0	680	2 183	1 837	2 499
N02AD Benzomorphan derivatives	79	52	49	45	41	51	0	<5	28	9	533
N02AD01 pentazocine	79	52	49	45	41	51	0	<5	28	9	533
N02AE Oripavine derivatives	5 304	7 911	10 244	12 080	13 170	70	<5	1 262	3 506	8 398	39 190
N02AE01 buprenorphine	5 304	7 911	10 244	12 080	13 170	70	<5	1 262	3 506	8 398	39 190
N02AG Opioids in combination with antispasmodics	1 867	1 857	1 819	1 729	1 840	57	0	522	900	418	1 531
N02AG01 morphine and antispasmodics	165	179	218	218	263	51	0	8	94	161	55
N02AG02 ketobemidone and antispasmodics	1 709	1 686	1 608	1 515	1 584	58	0	514	807	263	1 475
N02AX Other opioids	77 722	91 978	106 796	114 946	127 881	60	144	36 416	56 910	34 411	43 918
N02AX02 tramadol	77 722	91 978	106 796	114 946	127 881	60	144	36 416	56 910	34 411	43 918
N02B OTHER ANALGESICS AND ANTIPYRETICS	198 098	226 320	255 892	281 467	305 683	64	2 775	73 290	132 226	97 392	60 336
N02BA Salicylic acid and derivatives	1 222	792	769	806	839	57	175	234	237	193	215
N02BA01 acetylsalicylic acid ¹⁾	705	780	768	802	835	56	175	234	233	193	190
N02BA11 diflunisal	517	11	0	<5	<5	100	0	0	<5	0	17
N02BA51 acetylsalicylic acid, combinations excl. psycholeptics	<5	<5	<5	<5	<5	100	0	0	<5	0	8
N02BB Pyrazolones	1 045	988	909	885	887	66	5	346	349	187	314

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group N

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
N02BB02 metamazole sodium	<5	6	15	22	12	58	0	<5	6	5	17
N02BB51 phenazone, combinations excl. psycholeptics ¹⁾	1 041	982	894	863	875	66	5	345	343	182	297
N02BE Anilides	196 377	225 013	254 653	280 252	304 460	64	2 598	72 852	131 845	97 165	59 807
N02BE01 paracetamol ¹⁾	196 377	225 013	254 653	280 252	304 460	64	2 598	72 852	131 845	97 165	59 807
N02BE51 paracetamol, combinations excl. psycholeptics	0	<5	0	0	0	0	0	0	0	0	0
N02BG Other analgesics and antipyretics	<5	<5	<5	<5	0	0	0	0	0	0	0
N02BG07 flupirtine	<5	<5	<5	<5	0	0	0	0	0	0	0
N02C ANTIMIGRAINE PREPARATIONS	83 841	86 670	88 060	87 606	88 898	79	1 661	42 406	41 450	3 381	237 595
N02CA Ergot alkaloids	4 811	4 265	3 827	3 477	3 071	82	7	527	1 890	647	1 370
N02CA04 methysergide	8	5	8	6	6	33	0	<5	<5	<5	46
N02CA52 ergotamine, combinations excl. psycholeptics	16	14	14	13	15	60	0	<5	10	<5	23
N02CA72 ergotamine, combinations with psycholeptics	4 790	4 247	3 808	3 458	3 052	82	7	524	1 879	642	1 301
N02CC Selective serotonin (5HT₁) agonists	77 249	80 455	82 235	81 969	83 455	79	1 608	41 234	38 023	2 590	234 437
N02CC01 sumatriptan	31 851	32 326	35 885	40 471	41 832	77	1 433	22 211	16 916	1 272	87 396
N02CC02 naratriptan	1 563	1 529	1 515	1 497	1 501	84	<5	658	784	57	4 412
N02CC03 zolmitriptan	13 667	13 948	14 983	14 223	14 226	82	87	6 545	7 115	479	42 275
N02CC04 rizatriptan	22 385	24 819	24 519	22 305	22 393	81	160	11 639	9 982	612	57 144
N02CC05 almotriptan	5 124	4 687	3 915	3 286	3 052	83	7	1 611	1 364	70	6 459
N02CC06 eletriptan	12 526	12 534	11 871	11 192	11 285	83	52	5 267	5 721	245	36 737
N02CC07 frovatriptan	0	0	12	19	6	83	0	<5	5	0	13
N02CX Other antimigraine preparations	3 093	3 154	3 129	3 163	3 416	77	55	992	2 166	203	1 787
N02CX01 pizotifen	81	75	63	53	61	80	0	19	34	8	133
N02CX02 clonidine	3 013	3 081	3 067	3 111	3 355	77	55	973	2 132	195	1 654
N03 ANTIEPILEPTICS	83 664	90 882	97 238	100 381	103 939	55	3 493	34 022	47 257	19 167	409 273
N03A ANTIEPILEPTICS	83 664	90 882	97 238	100 381	103 939	55	3 493	34 022	47 257	19 167	409 273
N03AA Barbiturates and derivatives	3 341	3 110	2 959	2 844	2 700	51	19	314	1 432	935	1 996
N03AA02 phenobarbital	3 111	2 884	2 718	2 574	2 426	51	19	284	1 291	832	1 498
N03AA03 primidone	247	243	255	284	288	49	0	31	145	112	499
N03AB Hydantoin derivatives	2 661	2 486	2 332	2 218	2 051	42	15	259	1 127	650	992
N03AB02 phenytoin	2 661	2 485	2 332	2 217	2 051	42	15	259	1 127	650	992
N03AB05 fosphenytoin	<5	<5	0	<5	0	0	0	0	0	0	0

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group N

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
N03AD Succinimide derivatives	110	110	116	139	149	62	73	50	22	<5	1 043
N03AD01 ethosuximide	110	110	116	139	149	62	73	50	22	<5	1 043
N03AE Benzodiazepine derivatives	13 950	13 991	13 927	13 712	13 528	54	199	4 016	6 801	2 512	7 113
N03AE01 clonazepam	13 950	13 991	13 927	13 712	13 528	54	199	4 016	6 801	2 512	7 113
N03AF Carboxamide derivatives	22 318	21 523	20 748	20 004	19 236	46	751	5 625	9 210	3 650	30 981
N03AF01 carbamazepine	20 413	19 480	18 586	17 750	16 828	47	439	4 647	8 362	3 380	16 616
N03AF02 oxcarbazepine	2 009	2 104	2 173	2 236	2 298	43	296	893	828	281	9 382
N03AF03 rufinamide	0	41	80	96	96	36	27	62	6	<5	2 262
N03AF04 eslicarbazepine	0	0	0	<5	205	47	6	107	84	8	2 722
N03AG Fatty acid derivatives	12 452	12 756	13 320	13 867	14 183	46	1 615	5 936	5 444	1 188	31 756
N03AG01 valproic acid	12 336	12 656	13 227	13 786	14 110	46	1 592	5 916	5 415	1 187	30 852
N03AG04 vigabatrin	142	120	127	114	100	48	41	28	29	<5	674
N03AG06 tiagabine	29	19	15	12	11	45	0	<5	7	0	229
N03AX Other antiepileptics	42 118	50 441	57 604	61 469	66 041	59	1 826	23 088	29 308	11 819	335 393
N03AX03 sultiame	39	51	54	64	98	43	70	26	<5	0	586
N03AX09 lamotrigine	16 504	18 798	20 820	22 368	23 708	59	1 060	12 040	8 656	1 952	114 649
N03AX10 felbamate	25	23	24	25	23	30	<5	16	<5	0	500
N03AX11 topiramate	2 926	2 975	3 051	3 039	3 060	68	302	1 680	984	94	19 854
N03AX12 gabapentin	7 618	7 483	14 682	20 412	24 441	60	39	5 452	12 703	6 247	37 159
N03AX14 levetiracetam	2 746	3 496	4 320	4 977	5 539	50	556	2 335	1 923	725	58 182
N03AX15 zonisamide	180	298	349	444	457	53	64	251	128	14	6 447
N03AX16 pregabalin	15 405	21 046	20 274	17 120	15 258	59	6	3 689	7 786	3 777	93 482
N03AX17 stiripentol	0	0	0	19	33	42	26	7	0	0	1 624
N03AX18 lacosamide	0	0	0	122	262	54	17	152	85	8	2 909
N04 ANTI-PARKINSON DRUGS	14 220	17 101	17 191	17 238	17 785	51	14	1 512	7 690	8 569	131 157
N04A ANTICHOLINERGIC AGENTS	3 484	3 271	3 162	3 034	2 915	51	<5	669	1 764	478	1 651
N04AA Tertiary amines	3 399	3 205	3 104	2 991	2 880	50	<5	667	1 738	471	1 552
N04AA01 trihexyphenidyl	18	19	15	15	22	45	<5	6	10	<5	124
N04AA02 biperiden	3 375	3 182	3 085	2 971	2 854	50	0	661	1 727	466	1 423
N04AA04 procyclidine	7	<5	<5	5	<5	50	0	0	<5	<5	5
N04AB Ethers chemically close to antihistamines	132	81	65	48	40	63	0	<5	30	7	99
N04AB02 orphenadrine (chloride)	132	81	65	48	40	63	0	<5	30	7	99
N04B DOPAMINERGIC AGENTS	10 829	13 906	14 096	14 267	14 938	51	10	847	5 958	8 123	129 506
N04BA Dopa and dopa derivatives	7 532	7 602	7 606	7 716	7 906	44	7	103	2 278	5 518	62 452
N04BA02 levodopa and decarboxylase inhibitor	7 121	7 067	6 995	7 051	7 180	46	7	95	1 966	5 112	45 452

ATC group N

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
N04BA03 levodopa, decarboxylase inhibitor and COMT inhibitor	969	1 133	1 255	1 358	1 448	36	0	14	613	821	17 000
N04BB Adamantane derivatives	104	116	111	114	114	62	0	35	73	6	508
N04BB01 amantadine	104	116	111	114	114	62	0	35	73	6	508
N04BC Dopamine agonists	5 144	8 302	8 542	8 784	9 440	54	<5	729	4 786	3 922	48 274
N04BC01 bromocriptine	9	<5	<5	<5	<5	0	0	0	<5	0	12
N04BC02 pergolide	<5	<5	0	0	0	0	0	0	0	0	0
N04BC04 ropinirole	1 125	1 820	1 842	2 316	2 665	46	0	165	1 476	1 024	19 408
N04BC05 pramipexole	3 226	5 919	6 236	6 258	6 499	57	<5	574	3 206	2 717	20 152
N04BC06 cabergoline	978	796	514	322	209	50	<5	6	69	133	921
N04BC07 apomorphine	11	13	18	19	18	39	0	0	13	5	2 117
N04BC09 rotigotine	5	232	393	427	517	43	0	19	280	218	5 664
N04BD Monoamine oxidase B inhibitors	2 223	2 414	2 571	2 862	3 184	38	0	41	1 593	1 550	16 634
N04BD01 selegiline	2 113	2 099	2 081	2 116	2 126	38	0	26	1 080	1 020	3 670
N04BD02 rasagiline	173	405	575	864	1 183	39	0	22	577	584	12 964
N04BX Other dopaminergic agents	424	341	287	230	192	49	0	<5	73	118	1 637
N04BX01 tolcapone	20	15	13	13	11	27	0	0	<5	7	229
N04BX02 entacapone	404	327	274	218	181	51	0	<5	69	111	1 408
N05 PSYCHOLEPTICS	591 655	603 189	611 549	616 953	614 180	63	8 570	137 823	276 239	191 548	562 029
N05A ANTIPSYCHOTICS	106 277	105 763	104 086	104 077	104 041	56	835	34 874	45 875	22 457	271 252
N05AA Phenothiazines with aliphatic side-chain	31 417	29 896	26 862	25 877	24 609	57	29	6 944	12 514	5 122	9 581
N05AA01 chlorpromazine	6 646	3 952	702	492	439	63	<5	210	166	62	861
N05AA02 levomepromazine	25 296	26 807	26 247	25 435	24 204	57	28	6 744	12 370	5 062	8 720
N05AB Phenothiazines with piperazine structure	25 164	23 022	20 901	19 829	18 265	67	13	3 912	7 580	6 760	9 447
N05AB01 dixyrazine	1 815	620	76	54	32	59	0	9	17	6	70
N05AB02 fluphenazine	101	89	59	27	22	50	0	0	18	<5	64
N05AB03 perphenazine	6 344	6 182	5 992	5 736	5 422	59	<5	1 295	3 059	1 067	6 807
N05AB04 prochlorperazine	17 059	16 340	14 841	14 075	12 850	71	12	2 622	4 517	5 699	2 501
N05AB06 trifluoperazine	5	<5	<5	<5	<5	50	0	0	0	<5	5
N05AC Phenothiazines with piperidine structure	111	85	79	70	62	53	0	5	38	19	217
N05AC01 periciazine	<5	<5	<5	<5	<5	100	0	0	<5	0	2
N05AC02 thioridazine	102	77	73	66	58	50	0	5	36	17	184
N05AC04 pipotiazine	7	6	5	<5	<5	100	0	0	<5	<5	31
N05AD Butyrophenone derivatives	4 797	4 830	4 735	4 472	4 272	55	14	454	1 513	2 291	1 591
N05AD01 haloperidol	4 785	4 819	4 725	4 465	4 266	55	14	452	1 511	2 289	1 584

ATC group N

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
N05AD03 melperone	12	11	10	7	6	50	0	<5	<5	<5	7
N05AE Indole derivatives	1 574	1 463	1 383	1 302	1 164	60	9	621	494	40	16 798
N05AE03 sertindole	43	119	165	186	161	59	0	119	42	0	1 740
N05AE04 ziprasidone	1 535	1 355	1 231	1 118	1 006	60	9	504	453	40	15 057
N05AF Thioxanthene derivatives	22 910	24 177	24 515	24 243	23 740	55	27	8 328	11 566	3 819	11 549
N05AF01 flupentixol	5 595	5 519	5 381	5 006	4 915	67	<5	1 269	2 492	1 153	2 670
N05AF03 chlorprothixene	14 612	16 186	16 666	17 011	16 649	52	25	6 618	7 851	2 155	6 349
N05AF05 zuclopentixol	3 336	3 198	3 156	2 907	2 821	52	<5	701	1 553	566	2 530
N05AG Diphenylbutylpiperidine derivatives	179	172	165	142	135	33	9	74	40	12	314
N05AG02 pimozone	148	138	133	116	118	36	9	63	36	10	272
N05AG03 penfluridol	31	34	33	27	17	18	0	11	<5	<5	43
N05AH Diazepines, oxazepines, thiazepines and oxepines	22 531	24 918	26 510	28 508	31 681	50	91	15 027	13 194	3 369	109 769
N05AH02 clozapine	1 989	2 099	2 185	2 299	2 361	38	0	1 207	1 083	71	9 529
N05AH03 olanzapine	14 913	15 644	15 960	16 067	15 797	47	18	6 598	7 150	2 031	54 129
N05AH04 quetiapine	6 622	8 314	9 547	11 508	15 090	55	73	8 067	5 605	1 345	46 111
N05AL Benzamides	725	665	589	580	548	45	<5	296	231	17	3 554
N05AL01 sulpiride	<5	<5	0	0	0	0	0	0	0	0	0
N05AL03 tiapride	11	9	7	5	7	43	<5	<5	<5	0	59
N05AL05 amisulpride	713	655	582	575	541	45	<5	294	229	17	3 496
N05AN Lithium	7 749	7 717	7 927	7 995	7 876	56	<5	2 369	4 326	1 180	10 025
N05AN01 lithium	7 749	7 717	7 927	7 995	7 876	56	<5	2 369	4 326	1 180	10 025
N05AX Other antipsychotics	9 651	10 222	10 930	11 444	12 290	48	696	5 656	3 941	1 997	98 404
N05AX08 risperidone	7 812	7 896	8 158	8 149	8 250	47	561	3 087	2 717	1 885	46 915
N05AX12 aripiprazole	2 042	2 611	3 055	3 624	4 375	49	162	2 782	1 306	125	51 489
N05B ANXIOLYTICS	281 239	285 149	285 501	282 066	277 791	65	3 421	63 316	128 910	82 144	111 920
N05BA Benzodiazepine derivatives	261 616	264 682	265 343	261 070	255 376	65	3 011	54 951	120 372	77 042	99 118
N05BA01 diazepam	146 680	145 984	143 631	138 282	132 542	63	2 892	27 532	63 172	38 946	51 519
N05BA02 chlordiazepoxide	6	6	<5	<5	<5	0	0	0	<5	0	2
N05BA04 oxazepam	126 390	130 709	134 011	134 699	133 930	67	39	30 257	62 204	41 430	39 588
N05BA06 lorazepam	35	34	18	20	21	43	0	10	5	6	74
N05BA08 bromazepam	9	8	5	7	5	60	0	0	<5	<5	28
N05BA09 clobazam	507	532	547	558	615	50	205	288	117	5	1 747
N05BA12 alprazolam	5 009	4 680	4 631	4 521	4 340	49	<5	1 880	2 006	452	6 159
N05BB Diphenylmethane derivatives	25 710	27 098	27 293	28 280	30 141	61	412	10 612	12 120	6 997	8 127
N05BB01 hydroxyzine	25 710	27 098	27 293	28 280	30 141	61	412	10 612	12 120	6 997	8 127

ATC group N

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
N05BC Carbamates	14	10	9	10	6	83	0	0	0	6	13
N05BC01 meprobamate	14	10	9	10	6	83	0	0	0	6	13
N05BE Azaspirodecanedione derivatives	2 965	3 025	2 808	2 394	2 345	57	<5	887	1 140	317	4 662
N05BE01 buspirone	2 965	3 025	2 808	2 394	2 345	57	<5	887	1 140	317	4 662
N05C HYPNOTICS AND SEDATIVES	374 211	385 861	397 066	405 808	406 026	65	5 161	78 103	181 685	141 077	178 856
N05CA Barbiturates, plain	<5	<5	<5	<5	<5	0	0	<5	0	0	0
N05CA04 barbital	<5	<5	<5	<5	<5	0	0	<5	0	0	0
N05CD Benzodiazepine derivatives	52 549	49 522	46 684	44 519	41 795	61	735	7 663	16 238	17 159	19 843
N05CD01 flurazepam	28	24	22	20	17	47	0	0	10	7	52
N05CD02 nitrazepam	41 497	39 705	37 540	35 855	33 397	62	349	6 049	12 975	14 024	10 600
N05CD03 flunitrazepam	11 740	10 179	9 223	8 479	7 689	56	<5	1 257	3 282	3 146	5 477
N05CD04 estazolam	0	<5	<5	<5	0	-	0	0	0	0	0
N05CD05 triazolam	102	99	103	105	115	57	0	41	39	35	101
N05CD08 midazolam	441	639	831	1 071	1 490	48	480	587	273	150	3 613
N05CF Benzodiazepine related drugs	328 954	341 196	346 258	351 043	349 429	66	77	61 329	162 838	125 185	131 480
N05CF01 zopiclone	295 024	303 779	306 243	308 362	304 937	66	56	49 253	141 509	114 119	112 695
N05CF02 zolpidem	44 381	48 400	51 245	53 834	55 229	66	23	15 016	26 118	14 072	18 784
N05CF03 zaleplon	<5	5	5	7	<5	50	0	<5	<5	0	1
N05CH Melatonin receptor agonists	9 481	12 427	29 906	38 868	42 769	59	4 550	16 864	15 947	5 408	25 219
N05CH01 melatonin	9 481	12 427	29 906	38 868	42 769	59	4 550	16 864	15 947	5 408	25 219
N05CM Other hypnotics and sedatives	1 491	1 762	1 899	1 944	2 107	45	0	190	554	1 363	2 313
N05CM02 clomethiazole	1 462	1 736	1 843	1 870	2 046	45	0	186	533	1 327	2 139
N05CM05 scopolamine	28	24	57	77	65	52	0	<5	21	40	174
N05CM11 bromides	<5	<5	0	0	0	-	0	0	0	0	0
N05CM18 dexmedetomidine	0	<5	0	0	0	-	0	0	0	0	0
N06 PSYCHOANALEPTICS	306 421	315 835	319 755	325 940	333 062	63	10 977	110 604	138 131	73 350	616 396
N06A ANTIDEPRESSANTS	279 503	286 775	288 416	292 395	297 057	65	626	96 178	135 824	64 429	345 210
N06AA Non-selective monoamine reuptake inhibitors	57 551	58 357	59 390	60 237	61 880	71	76	14 833	32 774	14 197	25 512
N06AA02 imipramine	41	40	47	34	26	54	7	<5	10	8	101
N06AA04 clomipramine	3 881	3 594	3 455	3 276	3 079	70	12	560	1 784	723	2 489
N06AA05 opipramol	<5	<5	5	5	6	33	0	0	<5	<5	12
N06AA06 trimipramine	13 449	13 344	12 627	11 930	11 430	69	<5	2 253	5 828	3 345	7 222
N06AA07 lofepramine	22	18	18	15	13	69	0	<5	8	<5	94
N06AA09 amitriptyline	34 912	36 529	38 809	40 585	43 063	72	50	11 460	23 412	8 141	12 709

ATC group N

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
N06AA10 nortriptyline	1 641	1 548	1 651	1 837	2 102	68	<5	582	966	550	730
N06AA12 doxepin	4 424	4 065	3 580	3 348	3 016	71	<5	200	1 241	1 574	2 151
N06AA21 maprotiline	<5	<5	<5	<5	<5	100	0	0	<5	0	5
N06AB Selective serotonin reuptake inhibitors	169 290	174 898	176 993	178 930	180 576	66	515	63 515	78 696	37 850	215 243
N06AB03 fluoxetine	8 564	8 632	8 827	9 010	9 285	75	188	5 077	3 318	702	13 890
N06AB04 citalopram	41 273	38 146	35 572	32 885	30 675	68	10	7 560	14 613	8 492	22 758
N06AB05 paroxetine	21 311	19 820	18 698	17 508	16 894	69	<5	3 692	9 108	4 091	16 525
N06AB06 sertraline	27 621	26 545	26 040	26 427	26 377	66	288	9 870	11 224	4 995	26 379
N06AB08 fluvoxamine	725	663	653	620	603	56	0	246	280	77	1 210
N06AB10 escitalopram	76 440	87 524	93 702	98 493	102 602	64	45	39 562	42 414	20 581	134 481
N06AF Monoamine oxidase inhibitors, non-selective	134	117	110	111	111	61	0	33	58	20	1 114
N06AF03 phenelzine	120	108	100	102	102	61	0	29	54	19	708
N06AF04 tranlycypromine	14	9	10	9	9	67	0	<5	<5	<5	405
N06AG Monoamine oxidase A inhibitors	1 292	1 204	1 081	965	879	64	0	176	518	185	2 030
N06AG02 moclobemide	1 292	1 204	1 081	965	879	64	0	176	518	185	2 030
N06AX Other antidepressants	88 877	90 985	88 987	90 567	92 827	60	44	29 531	42 236	21 016	101 311
N06AX01 oxitriptan	56	217	187	244	261	77	8	151	95	7	256
N06AX02 tryptophan	7	<5	11	5	<5	100	0	<5	0	0	3
N06AX03 mianserin	32 937	33 187	32 133	31 289	30 299	62	15	7 379	14 175	8 730	11 933
N06AX05 trazodone	<5	0	<5	<5	<5	100	0	0	<5	0	5
N06AX06 nefazodone	64	55	48	43	42	48	0	5	33	<5	301
N06AX11 mirtazapine	26 961	27 888	28 798	30 393	31 444	57	17	9 194	13 195	9 038	32 702
N06AX12 bupropion	6 944	4 434	3 892	5 978	7 638	58	<5	3 495	3 605	537	10 678
N06AX14 tianeptine	0	<5	<5	<5	<5	33	0	<5	<5	0	115
N06AX16 venlafaxine	27 897	28 833	28 349	28 734	28 788	61	<5	11 094	13 756	3 936	34 532
N06AX18 reboxetine	639	591	569	530	512	64	0	257	216	39	1 006
N06AX21 duloxetine	1 590	4 988	3 945	2 419	2 803	68	<5	891	1 486	425	9 422
N06AX22 agomelatine	0	0	0	0	28	64	0	13	14	<5	358
N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS	19 567	22 516	25 207	27 837	30 075	36	10 487	17 174	2 279	135	199 743
N06BA Centrally acting sympathomimetics	19 160	22 152	24 862	27 490	29 706	36	10 476	16 989	2 139	102	199 230
N06BA01 amfetamine	156	178	221	269	303	42	12	209	69	13	1 650
N06BA02 dexamfetamine	633	722	857	1 024	1 167	41	105	789	254	19	9 948
N06BA04 methylphenidate	16 273	19 200	21 769	24 240	26 466	36	9 793	14 928	1 685	60	151 544
N06BA07 modafinil	275	272	288	291	329	62	5	198	115	11	3 784

ATC group N

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70	<15		15-44	45-69	≥70		
N06BA09 atomoxetine	3 207	3 184	3 246	3 213	3 053	33	1 187	1 725	139	<5	32 303
N06BC Xanthine derivatives	364	327	294	281	285	50	<5	159	102	22	136
N06BC01 caffeine	364	327	294	281	285	50	<5	159	102	22	136
N06BX Other psychostimulants and nootropics	48	43	57	75	102	44	10	39	42	11	377
N06BX03 piracetam	48	43	49	65	77	42	5	25	36	11	258
N06BX13 idebenone	0	0	8	10	8	63	5	<5	0	0	106
N06BX17 adrafinil	0	0	0	0	18	44	0	11	7	0	13
N06D ANTI-DEMENTIA DRUGS	13 959	13 484	13 366	13 342	14 170	63	<5	90	1 280	12 798	71 443
N06DA Anticholinesterases	12 979	12 430	12 376	12 370	12 916	63	0	<5	1 117	11 795	59 577
N06DA02 donepezil	10 589	10 033	9 836	9 243	8 918	65	0	<5	695	8 220	33 584
N06DA03 rivastigmine	1 681	1 773	2 161	2 973	3 933	59	0	0	414	3 519	21 752
N06DA04 galantamine	1 058	890	694	558	502	62	0	<5	59	442	4 241
N06DX Other anti-dementia drugs	1 589	1 616	1 501	1 538	1 969	60	<5	86	261	1 620	11 866
N06DX01 memantine	1 589	1 616	1 501	1 538	1 816	58	0	<5	200	1 613	11 796
N06DX02 ginkgo biloba	0	0	0	0	153	78	<5	83	61	7	70
N07 OTHER NERVOUS SYSTEM DRUGS	11 054	34 308	42 737	46 047	47 155	49	9	18 026	26 599	2 521	222 341
N07A PARASYMPATHOMIMETICS	717	750	743	721	660	70	<5	107	317	232	2 073
N07AA Anticholinesterases	477	484	476	493	509	65	<5	96	214	196	1 082
N07AA02 pyridostigmine	477	482	476	492	505	65	<5	95	212	195	1 074
N07AA30 ambenonium	0	0	0	<5	<5	100	0	<5	<5	<5	8
N07AA51 neostigmine, combinations	0	<5	0	0	<5	0	0	0	<5	0	0
N07AB Choline esters	145	153	149	112	22	64	<5	<5	12	8	77
N07AB01 carbachol	145	153	149	112	22	64	<5	<5	12	8	77
N07AX Other parasympathomimetics	106	122	129	123	130	91	0	10	92	28	913
N07AX01 pilocarpine	106	122	129	123	130	91	0	10	92	28	913
N07B DRUGS USED IN ADDICTIVE DISORDERS	9 658	32 861	41 283	44 559	45 718	49	<5	17 805	25 843	2 067	207 636
N07BA Drugs used in nicotine dependence	1 126	23 368	31 433	34 174	34 790	55	0	12 362	20 628	1 800	48 993
N07BA01 nicotine ¹⁾	876	770	770	769	905	47	0	135	562	208	580
N07BA03 varenicline	250	22 656	30 731	33 475	33 970	55	0	12 245	20 128	1 597	48 413
N07BB Drugs used in alcohol dependence	4 287	4 867	4 990	4 984	4 865	30	<5	1 611	3 012	239	2 534
N07BB01 disulfiram	3 773	4 066	4 464	4 533	4 450	30	0	1 491	2 742	217	1 707
N07BB03 acamprosate	472	629	584	550	525	32	0	160	341	24	726
N07BB04 naltrexone	154	362	119	26	19	58	<5	7	6	<5	102

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group N

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
N07BC Drugs used in opioid dependence	4 301	4 853	5 164	5 709	6 375	30	0	3 970	2 367	38	156 109
N07BC01 buprenorphine	1 787	1 907	1 719	1 981	2 133	31	0	1 429	702	<5	53 466
N07BC02 methadone ²⁾	2 674	2 852	2 956	3 146	3 345	32	0	1 850	1 459	36	81 420
N07BC51 buprenorphine, combinations	219	970	1 156	1 194	1 562	26	0	1 183	379	0	21 223
N07C ANTIVERTIGO PREPARATIONS	382	408	413	421	424	62	<5	69	244	109	1 133
N07CA Antivertigo preparations	382	408	413	421	424	62	<5	69	244	109	1 133
N07CA01 betahistine	379	404	401	410	413	63	0	64	240	109	1 113
N07CA03 flunarizine	<5	<5	12	11	11	36	<5	5	<5	0	21
N07X OTHER NERVOUS SYSTEM DRUGS	304	310	311	361	366	41	0	49	204	113	11 499
N07XX Other nervous system drugs	304	310	311	361	366	41	0	49	204	113	11 499
N07XX02 riluzole	246	252	253	286	278	37	0	13	162	103	7 702
N07XX04 sodium oxybate	23	26	28	33	49	51	0	33	13	<5	3 069
N07XX06 tetrabenazine	35	32	30	42	37	51	0	<5	27	7	699
N07XX07 fampridine	0	0	0	0	<5	100	0	0	<5	0	29
N07XX06 tetrabenazine	35	32	30	42	37	51	0	<5	27	7	699
N07XX07 fampridine	0	0	0	0	<5	100	0	0	<5	0	29

²⁾The figures only include methadone dispensed according to prescription from the pharmacies. Patients may also receive methadone dispensed according to special arrangements in the health regions.

2.14 ATC group P – Antiparasitic products, insecticides and repellents

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS	83 433	88 000	89 343	86 714	88 665	64	2 964	41 883	33 915	9 903	31 623
P01 ANTIPROTOZOALS	80 301	84 808	86 259	83 638	85 550	64	1 850	40 544	33 409	9 747	30 559
P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES	50 679	51 756	53 345	54 583	55 529	67	566	25 271	21 836	7 856	6 000
P01AB Nitroimidazole derivatives	50 677	51 753	53 340	54 576	55 528	67	566	25 270	21 836	7 856	5 982
P01AB01 metronidazole	50 677	51 753	53 340	54 571	55 481	67	564	25 248	21 813	7 856	5 943
P01AB02 tinidazole	0	0	0	7	6	33	<5	<5	<5	0	18
P01AB03 ornidazole	0	0	0	0	46	76	<5	21	22	0	20
P01AC Dichloroacetamide derivatives	7	10	6	13	<5	50	0	<5	<5	0	5
P01AC01 diloxanide	7	10	6	13	<5	50	0	<5	<5	0	5
P01AX Other agents against amoebiasis and other protozoal diseases	0	<5	<5	<5	<5	100	0	<5	0	0	14
P01AX05 mepacrine	0	0	<5	0	0	-	0	0	0	0	0
P01AX11 nitazoxanide	0	<5	<5	<5	<5	100	0	<5	0	0	14
P01B ANTIMALARIALS	30 120	33 687	33 502	29 645	30 699	59	1 288	15 619	11 860	1 932	24 520
P01BA Aminoquinolines	8 430	8 698	7 804	5 421	5 682	81	48	1 525	3 200	909	3 260
P01BA01 chloroquine	4 012	4 219	2 630	40	21	71	0	7	11	<5	19
P01BA02 hydroxychloroquine	4 410	4 485	5 211	5 371	5 659	81	48	1 517	3 188	906	3 241
P01BA03 primaquine	26	8	17	12	<5	50	0	<5	<5	0	0
P01BB Biguanides	17 897	20 830	21 153	19 494	20 459	53	863	11 504	7 469	623	19 130
P01BB01 proguanil	525	340	62	22	11	64	0	8	<5	<5	9
P01BB51 proguanil, combinations	17 401	20 512	21 096	19 476	20 450	53	863	11 498	7 467	622	19 121
P01BC Methanolquinolines	4 749	5 013	5 056	5 044	4 796	59	379	2 732	1 278	407	2 125
P01BC01 quinine	606	621	595	629	569	67	<5	21	234	313	304
P01BC02 mefloquine	4 144	4 392	4 463	4 415	4 229	57	378	2 712	1 045	94	1 821
P01BD Diaminopyrimidines	<5	5	<5	5	<5	0	0	<5	<5	0	4
P01BD01 pyrimethamine	<5	5	<5	5	<5	0	0	<5	<5	0	4
P01BF Artemisinin and derivatives, combinations	0	0	0	0	<5	100	0	0	<5	0	1
P01BF01 artemether and lumefantrine	0	0	0	0	<5	100	0	0	<5	0	1
P01C AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS	<5	<5	<5	<5	<5	50	0	<5	0	0	39
P01CX Other agents against leishmaniasis and trypanosomiasis	<5	<5	<5	<5	<5	50	0	<5	0	0	39

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
P01CX01 pentamidine isethionate	<5	<5	<5	<5	<5	50	0	<5	0	0	39
P02 ANTHELMINTICS	2 061	2 025	2 008	2 047	2 105	58	979	732	322	72	616
P02B ANTITREMATODALS	10	11	16	19	26	46	<5	11	11	<5	88
P02BA Quinoline derivatives and related substances	10	11	16	19	26	46	<5	11	11	<5	88
P02BA01 praziquantel	10	11	16	19	26	46	<5	11	11	<5	88
P02C ANTINEMATODAL AGENTS	2 036	1 997	1 985	2 016	2 066	58	973	715	307	71	506
P02CA Benzimidazole derivatives	1 888	1 861	1 853	1 870	1 899	58	923	633	280	63	447
P02CA01 mebendazole	1 872	1 845	1 835	1 847	1 876	58	920	620	273	63	308
P02CA03 albendazole	16	17	18	24	23	74	<5	13	7	0	139
P02CF Avermectines	38	41	43	47	61	51	5	40	13	<5	44
P02CF01 ivermectin	38	41	43	47	61	51	5	40	13	<5	44
P02CX Other antinematodals	124	117	103	114	120	67	53	45	17	5	16
P02CX01 pyrvinium	124	117	103	114	120	67	53	45	17	5	16
P02D ANTICESTODALS	16	20	10	18	18	39	5	7	6	0	23
P02DA Salicylic acid derivatives	16	20	10	18	18	39	5	7	6	0	23
P02DA01 niclosamide	16	20	10	18	18	39	5	7	6	0	23
P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS	1 192	1 283	1 216	1 157	1 176	49	144	713	226	93	448
P03A ECTOPARASITICIDES, INCL. SCABICIDES	1 192	1 283	1 216	1 157	1 176	49	144	713	226	93	448
P03AC Pyrethrines, incl. synthetic compounds	1 028	1 139	1 126	1 085	1 093	48	125	678	199	91	419
P03AC04 permethrin ¹⁾	1 028	1 139	1 126	1 085	1 093	48	125	678	199	91	419
P03AX Other ectoparasiticides, incl. scabicides	178	152	97	77	86	64	19	38	27	<5	29
P03AX01 benzyl benzoate ¹⁾	41	38	36	18	24	50	<5	13	6	<5	10
P03AX03 malathion ¹⁾	138	114	61	59	62	69	15	25	21	<5	19

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.15 ATC group R – Respiratory system

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK	
	Number of individuals						Number of individuals per age group					
	<15	15–44	45–69	≥70								
R	RESPIRATORY SYSTEM	1 120 213	1 153 020	1 151 927	1 183 764	1 183 368	56	186 697	428 370	409 123	159 178	1 494 767
R01	NASAL PREPARATIONS	313 520	330 852	333 003	348 414	353 788	57	31 488	167 743	125 566	28 991	117 048
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE	261 104	274 863	278 004	294 860	297 048	55	30 091	136 073	104 607	26 277	111 237
R01AA	Sympathomimetics, plain	4 654	4 595	4 204	3 803	4 014	52	1 099	1 501	960	454	290
R01AA05	oxymetazoline ¹⁾	1 952	1 895	1 734	1 550	1 800	54	766	595	324	115	113
R01AA07	xylometazoline ¹⁾	2 726	2 722	2 483	2 264	2 232	50	342	909	641	340	177
R01AB	Sympathomimetics, combinations excl. corticosteroids	0	0	1 124	514	602	57	21	287	187	107	40
R01AB06	xylometazoline ¹⁾	0	0	1 124	514	602	57	21	287	187	107	40
R01AC	Antiallergic agents, excl. corticosteroids	44 158	47 363	44 710	44 853	39 403	56	10 137	19 281	8 472	1 513	10 632
R01AC01	cromoglicic acid ¹⁾	11 797	11 764	10 718	10 197	8 772	60	1 775	4 376	2 245	376	2 305
R01AC02	levocabastine ¹⁾	32 421	35 661	34 024	34 686	30 655	55	8 406	14 884	6 225	1 140	8 270
R01AC03	azelastine ¹⁾	276	303	261	227	198	50	31	98	61	8	58
R01AD	Corticosteroids	218 300	229 612	234 550	252 558	259 007	55	19 920	118 026	96 646	24 415	99 961
R01AD01	beclometasone	2 577	2 395	2 228	1 943	11	45	0	0	7	<5	2
R01AD04	flunisolide	4 811	4 527	4 133	2 634	11	64	0	<5	7	<5	16
R01AD05	budesonide	48 123	46 628	43 762	39 753	34 984	56	2 204	14 058	14 832	3 890	14 906
R01AD08	fluticasone	36 640	34 290	32 446	27 939	24 337	55	1 224	9 500	10 676	2 937	9 555
R01AD09	mometasone	117 997	133 991	142 286	143 465	141 062	55	10 117	64 596	52 860	13 489	55 277
R01AD11	triamcinolone	15 051	14 824	13 593	11 025	9 680	56	593	4 174	3 897	1 016	3 850
R01AD12	fluticasone furoate	0	0	3 945	38 321	60 405	55	6 389	30 722	19 100	4 194	16 356
R01AX	Other nasal preparations	431	439	459	572	630	53	45	167	187	231	314
R01AX03	ipratropium bromide	272	266	264	302	355	50	<5	41	121	191	224
R01AX06	mupirocin	159	173	195	270	276	57	43	127	66	40	90
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE	69 853	75 595	75 926	75 490	81 732	66	1 778	45 350	30 631	3 973	5 811
R01BA	Sympathomimetics	69 853	75 595	75 926	75 490	81 732	66	1 778	45 350	30 631	3 973	5 811
R01BA01	phenylpropanolamine	69 853	75 595	75 926	75 490	81 732	66	1 778	45 350	30 631	3 973	5 811
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	392 070	395 713	397 839	419 365	423 082	53	111 850	105 692	136 635	68 905	1 146 970
R03A	ADRENERGICS, INHALANTS	303 716	309 383	309 382	328 512	335 394	54	61 136	95 582	120 375	58 301	755 624
R03AA	Alpha- and beta-adrenoreceptor agonists	240	196	185	181	209	39	179	17	7	6	242
R03AA01	epinephrine	240	196	185	181	209	39	179	17	7	6	242
R03AC	Selective beta-2-adrenoreceptor agonists	222 364	230 948	230 012	244 325	248 977	54	57 396	72 235	81 328	38 018	150 722

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group R

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
R03AC02 salbutamol	161 605	171 636	175 373	190 767	198 197	53	55 051	56 046	59 899	27 201	85 066
R03AC03 terbutaline	46 583	43 401	39 227	38 318	35 534	57	2 208	13 723	14 033	5 570	16 487
R03AC04 fenoterol	192	22	23	17	17	41	0	0	12	5	65
R03AC12 salmeterol	9 630	11 119	10 847	10 555	10 559	54	236	1 109	5 059	4 155	20 531
R03AC13 formoterol	18 469	18 706	17 310	16 879	16 620	55	407	3 709	7 921	4 583	27 884
R03AC18 indacaterol	0	0	0	0	712	48	0	26	406	280	689
R03AK Adrenergics and other drugs for obstructive airway diseases	157 935	154 830	155 451	164 536	168 407	55	11 976	47 099	72 702	36 630	604 660
R03AK04 salbutamol and other drugs for obstructive airway diseases	<5	<5	<5	<5	<5	100	0	0	0	<5	7
R03AK06 salmeterol and other drugs for obstructive airway diseases	92 472	87 858	86 941	90 149	90 968	55	9 444	22 200	37 937	21 387	349 384
R03AK07 formoterol and other drugs for obstructive airway diseases	68 289	69 903	71 382	77 502	80 679	56	2 673	25 852	36 243	15 911	255 269
R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS	129 997	132 673	134 223	140 443	146 392	51	43 920	20 146	47 195	35 131	255 448
R03BA Glucocorticoids	88 344	87 587	85 762	88 434	91 579	50	43 673	17 308	20 896	9 702	91 959
R03BA01 beclometasone	5 090	4 906	4 825	4 729	4 378	56	871	1 041	1 677	789	3 933
R03BA02 budesonide	35 120	31 522	26 377	25 860	25 045	56	4 235	6 526	9 355	4 929	37 300
R03BA05 fluticasone	49 821	53 850	56 192	59 302	61 984	47	39 485	9 396	9 312	3 791	48 887
R03BA07 mometasone	<5	<5	<5	<5	<5	50	0	0	<5	0	4
R03BA08 ciclesonide	0	0	0	0	1 871	58	193	548	843	287	1 834
R03BB Anticholinergics	47 834	50 703	53 722	57 032	60 122	52	687	3 271	28 625	27 539	163 180
R03BB01 ipratropium bromide	39 150	41 597	41 832	39 555	38 281	55	687	2 892	17 238	17 464	51 964
R03BB04 tiotropium bromide	11 795	12 510	16 714	22 767	27 423	47	<5	473	14 106	12 842	111 216
R03BC Antiallergic agents, excl. corticosteroids	770	633	539	521	454	64	33	177	187	57	310
R03BC01 cromoglicic acid	770	633	539	521	454	64	33	177	187	57	310
R03C ADRENERGICS FOR SYSTEMIC USE	68 998	65 153	67 040	68 732	63 250	49	52 531	4 571	4 454	1 694	8 192
R03CA Alpha- and beta-adrenoreceptor agonists	53 608	50 378	53 610	55 607	49 352	49	41 985	3 267	3 075	1 025	6 159
R03CA02 ephedrine	53 608	50 378	53 610	55 607	49 352	49	41 985	3 267	3 075	1 025	6 159
R03CC Selective beta-2-adrenoreceptor agonists	18 677	17 449	16 509	16 104	16 905	49	13 502	1 326	1 401	676	2 033
R03CC02 salbutamol	6 242	5 885	5 091	4 877	4 731	48	3 959	348	295	129	369
R03CC03 terbutaline	12 399	11 467	11 420	11 149	12 096	49	9 701	936	987	472	1 391
R03CC12 bambuterol	215	222	227	238	245	62	0	46	122	77	272

ATC group R

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	35 628	37 528	39 324	40 012	41 115	55	9 886	10 175	14 933	6 121	127 707
R03DA Xanthines	7 134	6 529	5 938	5 287	4 782	58	<5	286	2 325	2 168	3 670
R03DA02 choline theophyllinate	15	13	12	8	10	90	0	0	9	<5	27
R03DA04 theophylline	7 096	6 499	5 916	5 272	4 765	58	<5	281	2 316	2 165	3 543
R03DA05 aminophylline	44	37	29	26	19	63	0	5	11	<5	100
R03DC Leukotriene receptor antagonists	29 701	32 110	34 436	35 710	37 215	54	9 881	9 978	13 158	4 198	114 025
R03DC01 zafirlukast	37	32	28	25	22	64	0	<5	15	5	229
R03DC03 montelukast	29 668	32 079	34 409	35 686	37 194	54	9 881	9 976	13 144	4 193	113 796
R03DX Other systemic drugs for obstructive airway diseases	24	34	44	53	145	55	5	50	66	24	10 011
R03DX05 omalizumab	24	34	44	53	84	55	5	49	29	<5	9 955
R03DX07 roflumilast	0	0	0	0	61	56	0	<5	37	23	56
R05 COUGH AND COLD PREPARATIONS	374 224	389 460	373 473	385 147	382 123	60	30 900	127 103	151 864	72 256	65 049
R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS	116 436	125 939	126 487	133 510	135 751	58	6 991	31 032	57 198	40 530	32 475
R05CA Expectorants	3 468	3 571	3 135	3 334	3 671	57	1 449	865	815	542	255
R05CA10 combinations ¹⁾	3 468	3 571	3 135	3 334	3 671	57	1 449	865	815	542	255
R05CB Mucolytics	113 575	122 993	123 897	130 750	132 732	58	5 607	30 309	56 642	40 174	32 220
R05CB01 acetylcysteine	108 132	118 352	119 890	126 966	128 867	59	4 284	29 571	55 650	39 362	25 487
R05CB02 bromhexine ¹⁾	6 431	5 508	4 836	4 561	4 655	54	1 339	844	1 306	1 166	752
R05CB12 tiopronin	<5	<5	<5	5	5	40	0	<5	<5	0	49
R05CB13 dornase alfa (desoxyribonuclease)	87	99	110	109	118	53	43	64	11	0	5 932
R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS	264 979	265 549	255 435	258 843	254 393	61	22 201	94 770	101 129	36 293	28 442
R05DA Opium alkaloids and derivatives	256 861	262 753	255 434	258 843	254 393	61	22 201	94 770	101 129	36 293	28 442
R05DA01 ethylmorphine	246 752	252 064	246 451	249 477	245 495	61	21 802	91 697	97 212	34 784	25 619
R05DA03 hydrocodone	643	650	570	581	592	62	<5	115	320	156	240
R05DA04 codeine	7 342	8 196	7 660	7 715	7 194	63	105	2 737	3 243	1 109	1 620
R05DA07 noscapine ¹⁾	1 590	1 848	1 561	1 763	1 872	57	341	612	595	324	160
R05DA08 pholcodine ¹⁾	887	292	0	0	0	0	0	0	0	0	0
R05DA09 dextromethorphan	<5	0	<5	<5	<5	50	0	<5	<5	0	6
R05DA20 combinations	3 439	3 981	2 881	3 036	2 834	63	26	882	1 412	514	798
R05DB Other cough suppressants	10 171	3 507	<5	0	0	-	0	0	0	0	0

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
R05DB05 pentoxyverine	10 171	3 507	<5	0	0	-	0	0	0	0	0
R05F COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS	34 874	47 005	37 584	41 525	41 833	62	3 057	15 984	16 560	6 232	4 131
R05FA Opium derivatives and expectorants	34 874	47 005	37 584	41 525	41 833	62	3 057	15 984	16 560	6 232	4 131
R05FA02 opium derivatives and expectorants	34 874	47 005	37 584	41 525	41 833	62	3 057	15 984	16 560	6 232	4 131
R06 ANTIHISTAMINES FOR SYSTEMIC USE	495 729	513 164	514 752	519 114	511 450	58	71 974	212 328	176 904	50 244	165 700
R06A ANTIHISTAMINES FOR SYSTEMIC USE	495 729	513 164	514 752	519 114	511 450	58	71 974	212 328	176 904	50 244	165 700
R06AA Aminoalkyl ethers	27	24	18	18	14	71	0	<5	8	<5	27
R06AA02 diphenhydramine	5	<5	<5	<5	<5	100	0	0	<5	0	0
R06AA04 clemastine	22	20	14	14	13	69	0	<5	7	<5	27
R06AB Substituted alkylamines	37 627	38 566	40 313	35 818	25 252	67	6 442	9 050	6 634	3 126	6 952
R06AB02 dexchlorpheniramine	37 627	38 566	40 313	35 818	25 252	67	6 442	9 050	6 634	3 126	6 952
R06AD Phenothiazine derivatives	59 279	61 384	62 532	62 798	64 433	61	4 822	22 711	27 194	9 706	35 290
R06AD01 alimemazine	52 701	54 771	55 908	56 465	57 894	61	4 770	20 191	24 379	8 554	32 464
R06AD02 promethazine	7 559	7 310	7 311	6 991	7 153	65	56	2 761	3 141	1 195	2 815
R06AD03 thiethylperazine	9	8	8	<5	5	80	0	0	<5	<5	11
R06AE Piperazine derivatives	224 629	260 076	272 060	294 718	285 360	58	43 207	116 572	97 416	28 165	56 629
R06AE03 cyclizine ¹⁾	801	607	276	655	736	67	8	210	327	191	287
R06AE05 meclozine ¹⁾	1 874	1 893	2 094	1 956	2 031	87	59	1 435	310	227	193
R06AE07 cetirizine ¹⁾	220 201	256 512	269 002	291 602	282 251	57	43 110	114 802	96 613	27 726	55 601
R06AE09 levocetirizine	2 297	1 518	1 040	844	703	61	36	305	296	66	548
R06AX Other antihistamines for systemic use	212 573	192 319	180 176	164 938	169 541	59	21 708	77 768	57 595	12 470	66 802
R06AX02 cyproheptadine	35	57	61	59	40	58	10	16	9	5	20
R06AX13 loratadine ¹⁾	56 305	72 006	74 764	92 307	83 850	59	6 590	40 752	29 493	7 015	19 459
R06AX17 ketotifen	<5	5	5	<5	7	71	0	<5	<5	<5	8
R06AX22 ebastine ¹⁾	31 167	25 660	23 548	11 035	10 314	64	275	4 782	4 413	844	8 588
R06AX26 fexofenadine	11 888	10 213	11 575	24 496	27 017	61	1 014	14 252	9 602	2 149	8 063
R06AX27 desloratadine	124 723	93 888	81 363	48 971	55 038	56	14 349	21 354	16 430	2 905	30 664

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

2.16 ATC group S – Sensory organs

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15–44	45–69	≥70							
S SENSORY ORGANS	575 548	585 905	596 098	596 286	609 134	57	125 507	176 979	180 669	125 979	319 907
S01 OPHTHALMOLOGICALS	513 023	519 135	525 641	526 626	538 534	57	112 453	154 794	154 470	116 817	306 615
S01A ANTIINFECTIVES	255 416	250 656	262 875	250 364	268 773	56	84 134	76 696	70 600	37 343	50 927
S01AA Antibiotics	250 735	247 682	260 246	247 635	265 926	56	83 941	75 733	69 530	36 722	49 612
S01AA01 chloramphenicol	187 151	184 832	192 708	182 290	197 017	55	54 198	59 030	55 055	28 734	39 967
S01AA02 chlortetracycline	0	0	<5	<5	<5	100	0	<5	0	0	0
S01AA11 gentamicin	2 278	2 121	2 022	1 763	1 701	58	198	643	547	313	188
S01AA12 tobramycin	480	2 218	2 455	2 332	2 299	59	354	700	733	512	214
S01AA13 fusidic acid	76 131	72 970	79 306	75 837	82 717	56	37 981	19 113	16 414	9 209	8 595
S01AA30 combinations of different antibiotics	4 516	4 584	4 917	4 936	5 102	59	296	1 284	1 985	1 537	648
S01AD Antivirals	3 157	3 092	3 080	3 249	3 263	57	148	942	1 312	861	802
S01AD01 idoxuridine	0	0	0	<5	0	-	0	0	0	0	0
S01AD02 trifluridine	0	<5	<5	0	0	-	0	0	0	0	0
S01AD03 aciclovir	3 157	3 091	3 079	3 248	3 263	57	148	942	1 312	861	802
S01BC Antiinflammatory agents, non-steroids	8 608	11 292	14 254	15 618	17 141	59	84	1 439	5 342	10 276	3 409
S01BC03 diclofenac	8 608	11 292	14 254	15 618	15 814	59	82	1 404	4 930	9 398	3 023
S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION	54 884	54 487	54 867	57 374	56 157	58	1 231	9 413	19 277	26 236	11 128
S01CA Corticosteroids and anti-infectives in combination	54 884	54 487	54 867	57 374	56 157	58	1 231	9 413	19 277	26 236	11 128
S01CA01 dexamethasone and anti-infectives	54 884	54 487	54 867	57 374	56 157	58	1 231	9 413	19 277	26 236	11 128
S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS	65 488	66 584	67 456	68 238	68 879	58	156	1 857	19 791	47 075	168 861
S01BA07 fluorometholone	19	17	19	15	17	53	<5	<5	10	<5	16
S01BA09 clobetasone	11	12	18	22	18	61	<5	5	7	<5	74
S01BA13 rimexolone	1 587	1 754	2 098	2 151	4 164	56	177	1 379	1 461	1 147	1 191
S01BB Corticosteroids and mydriatics in combination	<5	<5	<5	<5	<5	100	0	0	0	<5	3
S01BB03 fluorometholone and mydriatics	<5	<5	<5	<5	<5	100	0	0	0	<5	3
S01BC Antiinflammatory agents, non-steroids	8 001	8 608	11 294	14 254	15 596	59	91	1 503	4 973	9 029	2 958
S01BC03 diclofenac	8 001	8 608	11 294	14 254	15 596	59	91	1 503	4 973	9 029	2 958
S01BC10 nepafenac	0	0	0	0	1 528	59	<5	52	469	1 005	386
S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION	54 488	54 854	57 374	56 226	56 887	58	1 153	9 103	19 891	26 740	11 058

ATC group S

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
S01CA Corticosteroids and anti-infectives in combination	54 488	54 854	57 374	56 226	56 887	58	1 153	9 103	19 891	26 740	11 058
S01CA01 dexamethasone and anti-infectives	54 488	54 854	57 374	56 226	56 887	58	1 153	9 103	19 891	26 740	11 058
S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS	66 584	67 453	68 238	68 940	70 034	57	184	1 981	20 312	47 557	163 101
S01EA Sympathomimetics in glaucoma therapy¹⁾	3 583	3 655	3 953	3 992	4 076	54	7	128	1 056	2 885	4 556
S01EA01 epinephrine	<5	<5	5	<5	<5	0	<5	0	0	0	1
S01EA02 dipivefrine	275	234	217	122	9	56	0	0	<5	7	25
S01EA03 apraclonidine	70	69	91	97	115	45	<5	8	39	66	49
S01EA05 brimonidine	3 275	3 400	3 706	3 838	3 982	54	5	123	1 030	2 824	4 481
S01EB Parasympathomimetics	1 802	1 637	1 498	1 433	1 291	61	5	67	317	902	795
S01EB01 pilocarpine	1 799	1 634	1 496	1 431	1 289	61	5	67	315	902	791
S01EB02 carbachol	<5	<5	<5	<5	<5	100	0	0	<5	0	4
S01EC Carbonic anhydrase inhibitors	9 383	9 558	9 488	9 634	10 037	57	102	603	2 529	6 803	12 227
S01EC01 acetazolamide	1 580	1 695	1 597	1 531	1 699	54	44	470	594	591	969
S01EC03 dorzolamide	3 242	2 975	2 783	2 660	2 502	58	7	56	538	1 901	3 376
S01EC04 brinzolamide	4 887	5 148	5 415	5 811	6 192	58	55	95	1 489	4 553	7 883
S01EC05 methazolamide	8	6	<5	0	0	0	0	0	0	0	0
S01ED Beta blocking agents¹⁾	47 138	47 230	47 882	48 377	48 838	57	121	1 168	14 220	33 329	81 578
S01ED01 timolol	23 957	23 426	23 312	22 977	22 324	58	93	593	7 366	14 272	22 261
S01ED02 betaxolol	2 805	2 525	2 233	2 012	1 778	67	<5	12	379	1 385	1 235
S01ED51 timolol, combinations	22 593	23 685	24 676	25 922	27 057	56	35	649	7 201	19 172	58 082
S01EE Prostaglandin analogues¹⁾	34 375	35 231	35 402	36 048	36 692	58	19	635	9 896	26 142	63 945
S01EE01 latanoprost	29 521	29 947	29 658	28 946	27 888	59	7	446	7 238	20 197	44 957
S01EE03 bimatoprost	1 836	1 789	1 814	1 807	1 867	59	0	43	502	1 322	3 124
S01EE04 travoprost	3 607	4 050	4 469	4 844	5 032	55	<5	86	1 416	3 529	8 681
S01EE05 tafluprost	0	0	0	1 654	3 067	64	12	90	1 079	1 886	7 182
S01F MYDRIATICS AND CYCLOPLEGICS	5 233	4 586	4 744	4 899	5 062	46	423	1 193	2 320	1 126	938
S01FA Anticholinergics	5 225	4 568	4 737	4 891	5 058	46	423	1 192	2 318	1 125	933
S01FA01 atropine	3 398	2 598	2 750	2 670	2 548	46	348	581	1 090	529	490
S01FA02 scopolamine	5	<5	0	0	0	0	0	0	0	0	0
S01FA04 cyclopentolate	926	1 897	2 034	2 277	2 543	47	73	616	1 257	597	400
S01FA05 homatropine	1 048	127	0	0	0	0	0	0	0	0	0
S01FA06 tropicamide	112	185	164	157	189	56	14	70	82	23	43

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group S

ATC level	2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
	Number of individuals						Number of individuals per age group				
	<15	15-44	45-69	≥70							
S01FB Sympathomimetics excl. antiglaucoma preparations	39	62	48	39	29	31	<5	10	15	<5	5
S01FB01 phenylephrine	39	62	48	39	29	31	<5	10	15	<5	5
S01G DECONGESTANTS AND ANTIALLERGICS	167 399	175 153	164 722	172 049	158 604	58	29 180	71 837	45 842	11 745	49 083
S01GA Sympathomimetics used as decongestants	25 623	25 905	23 730	23 098	20 727	60	2 734	9 403	6 694	1 896	6 182
S01GA51 naphazoline, combinations	9	11	11	11	<5	75	0	<5	<5	0	1
S01GA52 tetrazyline, combinations ¹⁾	25 615	25 894	23 719	23 089	20 724	60	2 734	9 402	6 692	1 896	6 181
S01GX Other antiallergics	145 883	153 727	144 669	152 775	141 071	58	27 131	63 819	40 079	10 042	42 901
S01GX01 cromoglicic acid ¹⁾	27 761	27 687	24 839	25 305	22 546	61	3 423	10 134	7 252	1 737	5 747
S01GX02 levocabastine ¹⁾	74 465	78 401	73 170	77 301	70 555	58	14 243	32 316	19 254	4 742	20 502
S01GX04 nedocromil	2 466	2 327	1 982	2 018	1 776	57	235	907	530	104	361
S01GX05 lodoxamide ¹⁾	470	444	339	35	0	-	0	0	0	0	0
S01GX06 emedastine	648	645	546	490	379	56	65	143	122	49	139
S01GX07 azelastine	923	901	755	691	579	58	104	226	173	76	171
S01GX08 ketotifen ¹⁾	18 528	18 601	16 912	17 926	16 304	59	2 987	7 213	4 874	1 230	7 141
S01GX09 olopatadine	25 834	30 543	30 751	34 046	32 854	56	7 058	14 311	9 068	2 417	8 841
S01X OTHER OPHTHALMOLOGICALS	5 768	6 080	6 859	18 266	26 364	76	232	2 720	11 527	11 885	18 708
S01XA Other ophthalmologicals	5 768	6 080	6 859	18 266	26 364	76	232	2 720	11 527	11 885	18 708
S01XA03 sodium chloride, hypertonic	19	18	16	20	15	53	0	<5	6	7	12
S01XA18 ciclosporin	7	25	27	41	70	59	<5	24	39	<5	832
S01XA20 artificial tears and other indifferent preparations ¹⁾	5 747	6 041	6 823	18 234	26 322	76	228	2 707	11 509	11 878	17 864
S02 OTOLOGICALS	7 290	11 998	13 048	14 496	14 920	53	2 850	3 874	5 852	2 344	2 929
S02A ANTIINFECTIVES	2 346	5 580	7 097	7 037	7 345	47	2 690	2 014	1 929	712	1 371
S02AA Antiinfectives	2 346	5 580	7 097	7 037	7 345	47	2 690	2 014	1 929	712	1 371
S02AA01 chloramphenicol	315	253	202	123	75	36	25	17	23	10	43
S02AA15 ciprofloxacin	2 046	5 349	6 923	6 937	7 289	47	2 674	2 000	1 911	704	1 328
S02B CORTICOSTEROIDS	4 982	6 630	6 139	7 724	7 844	58	178	1 967	4 037	1 662	1 548
S02BA Corticosteroids	4 982	6 630	6 139	7 724	7 844	58	178	1 967	4 037	1 662	1 548
S02BA07 betametasone	4 982	6 630	6 139	7 724	7 844	58	178	1 967	4 037	1 662	1 548
S02C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	66	75	58	70	57	65	<5	13	33	8	9
S02CA Corticosteroids and anti-infectives in combination	66	75	58	70	57	65	<5	13	33	8	9
S02CA02 flumetasone and anti-infectives	66	75	58	70	57	65	<5	13	33	8	9

¹⁾The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.

ATC group S

ATC level		2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
		Number of individuals						Number of individuals per age group				
								<15	15-44	45-69	≥70	
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS	73 529	74 455	78 318	75 321	76 979	54	14 988	23 173	27 343	11 475	10 363
S03C	CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION	73 529	74 455	78 318	75 321	76 979	54	14 988	23 173	27 343	11 475	10 363
S03CA	Corticosteroids and anti-infectives in combination	73 529	74 455	78 318	75 321	76 979	54	14 988	23 173	27 343	11 475	10 363
S03CA01	dexamethasone and antiinfectives	21 089	16 091	18 919	15 355	14 404	55	1 778	4 044	5 887	2 695	1 846
S03CA04	hydrocortisone and antiinfectives	55 889	61 091	62 532	62 503	64 986	54	13 494	19 899	22 421	9 172	8 517

2.17 ATC group V – Various

ATC level		2006	2007	2008	2009	2010	Share of women (%)	2010				Sales in 1000 NOK
		Number of individuals						Number of individuals per age group				
		<15	15–44	45–69	≥70							
V	VARIOUS	9 023	10 022	11 571	13 317	15 892	48	2 853	5 990	4 577	2 472	65 934
V01	ALLERGENS	3 343	4 173	4 962	6 170	7 287	46	1 461	4 507	1 291	28	34 149
V01A	ALLERGENS	3 343	4 173	4 962	6 170	7 287	46	1 461	4 507	1 291	28	34 149
V01AA	Allergen extracts	3 343	4 173	4 962	6 170	7 287	46	1 461	4 507	1 291	28	34 149
V01AA02	grass pollen	1 938	2 502	3 056	4 021	5 032	44	883	3 419	720	10	20 407
V01AA03	house dust mites	171	211	284	301	349	49	124	181	43	<5	1 630
V01AA05	tree pollen	2 139	2 693	3 104	3 705	4 148	49	857	2 468	809	14	9 640
V01AA07	insects	215	192	206	185	183	55	19	64	91	9	654
V01AA10	flowers	35	36	54	90	108	58	12	69	27	0	429
V01AA11	animals	140	178	201	217	288	48	87	133	68	0	1 388

Folkemengde i Norge 2006–2010 (per 1. juli)/
Population in Norway 2006–2010 (as of 1st July)

Year	2006	2007	2008	2009	2010
Population	4 661 041	4 709 284	4 768 076	4 829 800	4 888 946

Folkemengde etter alder i 2010 (per 1. juli)/
Population by age in 2010 (as of 1st July)

Age groups	<15	15–44	45–69	≥70
Population	887 738	1 986 158	1 483 850	531 200

Kilde: Statistisk sentralbyrå / Source: Statistics Norway

Liste over publikasjoner basert på data fra Reseptregisteret per mars 2011 / List of publications based on data from the Norwegian Prescription Database (NorPD) as of March 2011

2011:

Berg C, Sakshaug S, Handal M, Skurtveit S. Z-hypnotika - Sovemidlene som dominerer markedet i Norge. *Nor Farmaceut Tidsskr* 2011;119:20-3. In Norwegian.

Brekke M, Straand J. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observation study. *BMC Public Health*. 2011;11:144.

Dalen DM, Furu K, Locatelli M, Strøm S. Generic substitution: micro evidence from register data in Norway. *Eur J Health Econ* 2011;12:49-59.

Engeland A, Bjørge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, Furu K. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230.000 women in Norway. *Eur J Epidemiol* 2011;26:157-63.

Espnes MG, Bjørge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. *Pharmacoepidemiol Drug Saf* 2011;20:243-8.

Fredheim OM, Borchgrevink P, Nordstrand B, Clausen T, Skurtveit S. Prescription of analgesics to patients in opioid maintenance therapy: A pharmacoepidemiological study. *Drug Alcohol Depend* 2011 Jan 28. [Epub ahead of print].

Furu K, Karlstad Ø, Skurtveit S, Håberg SE, Nafstad P, London SJ, Nystad W. High validity of mother-reported use of antiasthmatics among children: a comparison with a population-based prescription database. *J Clin Epidemiol* 2011 Jan 12. [Epub ahead of print].

Furu K, Skurtveit S. Legemidler forskrevet til barn og ungdom i alderen 0-17 år i Norge. En studie basert på data fra Reseptregisteret. *Nor Farmaceut Tidsskr* 2011;119:16-9. In Norwegian.

Ghaderi S, Nordbø SA, Bakken IJ. Chlamydiainfeksjon i Sør-Trøndelag – behandling og oppfølging. [Chlamydia infections in South Trøndelag – treatment and follow-up]. *Tidsskr Nor Laegeforen* 2011;131:461-3. In Norwegian.

Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. *Expert Rev Pharmacoecon Outcomes Res*. 2011;11:121-9.

Handal M, Furu K, Engeland A, Rønning M, Skurtveit S. Use of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during and after pregnancy. A population based cohort study. *Eur J Clin Pharmacol* 2011. In press.

Hartz I, Tverdal A, Skurtveit S. Langtidsbruk av benzodiazepiner i kombinasjon med opioider og z-hypnotika blant uføretrygdede i Norge. *Nor Farmaceut Tidsskr* 2011;119:24-8. In Norwegian.

Hjellvik V, Tverdal A, Strøm H. Boiled coffee intake and subsequent risk for Type 2 Diabetes. *Epidemiology* 2011 Mar 12. [Epub ahead of print].

Johannessen Landmark C, Fossmark H, Larsson PG, Rytter E, Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. *Epilepsy Res* 2011 Mar 22. [Epub ahead of print].

Karlstad Ø, Tverdal A, Skurtveit S, Nafstad P, Furu K. A prospective study of asthma and subsequent use of hypnotics in young adults. *Pharmacoepidemiol Drug Saf* 2011 Jan 24. [Epub ahead of print].

Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial prescription of antipsychotics and antidepressants in general practice and specialist care in Norway. *Acta Psychiatr Scand* 2011 Mar 14. [Epub ahead of print].

Log T, Hartz I, Handal M, Tverdal A, Furu K, Skurtveit S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults – a population-based cohort study. *Pharmacoepidemiol Drug Saf* 2011;20:90-8.

Log T, Hartz I, Tverdal A, Furu K, Skurtveit S. Dispensing of prescribed analgesics in Norway among young people with foreign- or Norwegian-born parents. *Scand J Pain* 2011. In press.

Skurtveit S, Furu K, Handal M, Borchgrevink P, Fredheim O. To which extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? *Pain* 2011 Mar 29.[Epub ahead of print].

Ødegaard KJ, Riise T, Dilsaver S, Lund A, Akiskal H, Fasmer OB, Hundal Ø. A pharmaco-epidemiological study of migraine and antidepressant medications: Complete one year data from the Norwegian population. *J Affective Disorders* 2011;129:198-204.

2010:

Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study. *Pharmacoepidemiol Drug Saf* 2010;19:273-9.

Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. *Eur J Neurol* 2010;17:1445-50.

Berg A, Furu K, Einen M, Spigseth O: Bør barn behandles med efedrin mikstur? [Should children be treated with ephedrine mixture?]. *Tidsskr Nor Lægeforen* 2010;24: 2474-5. In Norwegian.

Berge HM, Gjelstad S, Furu K, Straand J. Glukosaminbruk reduserer ikke behovet for analgetika [Use of glucosamine does not reduce the need for other pain-relieving drugs]. *Tidsskr Nor Laegeforen* 2010;130:1463-6. In Norwegian.

Bramness J, Sandvik P, Engeland A, Skurtveit S. Does pregabalin (Lyrica) help patients reduce their use of benzodiazepines? A comparison with gabapentin using the Norwegian Prescription Database. *Basic Clin Pharmacol Toxicol* 2010 Apr 23 [Epub ahead of print].

Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Søgaaard AJ. Prescription of anti-osteoporosis drugs during 2004-2007 – a nationwide register study in Norway. *Eur J Clin Pharmacol* 2010;66:299-306.

Fasmer OB, Riise T, Eagan TM, Lund A, Dilsaver SC, Hundal Ø, Ødegaard KJ. Comorbidity of asthma with ADHD. *J Atten Disord* 2010 Jun 23 [Epub ahead of print].

Fasmer OB, Riise T, Lund A, Dilsaver SC, Hundal O, Ødegaard KJ. Comorbidity of migraine with ADHD. *J Attend Disord* 2010 Dec 20 [Epub ahead of print].

Fredheim OM, Skurtveit S, Breivik H, Borchgrevink P. Increasing use of opioids from 2004 to 2007 – Pharmacoepidemiological data from a complete national prescription database in Norway. *Eur J Pain* 2010;14:289-294.

Fredheim OM, Log T, Olsen W, Skurtveit S, Sagen Ø, Borchgrevink P. Prescription of opioids to children and adolescents; a study from a national prescription database in Norway. *Pediatric Anesthesia* 2010;20:537-544.

Furu K, Skurtveit S, Strøm H, Rønning M. Reseptregisteret 2004-2009 - en kilde til informasjon. *Norsk Farmaceutisk Tidsskrift* 2010;12:29-31.

Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sørensen HT. The Nordic Countries as a cohort for pharmacoepidemiological research. *Basic Clin Pharmacol Toxicol* 2010;106:86-94.

Gjerden P, Slørdal L, Bramness JG. Prescription persistence and safety of antipsychotic medication: a national registry-based 3-year follow-up. *Eur J Clin Pharmacol* 2010;66:911-7.

Hartz I, Tverdal A, Skille E, Skurtveit S. Disability pension as a predictor of later use of benzodiazepines among benzodiazepines users. *Soc Sci Med* 2010;70:921-5.

Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of anxiolytic drugs - a prospective population-based cohort study of 16 000 individuals. *Scand J Public Health* 2010;38:465-73.

Hjellvik V, Tverdal A, Furu K. Body mass index as predictor for asthma: a cohort study of 118 723 males and females. *Eur Resp J* 2010;35:1235-42.

Karlstad Ø, Nafstad P, Tverdal A, Skurtveit S, Furu K. Prevalence, incidence and persistence of anti-asthma medication use in 2- to 29-year-olds: a nationwide prescription study. *Eur J Clin Pharmacol* 2010;66:399-406.

Karouni M, Arulthas S, Larsson PG, Rytter E, Johannessen SI, Landmark CJ. Psychiatric comorbidity in patients with epilepsy: a population-based study. *Eur J Clin Pharmacol* 2010;66:1151-60.

Kjome RL, Granas AG, Nerhus K, Roraas TH, Sandberg S. The prevalence of self-monitoring of blood glucose and costs of glucometer strips in a nationwide cohort. *Diabetes Technol Ther* 2010;12:701-5.

Kornør H, Pedersen W, von Soest T, Rossow I, Bramness JG. Bruk av benzodiazepiner og cannabis blant unge voksne [Use of benzodiazepines and cannabis in young adults]. *Tidsskr Nor Laegeforen* 2010 ;130:928-31. In Norwegian.

Mahic M, Skurtveit S, Selmer R, Rønning M, Furu K. Prevalence, incidence and persistence of etanercept and adalimumab in Norway 2005-2009. *Pharmacoepidemiol Drug Saf* 2010 Dec 30 [Epub ahead of print].

Skurtveit S, Furu K, Bramness J, Selmer R, Tverdal A. Benzodiazepines predict use of opioids– a follow-up study of 17 074 men and women. *Pain Med* 2010;11:805-14.

Skurtveit S, Furu K, Selmer R, Handal M, Tverdal A. Nicotine dependence predicts repeated use of prescribed opioids. Prospective population-based cohort study. *Ann Epidemiol* 2010;20:890-7.

Vandraas K, Spigset O, Mahic M, Slørdal S. Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly. *Eur J Clin Pharmacol* 2010;66:823-9.

Zoëga H, Furu K, Halldórsson M, Thomsen PH, Sourander A, Martikainen JE. Use of ADHD drugs in the Nordic countries: a population-based comparison study. *Acta Psychiatr Scand* 2010 Sep 23 [Epub ahead of print].

2009:

Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs- a population based study. *Pharmacoepidemiol Drug Saf* 2009;19:273-279.

Bachs LC, Engeland A, Mørland JG, Skurtveit S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or tramadol. *Clin Pharmacol Ther* 2009;85:596-9.

Bramness JG. Bruk av litium i Oslo og i Sogn og Fjordane [Use of lithium in the Norwegian counties Oslo and Sogn og Fjordane]. *Tidsskr Nor Laegeforen* 2009;129:855-7. In Norwegian.

Bramness JG. Ungdom og dagliglivets smerter. [Adolescents and everyday life pains]. *Tidsskr Nor Laegeforen* 2009; 129:1444. In Norwegian.

Bramness JG, Grøholt B, Engeland A, Furu K. The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004-2007 – a prescription database study. *J Affect Disord* 2009; 117:208-11.

Bramness JG, Skurtveit S, Neutel I, Mørland J, Engeland A. An increased risk of road traffic accidents after prescriptions of lithium or valproate? *Pharmacoepidemiol Drug Saf* 2009;18:492-6.

Bramness JG, Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. *J Affect Disord* 2009;118:224-8.

Devold H, Molden E, Skurtveit S, Furu K. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. *Brit J Clin Pharmacol* 2009;67:234-41.

Engeland A, Bjørge T, Daltveit AK, Vollset SE, Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. *Acta Obstet Gynecol Scand* 2009;88:1083-9.

Fredheim OM, Skurtveit S, Moroz A, Breivik H, Borchgrevink P. Prescription pattern of codeine for non-malignant pain in Norway- a pharmacoepidemiological study from The Norwegian Prescription Database. *Acta Anaesthesiol Scand* 2009;53:627-33.

- Gjerden P, Bramness JG, Slørdal L. The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study. *Br J Clin Pharmacol* 2009;67:228-33.
- Gjerden P, Slørdal L, Bramness JG. Association between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of antipsychotic agents. *Eur J Clin Pharmacol* 2009 Jul 31[Epub ahead of print].
- Gjerden P, Slørdal L, Bramness JG. The use of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal of orphenadrine. *Br J Clin Pharmacol* 2009;68:238-42.
- Hartz I, Lundesgaard E, Tverdal A, Skurtveit S. Disability pension is associated with the use of benzodiazepines 20 years later: A prospective study. *Scand J Public Health* 2009;37:320-6.
- Hartz I, Tverdal A, Skurtveit S. A comparison of self-reported data on disability pension status with data from a nationwide administrative register. *Nor J Epidemiol* 2009;19:169-172.
- Hartz I, Tverdal A, Skurtveit S. Social inequalities in use of potentially addictive drugs in Norway – use among disability pensioners. *Nor J Epidemiol* 2009;19:209-218.
- Hauge S, Blix HS, Borgen K, Hungnes O, Dudman SG, Aavitsland P. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. *Virology* 2009;6:54.
- Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. *Eur J Clin Pharmacol* 2009;65:295-301.
- Håkonsen GD, Pettersen MH, Skurtveit S, Giverhaug T. Samtidig bruk av warfarin, analgetika og antiinflammatoriske midler. *Tidsskr Nor Laegeforen* 2009;129:1217-20. In Norwegian.
- Kjosavik SR, Ruths S, Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database *Pharmacoepidemiol Drug Saf* 2009;18:572-8.
- Landmark CJ, Larsson P, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders – a population-based study of prescriptions. *Epilepsy Res* 2009; 87: 31-9.
- Selmer R, Sakshaug S, Skurtveit S, Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. *Brit J Clin Pharmacol* 2009;67:355-62.
- Skurtveit S, Strøm H, Skrivarhaug T, Mørland J, Bramness J, Engeland A. Road traffic accident risk in patients with diabetes mellitus, receiving blood glucose-lowering drugs. Prospective follow-up study. *Diabet Med* 2009; 26:404-08.
- Viktil K, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy – a population-based cohort study *Pharmacoepidemiol Drug Saf* 2009;18:737-42.
- Winther RB, Bramness JG. Legemiddelshopping av vanedannende medikamenter i Norge [Prescription shopping of addictive drugs in Norway]. *Tidsskr Nor Laegeforen* 2009;129:517-20. In Norwegian.
- 2008:**
- Bachs LC, Bramness JG, Engeland A, Skurtveit S. Repeated dispensing of codeine is associated with high consumption of benzodiazepines. *Nor J Epidemiol* 2008;18:185-90.
- Berg A, Furu K, Spigset O. Slimhinneavsvellende nesedråper og nesesypray hos barn [Nasal decongestants and nasal sprays in children]. *Tidsskr Nor Laegeforen* 2008;128:2582-3. In Norwegian.
- Bramness JG, Buajordet I, Skurtveit S. The role of pharmacoepidemiological studies in the market withdrawal of carisoprodol (Somadril®) in Europe. *Nor J Epidemiol* 2008;18:167-72.
- Bramness JG, Skurtveit S. Carisoprodol should be taken off the market. *South Med J* 2008;101:1074-5.

Bramness JG, Skurtveit S, Neutel CI, Mørland J, Engeland A. Minor increase in risk of road traffic accidents after prescriptions of antidepressants. *J Clin Psych* 2008; 69:1099-1103.

Brekke M, Rogstad, Straand J, Furu K, Gjelstad S, Bjørner T, Dalen I. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study. *Scand J Prim Health Care* 2008;26:80-5.

Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-06. *Br J Clin Pharmacol* 2008;65:653-60.

Engeland A, Bramness JG, Mørland J, Skurtveit S. Veitrafikkulykker knyttet til forskrivning av legemidler: en registerbasert kohortstudie. [Traffic accident risks associated with the prescription of medicinal drugs: a registry-based cohort study] *Nor J Epidemiol* 2008;18: 159-66.

Fetveit A, Straand J, Bjorvatn B. Sleep disturbances in an arctic population: the Tromsø Study. *BMC Health Serv Res* 2008;8:117.

Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - New opportunities for research in pharmacoepidemiology in Norway. *Nor J Epidemiol* 2008; 18:129-36.

Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel CI, Mørland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. *Sleep Med* 2008;9:818-22.

Hagen K, Stovner LJ, Skorpen F, Pettersen E, Zwart JA. COMT genotypes and use of antipsychotic medication: linking population-based prescription database to the HUNT study. *Pharmacoepidemiol Drug Saf* 2008;17:372-7.

Litleskare I, Blix H, Rønning M. Antibiotikaforbruk i Norge [Antibiotic use in Norway]. *Tidsskr Nor Laegeforen* 2008;128:2324-9. In Norwegian.

Olsen AS, Ottesen S. Varierende forskrivning av opioider til norske kreftpasienter [Variable prescription of opioids to cancer patients in Norway]. *Tidsskr Nor Laegeforen* 2008;128:1271-4. In Norwegian.

Skurtveit S, Furu K, Bramness JG, Tverdal A. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20 years later – a follow-up study of 13 390 men and women aged 40-42 years. *Pharmacoepidemiol Drug Saf* 2008;17:926-933.

Skurtveit S, Furu K, Kaasa S, Borchgrevink P. Introduction of low dose transdermal buprenorphine - did it influence use of potentially addictive drugs in chronic non-malignant pain patients? *Eur J Pain* 2009;13:949-53.

Skurtveit S, Selmer R, Tverdal A, Furu K. The validity of self-reported prescription medication use among adolescents varied by therapeutic class. *J Clin Epidemiol* 2008;61:714-17.

Strøm H, Sakshaug S, Skurtveit S. Use of statins in patients receiving oral blood glucose-lowering drugs. *Nor J Epidemiol* 2008;18:191-94.

2007:

Al-Haroni M, Skaug N. Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption. *J Antimicrob Chemother* 2007;59:1161-6.

Blix HS, Engeland A, Litleskare I, Rønning M. Age- and gender-specific antibacterial prescribing in Norway. *J Antimicrob Chemother* 2007;59:971-6.

Bramness JG, Engeland A, Furu K. Antidepressiver hos barn og ungdom – førte advarsler til færre forskrivninger? [The use of antidepressants amongst children and adolescents – did the warnings lead to fewer prescriptions?] *Tidsskr Nor Laegeforen* 2007;127:2653-5. In Norwegian.

Bramness JG, Furu K, Engeland A, Skurtveit S. Carisoprodol use and abuse in Norway. A pharmacoepidemiological study. *Br J Clin Pharmacol* 2007;64: 210-8.

Bramness JG, Kornør H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. *Drug Alcohol Depend* 2007;90:203-9.

Bramness JG, Skurtveit S, Mørland J, Engeland A. The risk of road traffic accidents after prescriptions of carisoprodol. *Accid Anal Prev* 2007;39:1050-5.

Engeland A, Skurtveit S, Mørland J. Risk of road traffic accidents associated with the prescription of medicinal drugs: a registry-based cohort study. *Ann Epidemiol* 2007;17:597-602.

Furu K, Skurtveit S, Langhammer A, Nafstad P. Use of anti-asthmatic medications as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription database analysis. *Eur J Clin Pharmacol* 2007;63:693-8.

Hartz I, Sakshaug S, Furu K, Engeland A, Eggen AE, Njølstad I, Skurtveit S. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study. *BMC Clin Pharmacol* 2007;7:14.

Nygard K, Schimmer B, Sobstad O, Walde A, Tveit I, Langeland N, Hausken T, Aavitsland P. A large community outbreak of waterborne giardiasis--delayed detection in a non-endemic urban area. *BMC Public Health* 2006;6:141.

Sakshaug S, Furu K, Karlstad Ø, Rønning M, Skurtveit S. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. *Br J Clin Pharmacol* 2007;64:476-81.

Torkildsen O, Grytten N, Myhr KM. Immunomodulatory treatment of multiple sclerosis in Norway. *Acta Neurol Scand Suppl* 2007;187:46-50.

Åsheim H, Nilsen KB, Johansen K, Furu K. Forskrivning av sentralstimulerende legemidler ved ADHD i Nordland. [Prescribing of stimulants for ADHD in Nordland county] *Tidsskr Nor Laegeforen* 2007;127:2360-2. In Norwegian.

2006:

Bramness JG, Skurtveit S, Furu K, Engeland A, Sakshaug S, Rønning M. Endringer i salg og bruk av flunitrazepam etter 1999. [Changes in the sale and use of flunitrazepam in Norway, 1999 - 2004]. *Tidsskr Nor Laegeforen* 2006;126:589-90. In Norwegian.

Gjelstad S, Fetveit A, Straand J, Dalen I, Rognstad S, Lindback M. Can antibiotic prescriptions in respiratory tract infections be improved? A cluster-randomized educational intervention in general practice--the Prescription Peer Academic Detailing (Rx-PAD) Study [NCT00272155]. *BMC Health Serv Res* 2006;6:75.

Mellingsæter T, Bramness JG, Slørdal L. Benzodiazepinlignende z-hypnotika: bedre og tryggere søvnmidler? [Are z-hypnotics better and safer sleeping pills than benzodiazepines?] *Tidsskr Nor Laegeforen* 2006; 126: 2954-6. In Norwegian.

Straand J, Fetveit A, Rognstad S, Gjelstad S, Brekke M, Dalen I. A cluster-randomized educational intervention to reduce inappropriate prescription patterns for elderly patients in general practice--The Prescription Peer Academic Detailing (Rx-PAD) study [NCT00281450]. *BMC Health Serv Res* 2006;6:72.

Strøm H, Engeland A, Eriksen E, Sakshaug S, Rønning M. Hvor mange og hvem behandles medikamentelt for diabetes mellitus? [How many and who are receiving medication for diabetes mellitus?] *Tidsskr Nor Laegeforen* 2006;126:768-70. In Norwegian.

2005:

Bramness JG, Hausken AM, Sakshaug S, Skurtveit S, Rønning M. Forskrivning av selektive serotoninreuptakshemmere 1990 - 2004. [Prescription of selective serotonin reuptake inhibitors 1990-2004]. *Tidsskr Nor Laegeforen* 2005;125:2470-3. In Norwegian.

2004:

Strøm H. Reseptbasert legemiddelregister: Et viktig verktøy for å oppnå detaljert legemiddelstatistikk [The Norwegian Prescription Database: An important tool for detailed information on drug use]. *Nor J Epidemiol* 2004;14:53-56.

2001:

Furu K. Drug utilisation in a public health perspective: Establishing a national prescription register in Norway. *Nor J Epidemiol* 2001;11:55-60.

Utgitt av Nasjonalt folkehelseinstitutt

Postboks 4404 Nydalen, 0403 Oslo

Tel: +47 21 07 70 00

E-post: folkehelseinstituttet@fhi.no

www.fhi.no

Bestilling:

E-post: publikasjon@fhi.no

Telefon: +47 21 07 82 00

Telefax: +47 21 07 81 05

Published by Norwegian Institute of Public Health

P.O. Box 4404 Nydalen, NO-0403 Oslo

Telephone: +47 21 07 70 00

E-mail: folkehelseinstituttet@fhi.no

www.fhi.no

Order:

E-mail: publikasjon@fhi.no

Telephone: +47 21 07 82 00

Telefax: +47 21 07 81 05

ISSN: 1890-9647

ISBN: 978-82-8082-457-8 trykt utgave/printed version

ISBN: 978-82-8082-458-5 elektronisk utgave/electronic version